Page last updated: 2024-08-17

levodopa and Parkinsonian Disorders

levodopa has been researched along with Parkinsonian Disorders in 852 studies

Research

Studies (852)

TimeframeStudies, this research(%)All Research%
pre-19905 (0.59)18.7374
1990's4 (0.47)18.2507
2000's365 (42.84)29.6817
2010's377 (44.25)24.3611
2020's101 (11.85)2.80

Authors

AuthorsStudies
Ardashov, OV; Il'ina, IV; Karpova, EV; Korchagina, DV; Morozova, EA; Pavlova, AV; Salakhutdinov, NF; Tolstikova, TG; Volcho, KP1
Gilmour, TP; Handly, E; Iyer, V; Kunselman, AR; Lieu, CA; Savaliya, S; Subramanian, T; Venkiteswaran, K1
Chen, HY; Chen, YC; Cheng, ML; Cheng, YC; Chiu, CC; Huang, GJ; Huang, YC; Huang, YZ; Liu, HF; Liu, YC; Lu, CS; Yeh, TH1
Borsek, M; Jeleňová, B; Necpál, J1
Gourdon, JC; Huot, P; Maddaford, S; Nuara, SG1
Chen, Y; Li, L; Tang, J; Yuan, L1
Balint, B; Bhatia, KP; Fung, VSC; Morales-Briceno, H1
Merello, M; Perez-Lloret, S; Rossi, M1
Gao, L; González-Rodríguez, P; Guzman, JN; Ilijic, E; Kaplitt, MG; López-Barneo, J; Schumacker, PT; Stavarache, MA; Stout, KA; Surmeier, DJ; Tkatch, T; Wokosin, DL; Yang, B; Zampese, E1
Blass, BE; Bohmann, J; Chen, PJ; Daadi, ES; Daadi, EW; Daadi, MM; Kim, J; Oh, T; Roy-Choudhury, G1
Bergman, H; Deffains, M; Eitan, R; Fonar, G; Iskhakova, L; Israel, Z; Marmor, O; Paz, R; Rappel, P1
Cubo, E; Miranda, J1
Daida, K; Hattori, N; Kamo, R; Nishioka, K; Shimada, T; Tsunemi, T1
Cerquera-Cleves, C; Dulski, J; Koziorowski, D; Kwiatek-Majkusiak, J; Milanowski, L; Pentela-Nowicka, J; Ross, OA; Sławek, J; Wszolek, ZK1
Ahlskog, JE; Ali, F; Botha, H; Carlos, AF; Clark, HM; Coon, EA; Dickson, DW; Josephs, KA; Koga, S; Lowe, V; Pham, NTT; Sekiya, H; Trejo-Lopez, JA; Whitwell, JL1
Bédard, D; Belliveau, S; Bourgeois-Cayer, É; Frouni, I; Hadj-Youssef, S; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Ohlund, L; Sleno, L1
Hu, BL; Huang, JF; Huang, SS; Liu, RP; Wang, JY; Zhang, X; Zhu, JH; Zhu, SG1
Djoukhadar, I; Jabbari, E; Kobylecki, C; Lally, I; Leahy, CB; Morris, HR; Robinson, AC; Roncaroli, F1
Kuo, MC; Tai, CH; Tseng, SH; Wu, RM1
Anceaume, E; Caboche, J; Calabrese, V; Calabresi, P; Campanelli, F; Charvin, D; Conquet, F; Cuoc, E; Ghiglieri, V; Heck, N; Marino, G; Natale, G; Picconi, B; Sciaccaluga, M; Tozzi, A1
Fanciulli, A; Sidoroff, V; Stankovic, I; Wenning, GK1
McCarter, SJ; Savica, R1
Isonishi, A; Kawabe, Y; Nakahara, K; Okuda, H; Tanaka, T; Tatsumi, K; Wanaka, A1
Holla, VV; Kamble, N; Muthusamy, B; Neeraja, K; Pal, PK; Prasad, S; Surisetti, BK; Yadav, R1
Bourque, M; Di Paolo, T; Dickens, D; Grégoire, L; Patel, W; Snodgrass, R1
Chiu, R; Frank, C; Lee, J1
Bernhard, D; Bonno, SQ; Briscione, MA; Campbell, SA; Donsante, Y; Downs, AM; Fan, X; Gutman, D; Hess, EJ; Ingram, J; Jinnah, HA; Roman, KM; Sardar, TA; Sutcliffe, DJ1
Feng, J; Gao, R; Gao, S; Liu, K; Song, M; Wang, L; Wang, Y; Yao, L; Zhang, L1
Fasano, A; Gorodetsky, C; Lang, AE; Lozano, AM; Youn, J1
Chang, HJ; Joo, JY; Kim, HJ; Lee, HS; Woo, KA1
Almela, P; Arenas-Betancur, L; Cuenca-Bermejo, L; De Pablos, V; Del Bel, E; Fernández-Villalba, E; Gonzalez-Cuello, A; Herrero, MT; Navarro-Zaragoza, J; Yuste, JE1
Belloso-Iguerategui, A; Cotman, CW; Fernández-Irigoyen, J; Gago, B; Merino-Galan, L; Prieto, GA; Quiroga-Varela, A; Rodríguez-Chinchilla, T; Rodríguez-Oroz, MC; Santamaria, E; Zamarbide, M1
Beltrami, D; Biagioli, N; Cavallieri, F; Di Fonzo, A; Di Rauso, G; Fioravanti, V; Fraternali, A; Gasparini, F; Grisanti, S; Marti, A; Monfrini, E; Napoli, M; Pascarella, R; Rossi, J; Toschi, G; Valzania, F; Versari, A1
Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Nuara, SG1
Del-Bel, E; Dias, FJ; Escobar-Espinal, D; Jacob, G; Leal-Luiz, G; Malzone, BL; Milan, BA; Nascimento, GC; Vivanco-Estela, AN1
Abe, Y; Dantsuji, M; Hata, J; Inoue, T; Matsumoto, M; Mochizuki, A; Nambu, A; Ohno, N; Okano, H; Sano, H; Suematsu, M; Sugiura, Y; Suzuki, T; Taira, S; Takeuchi, H; Tanaka, KF; Watanabe, M; Yagishita, S; Yoshimaru, D1
Abusrair, A; Aquino, CC; Mititelu, A; Pfeffer, G; Rosenegger, L1
Greene, LA; Kovalchuke, L; Levy, OA; Mosharov, EV1
Aristieta, A; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Ugedo, L2
Manalo, RVM1
Caparros Lefebvre, D1
Attar, A; Fong, C; Lu, JQ1
Adekenov, SM; Arystan, LI; Haydargalieva, LS; Muldaeva, GM; Nurmaganbetov, ZS1
Mannoury-la-Cour, C; Mantas, I; Millan, MJ; Svenningsson, P; Yang, Y; Zhang, X1
Clark, I; Egan, T; Rentsch, P; Stayte, S; Vissel, B1
Afonso, ND; Chapela, D; Coelho, JE; Ferreira, JJ; Lopes, LV; Outeiro, TF; Sousa, S; Vaz, RL1
Che, Y; Feng, X; Liu, Q; Tang, X; Zhang, S; Zhu, D1
Berardelli, A; Bologna, M; Fasano, A; Hallett, M; Paparella, G1
Ayala, A; Forjaz, MJ; Harmat, M; Janszky, J; Juhász, A; Kovács, N; Martinez-Martin, P; Pintér, D; Rodriguez-Blazquez, C1
Honsberger, S; Husnain, MG; Su, JS1
Andrén, PE; Bezard, E; Fridjonsdottir, E; Gunnarsdottir, H; Hulme, H; Nilsson, A; Shariatgorji, R; Svenningsson, P; Vallianatou, T; Wadensten, H; Zhang, X1
Arisoy, S; Atalay, O; Comoglu, T; Onal, D; Pehlivanoglu, B; Sayiner, O1
Bastioli, G; Caccia, C; Calabresi, P; Cardinale, A; Ghiglieri, V; Keywood, C; Mazzocchetti, P; Melloni, E; Mosci, P; Padoani, G; Picconi, B; Sciaccaluga, M; Tozzi, A; Vailati, S1
Arakawa, K; Maehara, S; Yuge, N1
Chen, PL; Chu, YT; Lin, CH; Lin, HY1
Auger, F; Barthelemy, C; Bezard, E; Bordet, R; Carta, N; Defebvre, L; Demailly, A; Deramecourt, V; Devedjian, JC; Devos, D; Duce, J; Fisichella, M; Kuchcinski, G; Laloux, C; Lannoy, D; Li, Q; Moreau, C; Odou, P; Pioli, E; Rolland, AS1
Baschieri, F; Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; Provini, F; Sambati, L; Tonon, C; Vitiello, M1
Altwal, F; Collier, TJ; Kordower, JH; Manfredsson, FP; Sandoval, IM; Sellnow, RC; Sortwell, CE; Steece-Collier, K; West, AR1
Margabandhu, G; Vanisree, AJ1
George, AL; Mitra, A; Ren, W; Shen, W; Surmeier, DJ; Vanoye, CG; Yang, B; Zhai, S1
Ayikobua, ET; Eze, ED; Jjesero, E; Kalange, M; Kasolo, J; Kasozi, KI; Kimanje, KR; Kiyimba, K; Mwandah, DC; Namulema, J; Nansunga, M; Ninsiima, HI; Okpanachi, AO; Safiriyu, A; Semuyaba, I; Ssempijja, F1
Bishop, C; Cole-Strauss, A; Collier, TJ; Conti, MM; Lipton, JW; Manfredsson, FP; Mercado, NM; Nillni, EA; Sellnow, R; Sortwell, CE; Stancati, JA; Steece-Collier, K; Winn, ME1
Aristieta Arbelaiz, A; Degos, B; Derousseaux, W; Gangarossa, G; Piette, C; Touboul, J; Valverde, S; Vandecasteele, M; Venance, L1
Gao, H; Li, W1
Arai, A; Ichinohe, N; Kon, T; Mori, F; Nishijima, H; Okada, M; Suzuki, C; Tomiyama, M; Ueno, S; Wakabayashi, K; Zhu, G1
Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG3
Manalo, RVM; Medina, PMB1
Bloem, BR; Coelho, M; Dodel, R; Ferreira, JJ; Hommel, AALJ; Hosking, A; Lorenzl, S; Meissner, WG; Odin, P; Schrag, A1
Frucht, S; Han, SC; Katus, L1
Brugnoli, A; Morari, M; Pisanò, CA1
Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A1
Chelban, V; Cortese, A; Houlden, H; O'Connor, E; Rossi, S; Sullivan, R; Wood, NW; Yau, WY1
Abe, K; Chan, CC; Chao, CC; Chen, ML; Cheng, J; Daida, K; Farrer, M; Funayama, M; Hattori, N; Hsieh, ST; Huang, CY; Hung, YC; Jeon, B; Ke, YC; Lai, HJ; Lee, NC; Li, Y; Lin, CH; Lin, HY; Lo, WC; Mukai, Y; Nishioka, K; Sato, K; Takahashi, Y; Tsai, HH; Tsai, PI; Tzeng, SR; Wu, RM; Wu, YS; Yen, RF; Yoshino, H1
Bonifácio, MJ; Soares-da-Silva, P; Sousa, F1
Costa, G; Marongiu, J; Morelli, M; Serra, M; Simola, N1
Altschüler, J; Böckmann, S; Güttler, C; Haumesser, JK; Kühn, AA; Nikulin, VV; Tanev, K; van Riesen, C1
Cairns, NJ; Criswell, S; Davis, AA; Hartlein, J; Kotzbauer, PT; Maiti, B; Martin, WRW; Miles, M; Norris, SA; Perlmutter, JS; Perrin, RJ; Racette, BA; Ushe, M; Zhong, Q1
Bezard, E; Canron, MH; Deffains, M; Dehay, B; Fernagut, PO; Li, Q; Teil, M1
Huang, X; Mailman, RB; Yang, Y1
Hetzelt, KLML; Kerling, F; Kraus, C; Rauch, C; Reis, A; Thiel, CT; Winterholler, M; Zweier, C1
Bédard, D; Frouni, I; Hamadjida, A; Huot, P; Kwan, C1
Altun, M; Bezard, E; Borgkvist, A; Dehay, B; Feyder, M; Fisone, G; Li, Q; Lieberman, OJ; Nilsson, P; Piccin, A; Plewnia, C; Santini, E; Spigolon, G; Sulzer, D; Urbina, L1
Agostinho, P; Aguiar, AS; Cunha, RA; Ferreira, SG; Prediger, RD; Silva, HB; Speck, AE; Tomé, ÂR1
Chung, SJ1
Calandra-Buonaura, G; Contin, M; Cortelli, P; Lopane, G; Mohamed, S; Sambati, L1
Geng, X; Kan, D; Li, Y; Liu, C; Liu, H; Wei, S; Xie, J; Zhang, H1
Bartlett, MJ; Cowen, SL; Falk, T; Sherman, SJ; Ye, T1
Bortolanza, M; Del Bel, EA; Ferrari, DP1
Dupré, N; Estiar, MA; Gan-Or, Z; Leveille, E; Rouleau, GA; Trempe, JF; Varghaei, P; Veyron, S; Yoon, G1
Bower, JH; Camerucci, E; Hajeb, M; Martin, P; Mielke, MM; Mullan, AF; Ross, OA; Savica, R; Stang, CD; Turcano, P1
Enomoto, T; Fujii, Y; Goda, M; Ikeda, K; Kitamura, A; Nakako, T; Wada, E1
Ghosh, S; Malaty, I; Salamatova, Y1
Grill, WM; Schmidt, SL1
Güttler, C; Nikulin, VV; van Riesen, C1
Ju, H; Kwon, KY; Lee, EJ; Lee, M1
Bossert, I; Brumberg, J; Ceravolo, R; Fasano, A; Isaias, IU; Minafra, B; Pacchetti, C; Pisano, P; Pozzi, NG; Todisco, M; Trifirò, G; Zangaglia, R1
Ishihara, T; Sawada, H; Togo, K; Yamamoto, K1
Gourdon, JC; Huot, P; Kwan, C; Nuara, SG1
Liu, Z; Song, L; Yan, A; Yang, S; Zhao, J1
Cheaha, D; Kumarnsit, E; Niyomrat, K; Nukitram, J1
Fukuda, T; Kawahara, Y; Kuroiwa, M; Miyamoto, Y; Nishi, A; Ohnishi, YN; Shuto, T; Sugiyama, K1
Bicho, E; Erlhagen, W; Fernandes, C; Ferreira, F; Gago, MF; Lopes, RL; Sousa, N1
Contu, L; Costa, G; Morelli, M; Pinna, A; Serra, M1
Bonifati, V; Dobricic, V; Dulovic Mahlow, M; Höglinger, G; Huppertz, HJ; Kasten, M; Klein, C; König, IR; Kuhnke, N; Lill, CM; Lohmann, K; Madoev, H; Marras, C; Petkovic, S; Respondek, G; Schaake, S; Stamelou, M; Trinh, J; Vollstedt, EJ; Weissbach, A; Wittke, C1
Armstrong, J; Artuch, R; Darling, A; De Oryazábal Sanz, AL; Díaz-Conradi, Á; García-Cazorla, À; Giraldo, P; Gort, L; Irún, P; O'Callaghan, M; Ormazábal, A; Yubero, D1
Asensio, MJ; García-Montes, JR; Garcia-Sanz, P; Herranz, AS; Hiroi, N; Kang, G; Moratalla, R; Solís, O1
Brefel-Courbon, C; Celebrini, S; Galitzky, M; Jardiné, V; Ory-Magne, F; Rosito, M; Séverac Cauquil, A1
Angrisano, S; Cicolin, A; Lopiano, L; Merola, A; Montanaro, E; Priano, L; Romagnolo, A; Tribolo, A; Zibetti, M1
Antonioli, L; Ballabeni, V; Barocelli, E; Bernardini, N; Blandini, F; Blandizzi, C; Cerri, S; Colucci, R; Fornai, M; Gentile, D; Ippolito, C; Levandis, G; Pellegrini, C; Segnani, C; Tirotta, E1
Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS1
Bhatkar, SR; Bhonsle, SK; de Souza, A; Fernandes, YS1
de Souza, A; de Souza, RJ1
Deng, M; Fang, Y; Gui, X; Huang, L; Lu, S; Zhang, S1
Bezard, E; Calabresi, P; De Rosa, A; Di Luca, M; Gardoni, F; Ghiglieri, V; Li, Q; Longhi, A; Mellone, M; Minocci, D; Napolitano, F; Picconi, B; Racca, C; Stanic, J; Thiolat, ML; Usiello, A; Zianni, E1
Avenali, M; De Icco, R; Fresia, M; Pacchetti, C; Perrotta, A; Sandrini, G; Serrao, M; Tassorelli, C1
Kim, HJ; Kim, KS; Lee, KE; Lee, MK; Park, HJ; Shin, KS; Zhao, TT2
Asselta, R; Blau, N; Cilia, R; Duga, S; Farrer, MJ; Follett, J; Goldwurm, S; Guella, I; Hattori, N; Nishioka, K; Parkkinen, L; Pezzoli, G; Priori, A; Rajput, A; Rajput, AH; Rimoldi, V; Soldà, G; Sossi, V; Stoessl, AJ; Straniero, L; Young, A1
Altschüler, J; Beck, MH; Haumesser, JK; Kühn, AA; Kühn, J; Nikulin, VV; van Riesen, C1
Donsante, C; Fan, X; Harrast, P; Hess, EJ; Jinnah, HA; Joers, V; Rose, SJ; Tansey, MG1
Ando, K; Inoue, R; Kawai, K; Nishime, C; Nishinaka, E; Tsutsumi, H; Urano, K1
Adams, DR; Bertoni, M; Burke, EA; Frucht, SJ; Gahl, WA; Huang, Y; Malicdan, MCV; Sincan, M; Taylor, RW; Thompson, K; Toro, C; Wolfe, LA; Yokoyama, T1
Brotchie, JM; Corey, R; Fox, SH; Hill, MP; Howson, PA; Johnston, TH; Ravenscroft, P; Reidenberg, BE; Versi, E1
Francardo, V; Tronci, E1
Amaral, LLFD; Barsottini, OG; Bueno, FL; França, MC; Marussi, VHR; Pedroso, JL; Vale, TC1
Gourdon, JC; Hamadjida, A; Huot, P; Nuara, SG1
Aparicio-Juárez, A; Ávila-Cascajares, F; Bargas, J; Calderón, V; Duhne, M; Galarraga, E; Lara-González, E1
Hershey, LA; Irwin, DJ1
Alhadhrami, A; Alharthi, SS; Alrobaian, MM; Kabel, AM; Omar, MS1
Ciucci, MR; Kelm-Nelson, CA; Trevino, MA1
Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H1
Baillargeon, J; Darlix, N; Lévesque, C; Lévesque, D; Maheux, J; Majeur, S; Paquet, B; Rouillard, C; St-Hilaire, M1
Du, CX; Liu, J; Sun, YN; Wang, HS; Wang, Y; Yao, L; Zhang, GJ; Zhang, L1
Bariotto-Dos-Santos, K; Bortolanza, M; Del-Bel, EA; Leite-Panissi, CRA; Nascimento, GC1
Ikram, R; Riaz, B; Sikandar, B1
Anand, T; Bhat, PV; Khanum, F; Mohan Manu, T1
Gupta, S; Patel, RK; Sharma, AK; Wardhan, N1
Ahanonu, B; Ding, JB; Ehlers, MD; Grewe, BF; Kim, TH; Li, JZ; Marshall, JD; Parker, JG; Schnitzer, MJ; Wu, YW; Zhang, Y1
Mbiydzenyuy, NE; Ninsiima, HI; Pieme, CA; Valladares, MB1
Baufreton, J; Bessière, B; Bezard, E; Chazalon, M; Courtine, G; Farjot, G; Ko, WKD; Li, Q; McGuire, S; Milekovic, T; Milet, A; Moraud, EM; Morin, S; Normand, E; Pioli, E; Porras, G; Pype, J; Sun, S1
Lim, SY; Ng, RX; Tan, AH1
Bair-Marshall, C; Nelson, AB; Ryan, MB1
Hänninen, R; Koski, SK; Leino, S; Rannanpää, S; Salminen, O; Tapanainen, T1
Gooneratne, IK; Udagedara, TB1
Jeon, B; Kim, R; Lee, WW1
Choi, DH; Go, J; Han, PL; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Noh, JR; Park, HY; Rhee, M; Ryu, YK1
Furtado, SV; Hegde, AS; Jagannatha, AT; Joshi, KC; Khanapure, KS; Perikal, PJ1
Ashkan, K; Aziz, TZ; Brown, P; Fischer, P; Foltynie, T; Green, AL; Limousin, P; Tan, H; Tinkhauser, G; Torrecillos, F; Zrinzo, L1
Bezard, E; Charvin, D; Conquet, F; Di Paolo, T; Duvey, G; Gregoire, L; Halldin, C; Medori, R; Pioli, E; Takano, A1
Bisagni, A; Cremaschi, F; De Marco, L; Di Fabio, S; Mengoli, MC; Montanari, P; Zanelli, M; Zanetti, E1
Kamińska, K; Konieczny, J; Lenda, T; Lorenc-Koci, E; Wardas, J1
Onder, H1
Amorim, BJ; Barsottini, OGP; Faber, I; França, MC; Friedman, JH; Lopes-Cendes, Í; Lourenço, CM; Maia, ML; Marques, W; Martinez, ARM; Martins, CR; Montecchiani, C; Orlacchio, A; Pedroso, JL; Ramos, CD; Souza, JP1
Caldarone, B; Dettmer, U; Ericsson, M; Minakaki, G; Müller, CP; Nuber, S; Rajsombath, M; Selkoe, DJ; Winkler, J1
Abdul Halim, S; Mohd Amin, NA1
Hamed, M; Lazarescu, A; Shetty, A; Suchowersky, O; Tremain, G1
Koya Kutty, S; Mohamed Ibrahim, N; Ramli, R; Shah, SA1
Avnor, Y; Bishop, C; Chambers, NE; Conti, MM; Gross, L; Lanza, K; Meadows, SM; Ostock, CY1
Kohtala, S; Koski, SK; Leino, S; Rannanpää, S; Rantamäki, T; Salminen, O1
Nambu, A; Sano, H1
Aguilera, J; Kulisevsky, J; Limón, ID; Palafox-Sanchez, V; Ramirez-García, G; Sosti, V1
Abd El Fattah, MA; Badawi, GA; El Sayed, MI; Zaki, HF1
Kuo, MC; Lin, CH; Lin, HI1
Gao, G; Gao, Y; Geng, X; Han, H; He, F; Wang, M; Wang, X; Wang, Y; Xie, J; Yao, X; Zhang, H; Zhang, X1
Beck, G; Calabresi, P; Cardinale, A; Costa, C; de Iure, A; Durante, V; Ghiglieri, V; Mancini, A; Mazzocchetti, P; Megaro, A; Napolitano, F; Papa, SM; Picconi, B; Punzo, D; Quiroga Varela, A; Sciaccaluga, M; Tantucci, M; Tozzi, A; Usiello, A1
Morris, GP; Rentsch, P; Stayte, S; Vissel, B1
Konishi, O; Manabe, Y; Odawara, T1
Chen, L; Deng, F; Liu, X1
Keifman, E; Moratalla, R; Murer, MG; Pafundo, DE; Paz, RM; Ruiz-DeDiego, I; Solís, O1
Bian, ZX; Chan, HY; Cheung, CY; Li, Y; Lyu, H; Poon, WS; Wang, KKW; Zheng, ZV1
Caetano, A; Meira, B; Pinto, M; Roque, R1
Alty, J; Currie, S; Khan, S; Sivakumar, G1
Cacace, F; Calabresi, P; Campanelli, F; Cardinale, A; Ghiglieri, V; Mancini, M; Marino, G; Mineo, D; Natale, G; Picconi, B; Vannelli, A1
Collier, NJ; Collier, TJ; Manfredsson, FP; Mercado, NM; Sandoval, IM; Sortwell, CE; Stancati, JA; Steece-Collier, K1
Jia, J; Jiang, X; Su, W; Wang, K; Wei, J; Yan, Y1
Chen, YC; Ho, PL; Huang, P; Teng, CH; Wu, CC1
Bezard, E; Fernagut, PO; Li, Q1
Goto, S; Kasahara, J; Ogawa, M; Tsuji, R; Zhou, Y1
Bicho, E; Carvalho, C; Ferreira, C; Ferreira, F; Gago, MF; Gama, J; Mollaei, N; Rodrigues, L; Rodrigues, PP; Sousa, N1
Ahn, TB; Cho, JW; Chung, SJ; Hong, JY; Jeon, B; Koh, SB; Kwon, DY; Lee, JH; Lee, JY; Lee, WW; Park, HY; Shin, C1
Agúndez, L; Antunes, AS; Bardelli, M; Bezard, E; Björklund, A; Björklund, T; Dovero, S; Henckaerts, E; Li, Q; Linden, RM; Pioli, EY; Rosenblad, C1
Jankovic, J; Niemann, N1
Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M1
Berbellini, A; Cacchiò, G; De Michele, G; De Rosa, A; Di Marzio, F; Manca, A; Pianese, L; Ragno, M; Scarcella, M; Silvestri, S1
Choi, HS; Choi, SO; Kwon, IH; Lee, MK; Shin, KS; Suh, KH; Zhao, TT1
Aguiar, AS; Córdova, FM; Cunha, RA; Glaser, V; Hoeller, AA; Latini, A; Leal, RB; Moreira, EL; Oliveira, PA; Prediger, RD; Walz, R1
Adlard, PA; Ayton, S; Bush, AI; Cherny, RA; Finkelstein, DI; George, JL1
Bär, KJ; Brodoehl, S; Klingner, C; Mentzel, H1
D'Andrea, JN; Furtado, S; Goodyear, BG; Haffenden, AM; Suchowersky, O1
Campos, FL; Carvalho, MM; Coimbra, B; Lima, R; Pêgo, JM; Rodrigues, AJ; Rodrigues, C; Salgado, AJ; Sousa, N1
Lambrecht, C; Richter, A; Sander, SE1
Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M1
Caramés, JM; Moratalla, R; Murer, MG; Solís, JM; Solís, O; Suárez, LM; Taravini, IR1
Asanuma, M; Diaz-Corrales, FJ; Higashi, Y; Miyazaki, I; Namba, M; Ogawa, N1
Amboni, M; Annesi, G; Barbosa, ER; Barone, P; Bonifati, V; Breedveld, GJ; Chien, HF; Erro, R; Fang, M; Graafland, J; Olgiati, S; Oostra, BA; Pappatà, S; Picillo, M; Quadri, M; Quarantelli, M; Quattrone, A; Wang, J; Wu, B; Xu, F1
Angrisano, S; Artusi, CA; Cocito, D; Lopiano, L; Merola, A; Rizzone, MG; Troiano, M; Zibetti, M1
Fox, S1
Coelho, M; Ferreira, JJ; Mestre, TA; Pita Lobo, P; Rosa, MM1
Ishii, K; Katayama, Y; Nagayama, H; Nakajima, N; Nishiyama, Y; Ueda, M1
Bergquist, F; Eklund, M; Holmberg, B; Thorlin, T; Zackrisson, T1
Carta, M; Collu, M; Devoto, P; Fidalgo, C; Lisci, C; Stancampiano, R; Tronci, E1
Bimpisidis, Z; Cenci, MA; Iderberg, H; Rylander, D1
Arbizu, J; Collantes, M; DiCaudo, C; Luquin, MR; Marcilla, I; Ordóñez, C; Peñuelas, I; Riverol, M1
Czarnecka, A; Domin, H; Konieczny, J; Lenda, T; Lorenc-Koci, E; Smiałowska, M1
Björklund, A; Carta, M; Fidalgo, C; Lisci, C; Shin, E; Stancampiano, R; Tronci, E1
Bézard, E; Björklund, A; Carta, M; Li, Q; Muñoz, A; Pioli, EY; Porras, G; Tronci, E1
Bonastre, M; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC1
Andrén, PE; Bezard, E; Bourdenx, M; Crossman, AR; Fälth, M; Li, Q; Nilsson, A; Wadensten, H1
Barraud, Q; Bezard, E; Ghorayeb, I; Hyacinthe, C; Tison, F1
Hagiwara, M; Kasahata, N; Kato, H; Nakamura, A; Uchihara, T1
Armentero, MT; Bonaventura, J; Canela, EI; Casadó, V; Cortés, A; Farré, D; Franco, R; Lanciego, JL; Lluís, C; Luquin, N; Mallol, J; Martínez-Pinilla, E; McCormick, PJ; Moreno, E; Müller, CE; Pinna, A; Rico, AJ; Sánchez, M; Sierra, S1
Carlsson, T; Chiu, WH; Depboylu, C; Höglinger, GU; Oertel, WH; Ries, V1
Hamasaki, T; Kuratsu, J; Yamada, K1
Morelli, M; Pinna, A2
Aristieta, A; Azkona, G; Pérez-Navarro, E; Ruíz-Ortega, JA; Sagarduy, A; Sánchez-Pernaute, R; Ugedo, L; Vazquez, N; Zubillaga, V1
Barbui, C; Bovi, T; Cannas, A; Ceravolo, R; Cipriani, A; Dallocchio, C; Di Stefano, A; Frosini, D; Luca, A; Marrosu, F; Matinella, A; Minafra, B; Morgante, F; Morgante, L; Nicoletti, A; Pacchetti, C; Rossi, S; Sciarretta, M; Solla, P; Tinazzi, M; Ulivelli, M; Zappia, M1
Bonastre, M; Cortés, R; Giralt, A; Marin, C; Mengod, G; Obeso, JA; Schapira, AH1
Liu, Z; Song, L; Wei, J; Wu, N; Yang, X1
Miletić, V; Ozretić, D; Relja, M1
Arai, A; Baba, M; Migita, K; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T; Yamada, J1
Benecke, R; Walter, U; Wittstock, M; Wolters, A1
Farag, NE; Hammad, LN; Zaitone, SA1
Kelsey, JE; Neville, C1
Armentero, MT; Baqi, Y; Bonaventura, J; Canela, EI; Casadó, V; Cortés, A; Costa, G; Farré, D; Franco, R; Lanciego, JL; Lluís, C; Mallol, J; Martínez-Pinilla, E; McCormick, P; Müller, CE; Pinna, A; Sánchez, M; Simola, N1
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Lewis, KD; Piggott, MJ; Reyes, MG1
Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M2
Gan, J; Liu, ZG; Pan, JL; Xie, CL; Zhang, SF1
Ding, Y; Kang, UJ; Singh, P; Won, L1
Corrigan, F; Hassall, MM; Thornton, E; Vink, R1
Doo, AR; Hahm, DH; Jeon, S; Kim, J; Kim, SN; Lee, H; Park, HJ; Park, JY; Park, SU; Yoo, HH1
Jenner, P; Kanda, T; Kawai-Uchida, M; Mori, A; Tashiro, T; Uchida, S1
Czech, H; Zeidman, LA1
Azkona, G; López de Maturana, R; Luquin, MR; Marcilla, I; Pérez-Navarro, E; Sanchez-Pernaute, R; Sousa, A1
Chen, CH; Chen, NF; Chen, WF; Feng, CW; Hsiao, CD; Huang, SY; Hung, HC; Wang, HM; Wen, ZH; Yang, SN1
Ain, NM; Fakurazi, S; Hussein, MZ; Hussein-Al-Ali, SH; Kura, AU1
Choi, HS; Hwang, BY; Lee, CK; Lee, MK; Shin, KS; Zhao, TT1
De Deurwaerdère, P; Di Giovanni, G; Khalki, H; Lagière, M; Milan, L; Navailles, S1
Bagetta, V; Brambilla, R; Calabresi, P; Cerovic, M; Fasano, S; Ghiglieri, V; Giampà, C; Hardingham, N; Heuer, A; Marchisella, F; Morella, I; Papale, A; Pendolino, V; Picconi, B1
Andrade, DM; Borlot, F; Fasano, A; Lang, AE1
Mellstrom, B; Moratalla, R; Naranjo, JR; Ruiz-DeDiego, I; Vallejo, M1
Ampe, B; Aourz, N; Bentea, E; De Deurwaerdère, P; El Arfani, A; Massie, A; Michotte, Y; Sarre, S; Smolders, I; Van Eeckhaut, A1
Charlton, CG; Dent, L; Griffin, B; King, J; Mackey, V; Muthian, G; Smith, ML1
Cai, H; Matsubara, S; Mukai, M; Nakano, I; Sasaki, H; Sugaya, K; Yabe, I1
Bezard, E; Crossman, AR; Ko, WK; Martin-Negrier, ML; Ravenscroft, P1
Dopeso-Reyes, IG; Franco, R; Gómez-Bautista, V; Labandeira-García, JL; Lanciego, JL; Luquin, N; Martínez-Pinilla, E; Rico, AJ; Roda, E; Sierra, S; Vázquez, A1
Adrien, J; Arnulf, I; Belaid, H; Clark, SD; Drouot, X; François, C; Grabli, D; Hirsch, EC; Karachi, C; Laffrat, E; Tandé, D1
Agosta, F; Caso, F; Filippi, M; Inuggi, A; Kostic, VS; Petrovic, I; Stankovic, I; Svetel, M1
Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA2
Di Paolo, T; Grégoire, L; Morin, N; Morissette, M2
Bagetta, V; Branchi, I; Calabresi, P; Ghiglieri, V; Latagliata, EC; Morelli, E; Pascucci, T; Pendolino, V; Picconi, B; Poggini, S; Puglisi-Allegra, S; Sgobio, C1
Brazhnik, E; Cruz, AV; McCoy, AJ; Novikov, N; Walters, JR1
Chung, BH; Han, PL; Hwang, JH; Kang, Y; Kang, YM; Kim, KS; Kim, MR; Kim, YH; Lee, CH; Nam, KH; Park, HY; Park, TS; Ryu, YK1
Dyavarshetty, B; Greven, AC; Mouradian, MM; Papa, SM; Potts, LF; Uthayathas, S1
Brotchie, JM; Chen, B; Gertler, TS; Lo, C; Nash, JE; Surmeier, JD; Thiele, SL; Warre, R1
Appel-Cresswell, S; Dickson, DW; Dinelle, K; Farrer, MJ; McCormick, SE; McKenzie, J; Rajput, A; Rajput, AH; Robinson, CA; Silva, V; Sossi, V; Stoessl, AJ; Thompson, C; Vilariño-Güell, C1
Barros, P; Gago, MF; Martins, J; Miguel, R; Rosas, MJ; Vale, J1
Caboche, J; Feyder, M; Fisone, G; Gomes, AL; Hansen, K; Kryh, H; Lerdrup, M; Södersten, E; Spigolon, G1
Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG1
Danysz, W; Dekundy, A; Hofmann, M; Mela, F1
Garcia-Rubio, S; Giuliano, C; Karasawa, H; Pietra, C; Taché, Y; Wang, L; Xu, X; Yakabi, S1
Canela, EI; Canet-Pons, J; Casadó, V; Cortés, A; Dopeso-Reyes, IG; Farré, D; Franco, R; Labandeira-García, JL; Lanciego, JL; Lluís, C; Mallol, J; Moreno, E; Muñoz, A; Navarro, G; Reyes-Resina, I; Rico, AJ1
Cote, SR; Kuzhikandathil, EV1
Bergeron, Y; Bermejo, MK; Caron, MG; Cyr, M; Gainetdinov, RR; Hossain, MM; Kile, B; Masoud, ST; Miller, GW; Nguyen, LT; Ramsey, AJ; Richardson, JR; Salahpour, A; Siesser, WB; Sotnikova, TD; Vecchio, LM; Wightman, RM1
Ando, K; Inoue, T; Itoh, T1
Bernardi, G; Castelli, V; Cavaliere, F; D'Angelo, V; Ferrazzoli, D; Giorgi, M; Martorana, A; Morrone, LA; Sancesario, G; Sica, F; Sorge, R1
Antonini, A; Cantello, R; Carecchio, M; Comi, C; Fleetwood, T; Magistrelli, L; Mancini, F; Oggioni, GD1
Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A1
Dutta, D; Mohanakumar, KP; Naskar, A; Prabhakar, V; Singh, R1
Bamford, NS; Borgkvist, A; Choi, SJ; Mosharov, EV; Sulzer, D; Wong, MY1
Limón, ID; Palafox-Sánchez, V; Ramírez-García, G1
Akita, H; Habata, T; Igarashi, M; Noda, K; Ogata, M; Saji, M1
Bubser, M; Cenci, MA; Conn, PJ; Hopkins, CR; Iderberg, H; Jones, CK; Lindsley, CW; Maslava, N; Niswender, CM; Thompson, AD1
Di Paolo, T; Goodenowe, D; Grégoire, L; Miville-Godbout, E; Mochizuki, A; Senanayake, V; Smith, T1
Cao, X; Chen, Z; Shi, Q; Tang, B; Wang, T; Zhang, T1
Gut, NK; Winn, P1
Bordia, T; Drenan, RM; McGregor, M; McIntosh, JM; Quik, M1
Bhide, N; Bishop, C; Conti, M; George, JA; Hallmark, J; Ostock, CY; Palumbo, N1
Chiu, WH; Depboylu, C; Hermanns, G; Höglinger, GU; Maurer, L; Oertel, WH; Ries, V; Windolph, A1
Barnum, CJ; Bhide, N; Bishop, C; George, JA; Lindenbach, D; Surrena, MA1
Hwang, BY; Lee, CK; Lee, MK; Park, HJ; Park, KH; Shin, KS; Zhao, TT1
Cruz, AV; Delaville, C; Gerber, CM; McCoy, AJ; Walters, JR1
Li, L; Sagot, B; Zhou, FM1
Ambrosi, G; Antoninetti, G; Baqi, Y; Blandini, F; Cerri, S; Costa, G; Fuzzati-Armentero, MT; Levandis, G; Montepeloso, E; Müller, CE; Pinna, A; Simola, N; Volpini, R1
Bortolanza, M; Cavalcanti-Kiwiatkoski, R; Del-Bel, E; Dos Santos-Pereira, M; Mitkovski, M; Padovan-Neto, FE; Raisman-Vozari, R1
Bonastre, M; Cortés, R; Marin, C; Mengod, G; Rodríguez-Oroz, MC1
Garg, A; Jha, S; Khanna, A1
De Deurwaerdère, P; Di Giovanni, G; Navailles, S1
Bishop, C; Conti, MM; Dupre, KB; Lindenbach, D; Ostock, CY1
Feld, Y; Finberg, JP; Gross, RE; Gutekunst, CA; Mewes, K; Papa, SM; Singh, A; Uthayathas, S1
Hattori, N; Ishiguro, Y; Kawajiri, S; Noda, K; Okuma, Y; Tomizawa, Y; Tosaka, Y1
Daniels, WM; Mabandla, MV; Ndlovu, BC1
Alvarsson, A; Kadkhodaei, B; Millan, MJ; Perlmann, T; Schintu, N; Stan, TL; Svenningsson, P; Zhang, X1
Garcia-Montes, JR; González-Granillo, A; Moratalla, R; Solís, O; Xu, M1
Burgess, T; Cunningham, V; Glamuzina, E; Hill, R; Jacobsen, JC; Lehnert, K; Love, DR; Prosser, DO; Robertson, SP; Snell, RG; Swan, B; Taylor, J; Wilson, C1
Case, DT; Collier, TJ; Divito, CB; Edwards, RH; Rubio, ME; Seal, RP; Sortwell, CE; Stancati, JA; Steece-Collier, K; Sulzer, D; Williams, SP; Zhang, H; Zhi, L1
Bordia, T; Decker, MW; McGregor, M; McIntosh, JM; Perez, XA; Quik, M; Zhang, D1
Cruz, AV; Delaville, C; Dupre, KB; Eyring, KW; Gerber, CM; McCoy, AJ; Walters, JR1
Girasole, AE; Nelson, AB1
Bezard, E; Cenci, MA; Conn, PJ; Fieblinger, T; Francardo, V; Greengard, P; Ko, WK; Li, Q; Lindsley, CW; Neubig, RR; Plotkin, JL; Shen, W; Surmeier, DJ; Wess, J; Xie, Z1
Feng, Z; Gupta, DK; Hang, X; Hasan, A; Liu, R1
Jeon, BS; Park, H; Park, SH; Shin, JH1
Canning, SD; Wang, XP; Zhang, LL1
Cacace, F; Calabresi, P; Carta, M; di Maio, A; Fidalgo, C; Gardoni, F; Ghiglieri, V; Mancini, M; Mellone, M; Mineo, D; Napolitano, F; Pendolino, V; Picconi, B; Stancampiano, R; Stanic, J; Tronci, E; Usiello, A; Vannelli, A1
Daumas, S; El Mestikawy, S; Gangarossa, G; Guzman, M; Prado, MA; Prado, VF; Valjent, E1
Alam, M; Jin, X; Krauss, JK; Schwabe, K1
Kokare, DM; Shelkar, GP; Subhedar, NK; Upadhya, MA1
McCreary, AC; Newman-Tancredi, A; Varney, MA1
Alvarsson, A; Greengard, P; Kaplitt, MG; Marongiu, R; Schintu, N; Svenningsson, P; Zhang, X1
Bishop, C; Conti, MM; Eissa, S; Goldenberg, AA; Kuberka, A; Lindenbach, D; Mohamed, M1
Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Park, HY; Park, TS; Rhee, M; Ryu, YK1
Cheng, J; Fan, Q; Gan, J; Hu, R; Li, L; Liu, Z; Song, L; Wu, N; Zhang, Z; Zhou, M1
Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM1
Deng, M; Fang, Y; He, Y; Huang, L; Lu, S; Ma, R1
Lin, JY; Liu, ZG; Wang, MH; Wang, XJ; Xie, CL; Zhang, SF; Zhang, Y1
Moustafa, YM; Teema, AM; Zaitone, SA1
Dorban, S; Gustin, T; Mormont, E1
Abe, T; Fujita, K; Harada, M; Izumi, Y; Kaji, R; Osaki, Y1
Bhattacharjee, N; Borah, A; Choudhury, A; Choudhury, S; Mazumder, MK; Paul, R1
da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M; Guimarães, FS1
Bishop, C; Conti, MM; Hallmark, J; Lindenbach, D; Meadows, SM; Melikhov-Sosin, M; Werner, DF1
Cerquetti, D; Fariña, S; Merello, M; Morisset, P; Rossi, M; Wilken, M1
Barros, IS; Brito, BS; de Araújo, DF; de Araújo, IT; de Melo Neto, AP; Gondim, Fde A; Horta, WG; Lima, JW; Oliveira, ÍS1
Bale, E; Gray, WK; Hand, A; Jones, C; Oates, LL; Todd, A; Walker, RW; Wood, BH; Woolford, M1
Bishop, C; Conti, MM; George, JA; Goldenberg, AA; Lindenbach, D; Melikhov-Sosin, M; Nuss, EE; Ostock, CY1
Bender, D; Bjarkam, CR; Doudet, D; Glud, AN; Mogensen, P; Møller, A; Nielsen, MS; Sørensen, JC1
Khatoon, H; Mirza, T; Najam, R; Sikandar, B1
Czarnecka, A; Dudek, M; Kamińska, K; Knutelska, J; Lorenc-Koci, E; Zygmunt, M1
Cao, X; Chen, G; Han, C; Ma, K; Nie, S; Papa, SM; Wang, T; Xiong, N; Xu, Y; Zhang, Z1
Gee, L; Pilitsis, JG; Ramirez-Zamora, A; Shin, DS; Youn, Y1
Coenen, VA; Fischer, J; Frings, L; Jost, M; Klebe, S; Meyer, PT; Piroth, T; Rauschendorf, MA; Reinacher, PC; Rijntjes, M; Rösler, B; Stock, F; Weiller, C; Zimmer, A1
Itin, I; Jimenez-Shahed, J; Mehanna, R1
Rajput, AH; Rajput, EF1
Frouni, I; Gourdon, JC; Hamadjida, A; Harraka, MJ; Huot, P; Kwan, C; Nuara, SG; Sid-Otmane, L; Veyres, N1
Damberg, P; Monnot, C; Nikkhou-Aski, S; Svenningsson, P; Zhang, X1
Grabli, D1
Bordia, T; Perez, XA; Quik, M; Zhang, D1
Abdelhameed, AS; Ajmal, MR; Khan, RH; Nusrat, S; Siddiqi, MK; Siddique, IA; Zaidi, N; Zaman, M1
A Figge, D; Standaert, DG1
Arai, A; Kannari, K; Kawarabayashi, T; Kimura, T; Shen, H; Shoji, M; Suzuki, C; Tomiyama, M; Watanabe, M1
Bishop, C; Dupre, KB; Eskow, KL; Klioueva, A; Lormand, L; Negron, GE; Park, JY; Steiniger, A1
Bagetta, V; Barone, I; Calabresi, P; Ghiglieri, V; Picconi, B; Sgobio, C1
Aceves, J; Erlij, D; Florán, B; Floran, L; García-Ramírez, M; Rangel-Barajas, C; Sánchez-Lemus, E; Silva, I1
Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR1
DeLong, MR; Liang, L; Papa, SM1
Barnum, CJ; Bishop, C; Blandino, P; Deak, T; Dupre, K; Eskow, KL1
Jin, GZ; Mo, J; Sun, PH; Yu, LP; Zhang, H; Zhen, X1
Evans, AH; Farrell, MJ; Gibson, SJ; Helme, RD; Lang, AE; Lim, SY1
Bernardi, G; D'Angelo, V; Esposito, Z; Giorgi, M; Martorana, A; Nuccetelli, V; Sancesario, G; Sorge, R; Stefani, A1
Glavan, G1
Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC1
Ferrario, JE; Gomes, MZ; Hunot, S; Raisman-Vozari, R; Rojas-Mayorquín, AE; Saldaña-Ortega, M; Salum, C1
Gunzler, SA; Hogarth, P; Jamerson, B; Kirchhoff, T; Krams, M; Landen, JW; Menniti, FS; Nutt, JG; Weaver, JL1
Danysz, W; Dekundy, A; Quack, G; Valastro, B1
Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A1
Abdin, AA; Hamouda, HE1
Butz, M; Gross, J; Makhloufi, H; Pollok, B; Schnitzler, A; Timmermann, L; Wojtecki, L1
Bi, M; Fath, T; Götz, J; Gunning, P; Ittner, LM; Ke, YD; Li, KM; van Eersel, J1
Domino, EF; Ni, L1
Akamatsu, Y; Fujimori, K; Kawagishi, N; Miyagi, S; Sato, A; Satomi, S; Sekiguchi, S1
Berciano, J; Bonifati, V; Breedveld, G; Di Fonzo, A; García, A; Infante, J; Oostra, B; Sánchez-Juan, P1
Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C1
Marti, M; Morari, M; Trapella, C1
Fukuyama, H; Hashikawa, K; Hattori, N; Kohriyama, T; Matsumoto, M; Ohshita, T; Takahashi, T; Yamashita, H1
Ceda, G; Lauretani, F; Maggio, M; Nardelli, A; Saccavini, M1
Aguiar, PM; Barsottini, OG; Borges, V; Felício, AC; Ferraz, HB; Godeiro-Junior, C; Silva, SM1
Barnum, CJ; Bishop, C; Deak, T; Dupre, KB; Eskow, KL; Krolewski, DM; Walker, PD1
Brotchie, JM; Fox, SH; Johnston, T; Millan, MJ; Reyes, G; Visanji, NP1
Barodia, SK; Luthra, PM; Raghubir, R1
McCairn, KW; Turner, RS1
García-Horsman, JA; Kääriäinen, TM; Männistö, PT; Piltonen, M1
Bartoszyk, GD; Bédard, PJ; Di Paolo, T; Graham, J; Grégoire, L; Samadi, P1
Benabid, AL; Berger, F; Buggia-Prevot, V; El Atifi-Borel, M; Platet, N; Sgambato-Faure, V1
Calon, F; Di Paolo, T; Grégoire, L; Hornykiewicz, O; Rajput, A; Rajput, AH; Samadi, P1
Caron, MG; Fuentes, R; Nicolelis, MA; Petersson, P; Siesser, WB1
Ugrumov, MV1
Lima, MA; Maradei, S; Maranhao Filho, P1
Berthet, A; Bezard, E; Bloch, B; Cador, M; Doudnikoff, E; Porras, G; Stark, H1
Brundin, P; Cenci, MA; Lane, EL; Vercammen, L1
Collier, TJ; Maries-Lad, E; Soderstrom, KE; Sortwell, CE; Steece-Collier, K1
Blume, SR; Cass, DK; Tseng, KY1
Barbanoj, M; Gich, I; Kulisevsky, J; Pérez, V; Rodríguez-Alvarez, J; Rubio, A; Sosti, V1
Ballion, B; Chetrit, J; Frenois, F; Gonon, F; Murer, MG; Zold, CL1
Astradsson, A; Brownell, AL; Choi, JK; Hallett, PJ; Isacson, O; Jenkins, BG; Levesque, MA; McDowell, JS; Spealman, RD1
Ares, S; Darmopil, S; De Diego, IR; Martín, AB; Moratalla, R1
Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK1
Jiang, JJ; Lee, VS; Wang, EQ; Zhou, XP1
Cenci, MA; Lindgren, HS; Ohlin, KE1
Kerkerian-Le Goff, L; Khaindrava, V; Lacombe, E; Melon, C; Oueslati, A; Salin, P1
Fisone, G; Greengard, P; Heiman, M; Santini, E; Valjent, E1
Bishop, C; Dupre, KB; Jaunarajs, KL; Kelly, C; Klioueva, A; Moore, A; Steiniger, A1
Aguilar, E; Bonastre, M; Jiménez, A; Marin, C2
Diaz, J; Guilloux, JP; Massart, R; Mignon, V; Sokoloff, P1
Brocco, M; Mela, F; Millan, MJ; Morari, M1
Kostrzewa, RA; Kostrzewa, RM; Nowak, P; Skaba, D1
Ahn, YH; Lee, PH; Park, HJ; Shin, JY1
Menkes, DL; Silvers, DS1
Buck, K; Ferger, B1
Borah, A; Mohanakumar, KP4
Lee, KY; Lee, PH; Yong, SW1
Racette, BA; Sterling, C; Willis, AW1
Bezard, E; Brotchie, JM; Dunah, AW; Hallett, PJ; Kobylecki, C; Li, Q; Ravenscroft, P; Silverdale, MA1
Alp, R; Alp, SI; Ure, H1
Aoki, T; Hamaue, N; Hirafuji, M; Ogata, A; Sasaki, H; Terado, M; Togashi, H; Tsuchida, S; Yabe, I1
Alty, JE; Clissold, BG; Kempster, PA; McColl, CD; Reardon, KA; Shiff, M1
Biagioni, F; Fornai, F; Fulceri, F; Murri, L; Paparelli, A; Ruggieri, S1
Dick, JP; Kellett, MW; Kobylecki, C; Silverdale, MA; Varma, A1
Asmus, F; Berg, D; Reimold, M; Schöls, L; Synofzik, M1
Chung, CY; Hallett, PJ; Isacson, O; Koprich, JB1
Bélanger, N; Di Paolo, T; Hadj Tahar, A; Morissette, M; Samadi, P1
Chen, L; Wang, H; Xue, Y; Yung, WH; Zhang, SJ1
Bilbe, G; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hornykiewicz, O; Johns, DR; Morissette, M; Ouattara, B; Rajput, A; Rajput, AH; Vranesic, I1
Cho, C; Cohen, B; Kudo, K; Kunin, M; Olanow, CW; Osaki, Y; Raphan, T1
Bureau, G; Chagniel, L; Cyr, M; Lebel, M1
Adam, OR; Ferrara, JM; Ondo, WG1
Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N1
Anderson, AM; Johnson, SW; Lewis, JR; Meshul, CK; Paquette, MA; Paul Berger, S1
Bonanni, L; Cossu, G; Manca, D; Onofrj, M; Stocchi, F; Thomas, A1
Bioulac, B; De Deurwaerdère, P; Gross, C; Navailles, S1
Marti, M; Morari, M; Viaro, R1
Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Huot, P; Johnston, T; Reyes, G; Visanji, N1
Dale, RC; Earl, J; Fung, VS; Grattan-Smith, P; Houlden, H; Melchers, A1
Reichmann, H1
Glass, GA; Ku, S1
Ahmed, MR; Aubert, I; Berthet, A; Bezard, E; Bioulac, BH; Bloch, B; Bychkov, E; Carl, YT; Doudnikoff, E; Dovero, S; Gurevich, EV; Gurevich, VV; Kook, S; Li, Q; Porras, G1
Andersen, ML; Barnabé, GF; Dombrowski, PA; Lima, MM; Reksidler, AB; Tufik, S; Vital, MA1
Dunnett, SB; Lane, EL1
Fish, M; Hack, M; Majounie, E; Morris, HR; Newsway, V; Rohrer, JD; Warren, JD; Williams, N1
Hayashi, Y; Hozumi, I; Inuzuka, T; Kimura, A; Sakurai, T; Tanaka, Y; Yamada, M1
Jeong, SH; Kim, JM; Kim, JS; Kim, SE; Kim, SH; Kim, Y; Kim, YK1
Guan, Q; He, Y; Jin, L; Liu, X; Zhao, L1
Chen, CC; Chen, RS; Grattan-Smith, P; Jung, SM; Lai, SC; Lang, AE; Lin, YW; Lu, CS; Sugo, E; Wu-Chou, YH1
Liu, Z; Ren, T; Song, L; Wu, N; Yang, X; Yuan, W1
Espay, AJ; Metman, LV; O'Sullivan, JD; Paviour, DC; Revilla, FJ; Schmidt, RE1
Bajaj, N; Bhatia, KP; Brandner, S; Elahi, E; Emre, M; Federoff, M; Guevara, R; Hanagasi, H; Hardy, J; Houlden, H; Lees, AJ; Paisán-Ruiz, C; Schneider, SA; Schwingenschuh, P; Sina, F; Singleton, AB1
de la Fuente-Fernández, R; Dinelle, K; Doudet, DJ; Mak, E; Schulzer, M; Sossi, V1
Iravani, MM; Jackson, MJ; Jenner, P; Parent, A; Rose, S; Zeng, BY1
Fang, C; Gao, C; Wang, Y; Xu, H; Xu, Z; Yin, J; Zhou, H1
Aceves, J; Erlij, D; Florán, B; Lopéz-Santiago, LM; Rangel-Barajas, C; Silva, I1
Damon-Perrière, N; Meissner, WG; Tison, F1
Gupta, A; Lang, AE1
Bezard, E; Dovero, S; Fisone, G; Li, Q; Santini, E; Savasta, M; Sgambato-Faure, V1
Barraud, Q; Bezard, E; Fernagut, PO; Ghorayeb, I; Tison, F1
Chan, KY; Fung, CW; Hui, J; Ko, CH; Lam, CW; Low, L; Mak, CM; Siu, S; Wong, VC; Yau, E; Yeung, WL1
Brotchie, JM; Fox, SH; Johnston, TH; Piggott, MJ; Savola, JM1
Dowd, E; Finn, DP; Gorman, AM; Walsh, S1
Abele, M; Albanese, A; Barone, P; Berciano, J; Boesch, S; Bozi, M; Cardozo, A; Coelho, M; Colosimo, C; Daniels, C; Del Sorbo, F; Deuschl, G; Djaldetti, R; Dupont, E; Fowler, C; Galitzky, M; Gasser, T; Geser, F; Giladi, N; Gonzalez-Mandly, A; Gurevich, T; Kamm, C; Klockgether, T; Köllensperger, M; Mathias, CJ; Meco, G; Ndayisaba, JP; Nilsson, CF; Oertel, W; Ostergaard, K; Pellecchia, MT; Poewe, W; Quinn, N; Rascol, O; Sampaio, C; Schimke, N; Schrag, A; Seppi, K; Siebert, U; Tison, F; Tolosa, E; Wenning, GK; Widner, H; Yekhlef, F1
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Winkelmolen, L1
Auguet, M; Chabrier, PE; Charnet, C; Cornet, S; Roubert, V; Spinnewyn, B1
Archer, T; Fredriksson, A; Johansson, B1
Auguet, M; Chabrier, PE; Ferrandis, E; Grandoulier, AS; Marin, JG; Mautino, G; Rocher, MN; Spinnewyn, B1
Deogaonkar, M; Gilmour, TP; Lieu, CA; Nolt, MJ; Piallat, B; Subramanian, T1
Kim, BJ; Kim, JS; Kim, KK; Kim, SM; Lee, MC; Lim, YM; Park, HK1
Bagetta, V; Calabresi, P; Di Filippo, M; Fusco, FR; Ghiglieri, V; Giampà, C; Paillè, V; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A1
Gerlach, M; Grünblatt, E; Riederer, P; Scheller, DK; Schmidt, WJ1
Hu, WD; Huang, YX; Li, D; Liu, CF; Luo, WF1
Daly, CS; Dunnett, SB; Lane, EL; Smith, GA1
Bartoszyk, GD; Dean, O; Gerlach, M; Riederer, P; van den Buuse, M1
Bilbe, G; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Johns, D; Morin, N; Ouattara, B; Sahasranaman, S; Vranesic, I1
Gendelman, HE; Hutter-Saunders, JA; Kosloski, LM; McMillan, JM; Mosley, RL; Rinat, T; Yotam, N1
Barnum, CJ; Bhide, N; Bishop, C; Dupre, KB; Eskow Jaunarajs, KL; Lindenbach, D; Ostock, CY1
Braschinsky, M; Doherty, K; Hotter, A; Lees, AJ; Ling, H; Lüüs, SM; Poewe, W; Taba, P1
Brotchie, JM; DeHaven, RN; DeHaven-Hudkins, DL; Dolle, RE; Fox, SH; Goodman, A; Johnston, TH; Koprich, JB; Le Bourdonnec, B; Little, PJ1
Di Paolo, T; Morissette, M; Parent, M; Riahi, G1
Abe, H; Ebihara, K; Ishida, Y; Kawai, K; Magata, Y; Matsuo, H; Nishimori, T; Takeda, R1
Barroso-Chinea, P; Conte-Perales, L; Gómez-Bautista, V; Lanciego, JL; Luquin, N; Rico, AJ; Roda, E; Sierra, S1
Alachkar, A; Brotchie, JM; Jones, OT1
Gomez Heredia, MJ; Pérez Errazquin, F1
Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C1
Jog, MS; Rahimi, F; Typlt, M1
Egeland, M; Svenningsson, P; Zhang, X1
Ludin, HP1
Irie, S; Kanazawa, N; Mochizuki, H; Nomura, Y; Ryoh, M; Segawa, M1
Barroso-Chinea, P; Berthet, A; Bezard, E; Canron, MH; Charron, G; Delalande, F; Doudnikoff, E; Giros, B; Goumon, Y; Laux, A; Li, Q; Nosten-Bertrand, M; Porras, G; Qin, C; Van Dorsselaer, A; Vital, A1
Cenci, MA; Francardo, V; Konradi, C; Lees, AJ; Lindgren, HS; Luksik, AS; O'Sullivan, SS; Ohlin, KE; Sillivan, SE; Vassoler, FM1
Ahlskog, JE; Josephs, KA; Klassen, BT; Lee, KH; Matsumoto, JY; Savica, R; Stead, M1
Dziubina, A; Gołembiowska, K1
Cai, Y; Liu, Z; Ren, T; Wu, N; Yang, X; Yuan, W1
Ahlskog, JE; Josephs, KA; Kumar, N; Matsumoto, JY; McKeon, A; Savica, R1
Johnston, TH; Lane, EL1
Aristieta, A; Cenci, MA; Miguelez, C; Ugedo, L1
Bagetta, V; Bonito-Oliva, A; Calabresi, P; Carta, M; Di Luca, M; Errico, F; Fisone, G; Gardoni, F; Marinucci, S; Napolitano, F; Picconi, B; Romano, R; Usiello, A; Vitucci, D; Zianni, E1
Inoue, M; Inoue, Y; Kishimoto, T; Kiuchi, K; Kosaka, J; Morikawa, M; Norimoto, K1
Gerhardt, E; Kermer, P; Schulz, JB; Szego, ÉM1
Babapour, V; Mahmoudi, J; Nayebi, AM; Reyhani-Rad, S; Samini, M1
Janssen, ML; Sager, TN; Temel, Y; Westin, JE1
Dietrichs, E; Toft, M1
Modo, M; Vernon, AC1
Chao, OY; Huston, JP; Mattern, C; Nikolaus, S; Pum, ME; Ruocco, LA; Silva, AM; Wessler, J1
Chiba, S; Kadoyama, K; Kato, S; Suzuki, N; Tadokoro, M; Takada, E; Takenokuchi, M; Taniguchi, T1
Cacciatore, I; Conte, C; Cornacchia, C; Minelli, A; Pinnen, F1
Brioschi, A; Mauro, A; Pignatti, R; Semenza, C; Wenter, J; Zamarian, L1
Barroso-Chinea, P; Baufreton, J; Berthet, A; Bezard, E; Bloch, B; Dehay, B; Fasano, S; Giros, B; Li, Q; Martin-Negrier, ML; Martinez, A; Nosten-Bertrand, M; Porras, G; Thiolat, ML1
Ago, Y; Hiramatsu, N; Matsuda, T; Ota, Y; Takahashi, T; Takuma, K; Tanaka, T1
Goldstein, DS; Holmes, C; Sharabi, Y1
Abuirmeileh, A; Bloom, SR; Harkavyi, A; Lever, R; Rampersaud, N; Tadross, JA; Whitton, PS1
Abbruzzese, G; Antonini, A; Barone, P; Bonuccelli, U; Capus, L; Ceravolo, R; Cilia, R; Colosimo, C; Guerra, UP; Lopiano, L; Marconi, R; Morgante, L; Petrone, A; Quatrale, R; Ramat, S; Righini, A; Stefani, A; Tamma, F; Tinazzi, M; Vitale, C; Zappia, M1
Billet, F; Costentin, J; Dourmap, N1
Grady, SR; Hrachova, M; Huang, LZ; Mallela, A; McIntosh, JM; Park, KM; Quik, M1
Bishop, C; Eskow Jaunarajs, KL; George, JA1
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB1
Chung, SJ; Kim, J; Kim, JS; Kim, KK; Lee, CS; Lim, YM; Park, HK1
Bateup, HS; Feyder, M; Fisone, G; Gangarossa, G; Greengard, P; Santini, E1
Quintana, A; Savasta, M; Sgambato-Faure, V1
Bishop, C; Buchta, W; Dickinson, SO; Eissa, S; Eskow Jaunarajs, KL; George, JA; Goldenberg, AA; Mohamed, M1
Darmopil, S; Espadas, I; Martín, ED; Moratalla, R; Oliva, I; Ortiz, O; Vergaño-Vera, E; Vicario-Abejón, C1
Camargos, S; Cardoso, F; Lees, AJ; Singleton, A1
Berger, SP; Giuffrida, A; Johnson, SW; Macheda, T; Martinez, AA; Meshul, CK; Paquette, MA1
Chang, CC; Chang, WN; Chen, CH; Chen, NC; Huang, CW; Huang, SH; Lee, CC; Lin, YT; Lui, CC1
Desrayaud, S; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M1
Everett, CM; Houlden, H; Kara, E; Maresh, KE1
Brotchie, JM; Damude, S; Fox, SH; Huot, P; Johnston, TH; Jones, SW; Rusche, JR1
Di Paolo, T; Lévesque, D; Morissette, M; Parent, M; Riahi, G; Rouillard, C; Samadi, P1
Camargos, S; Cardoso, F1
Agosti, V; Amboni, M; Barone, P; Fasano, A; Iavarone, A; Iuppariello, L; Lista, I; Picillo, M; Santangelo, G; Sorrentino, G; Tranfaglia, R; Vitale, C1
Gittis, A1
Breger, LS; Dunnett, SB; Lane, EL1
Hatano, T; Hattori, N; Kubo, S; Niijima-Ishii, Y; Sugita, Y1
Chen, Y; Hong, X; Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W1
Bagetta, V; Calabresi, P; Del Papa, G; Gardoni, F; Ghiglieri, V; Giampà, C; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A; Zianni, E1
Auburger, G; Dehorter, N; Gispert, S; Hammond, C; Klinkenberg, M; Lopez, C; Lozovaya, N; Mdzomba, BJ; Michel, FJ; Tsintsadze, T; Tsintsadze, V1
Arai, A; Baba, M; Kimura, T; Migita, K; Mori, F; Nishijima, H; Tomiyama, M; Ueno, S; Wakabayashi, K; Yamada, J1
Bezard, E; Dupouy, S; Galitzky, M; Li, Q; Marquine, L; Meissner, WG; Milhet, A; Nègre-Pagès, L; Ory-Magne, F; Rascol, O; Spampinato, U; Thiolat, ML; Thiollier, T; Tison, F1
Burne, JA; Cathers, I; Cordato, D; Tawadros, PB1
Baraduc, P; Broussolle, E; Desmurget, M; Gan, J; Thobois, S1
Barbon, A; Fiorentini, C; Missale, C; Savoia, P; Savoldi, D1
Bjarnason, I; Charlett, A; Dobbs, RJ; Dobbs, SM; Iguodala, O; Lawson, AJ; Smee, C; Taylor, D; Weller, C1
Bordia, T; McIntosh, JM; Quik, M1
Hong, JY; Kim, KM; Lee, PH; Sohn, YH; Sunwoo, MK1
Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E1
Barone, P; Cicarelli, G; De Michele, G; Pellecchia, MT; Pizzolato, G1
Björklund, A; Cenci, MA; Kirik, D; Winkler, C1
Dass, B; Engber, TM; Galdes, A; Iravani, MM; Jackson, MJ; Jenner, P1
Balestre, E; Chrysostome, V; Poewe, W; Quinn, NP; Tison, F; Wenning, GK; Yekhlef, F1
Berciano, J; Ferrer, I; Marín, C; Pascual, J; Rey, MJ; Rumià, J; Tolosa, E; Valldeoriola, F1
Bar-Gad, I; Bergman, H; Goldberg, JA; Heimer, G1
Chang, JW; Kang, UJ; Lee, WY; Milstien, S1
Chang, HC; Chen, RS; Lu, CS; Tsai, CH; Wu Chou, YH; Yen, TC1
Archer, T; Fredriksson, A; Palomo, T1
Cenci, MA2
Archer, T; Fredriksson, A2
Bacci, JJ; Kerkerian-Le Goff, L; Salin, P1
Bonastre, M; Bové, J; Marin, C; Tolosa, E2
Ohye, C; Shibazaki, T1
de Rooij, SE; Jansen, PA; Moons, CG; Samson, MM; Verhaar, HJ1
Aziz, TZ; Giladi, N; Nandi, D; Stein, JF; Winter, J1
Bibbiani, F; Chase, TN; Oh, JD2
Feldon, J; Mintz, M; Mura, A1
Battaglia, G; Bernardi, G; Calabresi, P; Centonze, D; Nicoletti, F; Picconi, B; Pisani, A; Storto, M1
Cannizzaro, C; Jenner, P; Pearce, RK; Rose, S; Tel, BC; Zeng, BY1
Bioulac, B; Fernagut, PO; Ghorayeb, I; Stefanova, N; Tison, F; Wenning, GK1
Caudle, WM; Miller, GW; Reverón, ME; Tillerson, JL1
Hirsch, EC; Muriel, MP; Orieux, G1
Brotchie, J; Crossman, A; Fox, SH; Henry, B; Hill, M1
Al-Barghouthy, G; Jackson, M; Jenner, P; Kuoppamäki, M; Quinn, N; Smith, L; Zeng, BY1
Chacón, J; García-Moreno, JM1
Angelucci, ME; Canteras, NS; Da Cunha, C; Takahashi, RN; Wonnacott, S1
Bonastre, M; Hirsch, EC; Marin, C; Périer, C; Tolosa, E1
Cannizzaro, C; Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK1
D'Andreamatteo, G; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A1
Benecke, R1
Aniello, MS; De Mari, M; Defazio, G; Lamberti, P; Zenzola, A1
Ferrannini, E; Fraddosio, A; Iliceto, G; Lamberti, S; Maggio, F; Palagano, G; Russo, I; Serlenga, L; Zoccolella, S1
Beani, L; Bianchi, C; Marti, M; Mela, F; Morari, M; Paganini, F; Stocchi, S1
Minagar, A; Shulman, LM; Weiner, WJ1
Bezard, E; Bioulac, B; Dovero, S; Gross, CE; Jaber, M; Ravenscroft, P1
Cenci, MA; Lundblad, M; Vaudano, E1
Farrer, MJ; Hulihan, M; Hussey, JM; Krygowska-Wajs, A; Tsuboi, Y; Uitti, RJ; Wszolek, ZK1
Balmaceda, C; Chuang, C; Constantino, A; Eidelberg, D; Frucht, SJ1
Chung, YA; Han, SR; Kim, JS; Lee, KS1
Gerlach, M; Riederer, P1
Bernardi, G; Calabresi, P; Cenci, MA; Centonze, D; Fisone, G; Greengard, P; Håkansson, K; Picconi, B1
Bird, T; Farrer, M; Gancher, S; Gwinn-Hardy, K; Hardy, J; Hussey, J; Lockhart, P; McNeal, MG; Nutt, J; Payami, H; Seltzer, WK; Singleton, AA; Singleton, AB1
Chase, TN; Geller, AI; Oh, JD; Zhang, Gr1
Bari, M; Battista, N; Bernardi, G; Calabresi, P; Centonze, D; Finazzi-Agrò, A; Gubellini, P; Maccarrone, M; Picconi, B1
Hansard, MJ; Jackson, MJ; Jenner, P; Maratos, E; Smith, LA1
Bhatia, KP; Critchley, P; Graham, E; Khan, NL; Lees, AJ; Quinn, N; Schrag, AE; Wood, NW1
Balash, Y; Bartels, AL; Giladi, N; Gurevich, T; Hausdorff, JM; Schaafsma, JD1
Love, R1
Brotchie, JM; Crossman, AR; Engstrom, M; Fox, SH; Hill, M; McGuire, SG; Merivuori, H; Savola, JM; Wurster, S1
Brice, A; Illarioshkin, SN; Ivanova-Smolenskaya, IA; Limborska, SA; Lücking, CB; Markova, ED; Miloserdova, OV; Periquet, M; Rawal, N; Slominsky, PA; Zagorovskaya, TB1
Chassain, C; Durif, F; Eschalier, A2
Iida, Y; Saji, H; Shimazu, S; Takahata, K; Tamashiro, A; Yoneda, F1
Hironishi, M; Kondo, T; Miwa, H; Nakanishi, I1
Culjković, B; Djarmati, A; Dragasević, N; Kostić, VS; Romac, S; Savić, D; Svetel, M1
Bonastre, M; Hirsch, EC; Jimenez, A; Marin, C; Périer, C; Tolosa, E1
Albin, RL; Desmond, TJ; Frey, KA; Kemmerer, ES; Kilbourn, MR1
Landry, E; Lévesque, D; Rouillard, C; St-Hilaire, M1
GERSTENBRAND, F; PATEISKY, K; PROSENZ, P1
BAUMANN, D; UMBACH, W1
HIRSCHMANN, J; MAYER, K1
DIEMATH, HE; ENGE, S; HEPPNER, F; LECHNER, H1
BIRKMAYER, W; HORNYKIEWICZ, O1
Geser, F; Stampfer-Kountchev, M; Tison, F; Wenning, GK1
Jenner, P1
Grossman, RG; Hamilton, WJ; Jankovic, J; Kalhorn, CG; Ondo, WG; Sanghera, MK1
Iravani, MM; Jackson, MJ; Jenner, P; Kuoppamäki, M; Smith, LA1
Avila Cobo, MR; Cardozo, A; Katzenschlager, R; Lees, AJ; Tolosa, E1
Bösch, S; Brenneis, C; Büchel, C; Löscher, WN; Luginger, E; Müller, J; Poewe, W; Schocke, MF; Seppi, K; Wenning, GK1
Liu, HM; Su, PC; Tseng, HM1
Dryhurst, G; Foster, SB; Han, J; Wrona, MZ1
Ceballos-Baumann, A1
Lualdi, MM; Pasetti, C; Pinelli, P1
Komatsu, Y; Matsuda, W; Matsumura, A; Nose, T; Yanaka, K1
Bonastre, M; Bové, J; Jiménez, A; Marin, C; Tolosa, E1
Delfino, MA; Douhou, A; Ferrario, JE; Gershanik, OS; Murer, MG; Raisman-Vozari, R; Stefano, AV; Zbarsky, V1
Hwang, WJ; Ting, G; Wey, SP; Yao, WJ1
Bezard, E; Brotchie, JM; Crossman, AR; Grimée, R; Hill, MP; Klitgaard, H; McGuire, SG; Michel, A1
Carta, AR; Morelli, M; Pinna, A; Tronci, E1
Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L1
Aoyama, S; Bedard, P; Borrelli, E; Chase, TN; Hauser, RA; Ichimura, M; Ikeda, K; Ishii, A; Jenner, P; Kanda, T; Kase, H; Koga, K; Koike, N; Kurokawa, M; Kuwana, Y; Mori, A; Nakamura, J; Nonaka, H; Ochi, M; Richardson, PJ; Saki, M; Shimada, J; Shindou, T; Shiozaki, S; Suzuki, F; Takeda, M; Yanagawa, K1
Bara-Jimenez, W; Bibbiani, F; Chase, TN; Dimitrova, T; Oh-Lee, JD1
Ghil, GS; Joo, WS; Kim, EY; Kim, YS; Lee, YJ; Lim, J; Park, S; Wang, KC1
Brotchie, JM; Chalon, S; Crossman, AR; Ravenscroft, P1
Cheetham, SC; Hansard, MJ; Jackson, MJ; Jenner, P; Smith, LA1
Bruno, MK; Considine, E; Garraux, G; Gwinn-Hardy, K; Hallett, M; Hanson, M; Johnson, J; Ptacek, L; Ravina, B; Singleton, A1
Kase, H; Ochi, M; Shiozaki, S1
Allard, M; Guyot, M; Sibon, I; Tison, F1
De Groote, C; Fischer, G; Jenner, P; Kemp, JA; Klockgether, T; Löschmann, PA; Smith, L; Wüllner, U1
Der, TC; Hagner, D; Joyce, JN; Osredkar, T; Renish, L; Reploge, M; Sakakibara, S; Ueda, S1
Alam, M; Mayerhofer, A; Schmidt, WJ1
Benecke, R; Classen, J; Grossmann, A; Kunesch, E; Wolters, A1
Arai, H; Fujihara, K; Ichinose, H; Itoyama, Y; Kikuchi, A; Kimpara, T; Nagai, M; Okamura, N; Shiga, Y; Takeda, A; Tanji, H; Urano, F1
Barker, RA; Brown, JM; Wilkins, A1
Carter, JH; Nutt, JG; Sexton, GJ1
Bernardi, G; Calabresi, P; Cenci, MA; Centonze, D; Di Luca, M; Gardoni, F; Mauceri, D; Picconi, B1
Brotchie, JM; Crossman, AR; Millan, MJ; Nicholson, SL; Ravenscroft, P; Silverdale, MA1
Bird, TD; Bower, J; Calne, DB; de la Fuente-Fernandez, R; Farrer, M; Furtado, S; Gwinn-Hardy, K; Hanson, M; Hardy, J; Klimek, ML; Lockhart, PJ; Nutt, JG; Payami, H; Singleton, A; Singleton, AA; Stoessl, AJ; Suchowersky, O; Tsuboi, Y; Utti, RJ; Wszolek, ZK1
Brotchie, JM; Crossman, AR; McGuire, S; Menniti, FS; Nash, JE; Ravenscroft, P1
Berciano, J; Combarros, O; Corral, J; Infante, J; Pascual, J; Polo, JM; Volpini, V1
Chen, CM; Lee-Chen, GJ; Tang, LM; Wang, CK; Wang, SC; Wu, YR1
Alam, M; Schmidt, WJ1
Al-Din, A; Lily, O1
Baba, H; Hida, H; Isono, M; Jung, CG; Kobayashi, H; Kodama, Y; Nishino, H1
Asaoka, E; Dohgu, N; Inoue, H; Taguchi, Y; Takashima, S1
Annesi, F; Annesi, G; Bellesi, M; Candiano, IC; Capecci, M; Carrideo, S; Ceravolo, MG; Civitelli, D; De Marco, EV; Iacoangeli, M; Passamonti, L; Provinciali, L; Quattrone, A; Ricciuti, R; Scerrati, M; Tarantino, P; Zappia, M1
Auberson, YP; Greenamyre, JT; Papa, SM1
Antenor, J; Black, KJ; Burkey, A; Esper, GJ; Kotagal, V; Moerlein, SM; Ojemann, JG; Perlmutter, JS; Racette, BA; Videen, TO1
Aubert, I; Barthe, N; Bezard, E; Bioulac, BH; Bloch, B; Dovero, S; Fisone, G; Gross, CE; Guigoni, C; Håkansson, K; Li, Q1
Shinotoh, H1
Birman, S; Coulom, H1
Chang, S; Davis, M; Eunson, L; Graham, E; Horta, W; Johnson, JO; Khan, NL; Lees, AJ; Singleton, A; Wood, NW1
Bielicki, G; Chassain, C; Donnat, JP; Durif, F; Eschalier, A; Renou, JP1
Glöckler, T; Junghanns, S; Reichmann, H1
Akalan, N; Arica, B; Hincal, AA; Kaş, HS; Moghdam, A1
Benovic, JL; Bezard, E; Gross, CE; Gurevich, EV; Gurevich, VV; Qin, L1
Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E1
Amalric, M; Baunez, C; Breysse, N; Turle-Lorenzo, N1
Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Crossman, AR; Dovero, S; Gross, CE; Guigoni, C; Li, Q2
Ardayfio, P; Chesselet, MF; Fleming, SM; Hwang, DY; Kim, H; Kim, KS; Moran-Gates, T; Tarazi, FI1
Birk Møller, L; Diepold, K; Güttler, F; Hougaard, P; Romstad, A; Rostasy, K; Schütz, B; Wilken, B1
Jech, R; Mecír, P; Roth, J; Růzicka, E; Urgosík, D; Vladyka, V; Vymazal, J1
Berendse, HW; Booij, J; Farrer, MJ; Hulihan, MM; Kachergus, JM; Krygowska-Wajs, A; Searcy, JA; Wolters, ECh; Wszolek, ZK1
Chen, L; Di Monte, DA; Langston, JW; Quik, M; Togasaki, DM1
Connell, MA; Emborg, ME; Li, Q; Meglasson, MD; Merchant, K; Simmons, C; Stephenson, DT1
Alvarez, L; Castro, A; Gimenez-Roldan, S; Grandas, F; Hernandez, B; Jenner, P; Linazasoro, G; Luquin, MR; Macias, R; Marin, C; Obeso, JA; Pavon, N; Rodriguez, M; Rodriguez-Oroz, MC; Stochi, F; Tolosa, E; Vaamonde, J; Valldeoriola, F1
Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A1
Bernauer, E; Finsterer, J1
Ding, JH; Hu, G; Liu, SY; Liu, X; Long, Y; Sun, YH; Wang, F; Wang, H; Wu, J; Yang, Y; Yao, HH1
Alvano, A; Battaglia, G; Malaguarnera, M; Raffaele, R; Rampello, L; Vecchio, I1
Bédard, PJ; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R1
Albanese, A; Bellacchio, E; Dallapiccola, B; Elia, AE; Romito, LM; Valente, EM1
al-Din, AS; Hadeed, A; Lees, AJ; Williams, DR; Wreikat, AL1
Bédard, PJ; Di Paolo, T; Grégoire, L; Hadj Tahar, A; Rouillard, C; Samadi, P1
Cha, GH; Cho, KS; Chung, J; Kim, JM; Kim, M; Kim, S; Lee, E; Lee, SB; Park, J1
Brown, AM; Colbran, RJ; Deutch, AY1
Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Dovero, S; Gross, CE; Guigoni, C; Gurevich, EV; Li, Q1
Benabid, AL; Fraix, V; Gentil, M; Krack, P; Pinto, S; Pollak, P; Sauleau, P1
Diguet, E; Fernagut, PO; Ghorayeb, I; Tison, F1
Glavan, G; Zivin, M1
Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M1
Martín, AB; Mendialdua, A; Moratalla, R; Pavón, N1
Hedrich, K; Kann, M; Kis, B; Klein, C; Kömpf, D; Pramstaller, PP; Schwinger, E1
Bhat, V; Weiner, WJ1
Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Miyoshi, K; Ogawa, N1
Obara, K; Ohta, K1
Bédard, PJ; Bélanger, N; Di Paolo, T; Grégoire, L1
Björklund, A; Carlsson, T; Cenci, MA; Kirik, D; Lundblad, M; Winkler, C1
Haapasalo, H; Honkaniemi, J; Kähärä, V; Liimatainen, S; Paetau, A1
Haberkorn, U; Hähnel, S; Krause, M; Meinck, HM1
Goto, S; Kaji, R; Kuratsu, J; Yamada, K1
Cersosimo, MG; Koller, WC1
Brundin, P; Cenci, MA; Lane, EL; Winkler, C1
Aguilar, E; Marin, C; Obeso, JA1
Bédard, PJ; Berthiaume, L; Calon, F; Di Paolo, T; Hadj-Tahar, A; Julien, C; Julien, P; Rajput, AH1
Barthel, H; Hesse, S; Oehlwein, C; Polster, D; Sabri, O; Schwarz, J; Wagner, A1
Annie Hsieh, W; Chen, SY; Chou, YC; Hsin, YL; Lee, CC; Lee, CW; Lee, TW; Lin, SH; Lin, SZ; Su, CF; Yen, PS1
Aguilar, E; Bové, J; Cortés, R; Marin, C; Mengod, G; Serrats, J1
Brundin, P; Popovic, N1
Ahlskog, JE; Josephs, KA; Matsumoto, JY1
Carta, M; Cenci, MA; Fadda, F; Lindgren, HS; Lundblad, M; Stancampiano, R1
Bagetta, V; Bernardi, G; Calabresi, P; Cattabeni, F; Di Luca, M; Gardoni, F; Ghiglieri, V; Picconi, B; Polli, F1
Konitsiotis, S; Tsironis, C1
Aziz, TZ; Jenkinson, N; Nandi, D; Stein, JF1
Linazasoro, G; Magariños, C; Van Blercom, N1
Berry-Kravis, E; Hagerman, PJ; Hagerman, RJ; Hall, DA; Leehey, MA; Rice, CD1
Baraldi, PG; Fenu, S; Morelli, M; Simola, N; Tabrizi, MA1
Bishop, C; Eskow, KL; Kuhn, DM; Park, JY; Taylor, JL; Walker, PD1
Fujiki, N; Sasaki, H; Soma, H; Takei, A; Yabe, I; Yanagihara, T1
Bex, V; Daenen, F; Maertens de Noordhout, A1
Bain, PG; Hensman, DJ1
Carta, AR; Morelli, M; Pinna, A1
Ai, Y; Andersen, AH; Gash, DM; Gerhardt, GA; Hardy, PA; Loveland, A; Zhang, Z1
Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Pires, D; Visanji, NP; Voon, V1
Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Visanji, NP; Voon, V1
Brundin, P; Cenci, MA; Gardi, J; Lindgren, HS; Mohapel, P; Nyengaard, JR; Westin, JE1
Kanzato, N; Murao, H; Nishihira, T; Takara, H1
Aggarwal, A; Bhatt, M; Desai, S; Shah, S; Singh, J; Vaidya, S1
Eusebio, A; Gubellini, P; Kerkerian-Le Goff, L; Melon, C; Oueslati, A; Salin, P1
Giasson, BI; Ischiropoulos, H; Lynch, DR; Mazzulli, JR; Mishizen, AJ; Nagatsu, T; Nakashima, A; Ota, A; Thomas, SA1
Pierce, RC; Soghomonian, JJ; Yamamoto, N1
Ahmed, M; Bohlega, S; Carroll, P; Chishti, MA; Loualich, A; Rogaeva, E; Sato, C; St George-Hyslop, P; Westaway, D1
Battaglia, F; Di Rocco, A; Eidelberg, D; Feigin, AS; Ghilardi, MF; Mattis, P; Silvestri, G1
Caron, MG; Gainetdinov, RR1
Köllensperger, M; Poewe, W; Reindl, M; Stefanova, N; Wenning, GK1
Barker, RA; Kuan, WL; Lin, R; Tyers, P1
Bastia, E; Benn, CL; Cha, JH; Chen, JF; Peterson, TS; Schwarzschild, MA; Xiao, D; Xu, YH1
Jenner, P; Ramsay Croft, N; Rose, S1
Dagostino, P; Katz, J; Soghomonian, JJ; Wang, H1
Muhlack, S; Müller, T; Welnic, J; Woitalla, D1
Gacsalyi, I; Harsing, LG; Juranyi, Z; Levay, G; Marko, B; Megyeri, K; Sziray, N1
Marti, M; Morari, M; Trapella, C; Viaro, R1
Colau, JC; Ha, DE; Legendre, G1
Cenci, MA; Danysz, W; Dekundy, A; Lundblad, M1
Chen, L; Cox, H; Di Monte, DA; Langston, JW; Quik, M; Togasaki, DM1
Bezard, E; Bloch, B; Doudnikoff, E; Guigoni, C; Li, Q1
de Freitas, GR; Fontenelle, LF; Garcia, RF; Mendlowicz, MV; Nazar, BP; Ordacgi, L; Rosso, AL1
Jackson, MJ; Jenner, P; Katzenschlager, R; Lees, AJ; Rose, S; Smith, LA; Stockwell, K; Tayarani-Binazir, KA; Zubair, M1
Finberg, JP; Sader-Mazbar, O1
Abin-Carriquiry, JA; Costa, G; Dajas, F; Ferreira, M; Urbanavicius, J; Wonnacott, S1
Ding, Y; Hwang, DY; Kang, UJ; Kim, KS; Restrepo, J; Won, L1
Carvajal-Gonzalez, S; Childs, MA; Emborg, ME; Li, Q; Meglasson, MD; Merchant, K; Opsahl, A; Stephenson, DT; Tengowski, M1
Chung, EJ; Jeon, MY; Kang, HY; Lee, WY1
Constantinescu, R; Kurlan, R; Richard, I1
Aarsland, D; Boeve, B; Gjerstad, MD; Larsen, JP; Wentzel-Larsen, T1
Damier, P; Meyniel, C1
Choi, JK; Iris Chen, YC; Isacson, O; Jenkins, BG; Sánchez-Pernaute, R1
Kaneda, D; Oyanagi, K; Shintaku, M1
Mosekilde, L; Rejnmark, L; Vestergaard, P1
Calon, F; Di Paolo, T; Dridi, M; Huot, P; Lévesque, M; Morissette, M; Parent, A1
Aalto, S; Chang, JW; Lee, KO; Lee, MS; Lyoo, CH; Oh, SH; Rinne, JO1
Pavanni, R; Tan, EK; Tong, J; Wong, MC; Zhao, Y1
Bédard, PJ; Di Paolo, T; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R1
Guan, Q; He, Y; Tan, L; Zhan, Q1
Cox, H; Di Monte, D; Langston, JW; O'Leary, K; Parameswaran, N; Quik, M1
Ha Paek, S; Jeon, BS; Kim, HJ; Kim, JY1
Dressler, D; Lindemann, C; Miranda, M; Slachevsky, A; Walter, U1
Bédard, PJ; Belanger, N; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M; Samadi, P1
Chen, ST; Chu, YC; Huang, YC; Lyu, RK; Wu, YR1
Binelli, S; Bugiani, O; Capobianco, R; Di Fede, G; Fociani, P; Giaccone, G; Grisoli, M; Limido, L; Mangieri, M; Suardi, S; Tagliavini, F1
Alvarez-Erviti, L; Barroso-Chinea, P; Blesa, FJ; Guridi, J; Lanciego, JL; Obeso, JA; Rodríguez-Oroz, MC; Smith, Y1
Agid, Y; Brice, A; Durr, A; Fraix, V; Houeto, JL; Krack, P; Laine, S; Lesage, S; Lohmann, E; Mesnage, V; Pollak, P; Tanguy, ML; Welter, ML1
Chung, SJ; Ki, CS; Kim, MJ; Lee, MC; Park, HK1
Brotchie, JM; Gomez-Ramirez, J; Johnston, TH; Lee, J; Visanji, N1
Asanuma, M; Diaz-Corrales, FJ; Eslava-Alva, MJ; Higashi, Y; Miyazaki, I; Ogawa, N; Shimizu, M1
Cheetham, S; Jenner, P; Lane, EL1
Maeda, T; Nagata, K; Yoshida, Y1
Muthane, U; Ragothaman, M1
Bordet, R; Derambure, P; Destée, A; Houdayer, E; Jacquesson, JM; Laloux, C; Monaca, C1
Brown, P; Doyle, LM; Lees, AJ; Williams, DR1
Bermejo, PG; Espiga, PJ; López, IC; Tapia, DQ1
Artusi, R; Caselli, G; Lanza, M; Makovec, F; Michotte, Y; Sarre, S1
Kamogawa, K; Kawabata, K; Okamoto, K; Okuda, B; Tachibana, H1
Bezard, E; Brotchie, JM; Fox, SH; Hallett, PJ; Lubin, FD; Nicholas, AP; Ravenscroft, P; Standaert, DG; Sweatt, JD; Vattem, P; Zhou, S1
Bankiewicz, KS; Cummins, A; Eberling, J; Kohutnicka, M; Oiwa, Y; Sanchez-Pernaute, R1
Cenci, MA; Lundblad, M1
Netravathi, M; Pal, PK; Panda, S; Prashantha, DK; Ravishankar, S1
Orta Daniel, SJ; Ulises, RO1
Caslake, R; Counsell, C; Gordon, JC; Harris, CE; Moore, JN1
Abuirmeileh, A; Biggs, CS; Harkavyi, A; Kingsbury, AE; Lever, R; Whitton, PS1
Willis, GL1
Boxer, PA; Gregory, TF; Meltzer, LT; Serpa, KA; Wise, LD; Wright, JL1
Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM1
Andersson, M; Cenci, MA; Hilbertson, A; Tranberg, A1
Andersson, M; Cenci, MA; Hilbertson, A1
Ben-Aire, L; Contant, C; Grossman, R; Jankovic, J; Lai, E; Ondo, WG1
Albanese, A; Colosimo, C; Moro, E; Rossi, P; Tonali, P1
Bonastre, M; Chase, TN; Jimenez, A; Marin, C; Tolosa, E1
Di Monte, DA; He, L; Langston, JW; Police, S; Quik, M1
Bangassoro, E; Bédard, PJ; Bélanger, N; Grégoire, L; Hadj Tahar, A1
Brusa, L; Gasparini, M; Meco, G; Vanacore, N1
Emre, M; Hanağasi, HA; Kaptanoglu, G; Sahin, HA1
Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Doucet, JP; Goulet, M; Grondin, R; Hadj Tahar, A; Morissette, M; Nestler, E; Robertson, GS1
Chase, TN; Oh, JD1
Asanuma, M; Higashi, Y; Miyazaki, I; Nakanishi, T; Ogawa, N; Sogawa, CA; Tanaka, KI1
Ebinger, G; Jonkers, N; Michotte, Y; Sarre, S2
Vingerhoets, F1
Abbruzzese, G; Buccolieri, A; Marchese, R; Trompetto, C1
Cabral, J; Gálvez-Jiménez, N; Hanson, MR1
Discalzi, G; Herrero Hernandez, E; Meliga, F; Pira, E; Turbiglio, M; Valentini, C1
de Rijk-Van Andel, JF; Gabreëls, FJ; Geurtz, B; Smeitink, JA; Steenbergen-Spanjers, GC; van Den Heuvel, LP; Wevers, RA1
Kidd, PM1
Nutt, JG1
Hubble, J; Kieburtz, K1
Bangassoro, E; Bédard, PJ; Ekesbo, A; Grégoire, L; Hadj Tahar, A; Svensson, KA; Tedroff, J1
Mueller, J; Poewe, W; Puschban, Z; Scherfler, C; Seppi, K; Stefanova, N; Wenning, GK1
Hara, A; Matsushita, S; Mita, S; Murakami, T; Nakajima, M; Nakamura, T; Uchino, M; Uyama, E1
Casas, M; Pérez, V; Prat, G; Rubi, A; Unzeta, M1
Linazasoro, G1
Renier, WO; Rondot, P; Steenbergen-Spanjers, GC; Swaans, RJ; Van Den Heuvel, LP; Wevers, RA1
Masson, C1
García de Yébenes, J; Godoy, M; Hoenicka, J; Ochoa, JJ; Vidal, L1
Archer, T; Danysz, W; Fredriksson, A; Quack, G1
Gerlach, M; Kuhn, W; Lehnfeld, R; Riederer, P; Sontag, KH; Waldmeier, P; Xiao, AY1
Konieczny, J; Lorenc-Koci, E; Wardas, J1
Nutt, JG; Nygaard, TG1
Eriksson, B; Holmberg, B; Ingvarsson, P; Johnels, B; Rosengren, L1
Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK1
Carta, A; Fenu, S; Morelli, M1
Ballermann, M; Farr, T; Metz, GA; Whishaw, IQ1
Rajput, AH1
Jankovic, J; Tintner, R1
Brotchie, JM; Crossman, AR; Fox, SH; Henry, B1
Harbord, M1
Becker, G; Beckmann, H; Berg, D; Jabs, B; Merschdorf, U1
Abe, K; Miyatake, T; Ren, J; Sano, T; Shinohara, T; Taguchi, K; Utsunomiya, I; Wasai, T1
Agid, Y; Bonastre, M; Hirsch, EC; Jiménez, A; Marin, C; Tolosa, E; Vila, M1
Charles, KJ; Gray, J; Hunter, AJ; Jenner, P; Medhurst, AD; Reavill, C; Shale, JA; Zeng, BY1
Andersson, M; Cenci, MA; Lundblad, M; Westin, JE1
Boerman, RH; Hoefnagels, WH; Jansen, RW; Mehagnoul-Schipper, DJ1
Groenewegen, HJ; Van De Witte, SV; Voorn, P1
Albanese, A; Bentivoglio, AR; Cortelli, P; Elia, A; Ferraris, A; Ialongo, T; Montagna, P; Valente, EM1
Lee, SJ; Liao, KK; Liu, RS; Shan, DE; Soong, BW; Sun, CM1
Kuroiwa, Y; Momose, T; Okada, M; Yamada, H1
Abaul, J; Caparros-Lefebvre, D; Hocquemiller, R; Lannuzel, A; Michel, PP; Ruberg, M1
Campos, V; García De Yébenes, J; Mena, MA; Meseguer, E; Sánchez, V; Taboada, R1
Evidente, VG; Gwinn-Hardy, K; Hardy, J; Hernandez, D; Singleton, A1
Cebeira, M; de Ceballos, ML; Fernández-Ruiz, JJ; Jenner, P; Lastres-Becker, I; Ramos, JA; Zeng, BY1
Mellgren, SI; Sjøholm, H; Sundsfjord, J1
Mathias, CJ1
Earl, J; Fung, VS; Grattan-Smith, PJ; Steenbergen-Spanjers, GC; Wevers, RA; Wilcken, B1
Finsterer, J1
Cho, JW; Chu, K; Jeon, BS; Song, EC1

Reviews

59 review(s) available for levodopa and Parkinsonian Disorders

ArticleYear
"Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:12

    Topics: Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive; Systematic Reviews as Topic

2021
Parkinsonism and dystonia: Clinical spectrum and diagnostic clues.
    Journal of the neurological sciences, 2022, Feb-15, Volume: 433

    Topics: Animals; Dystonia; Dystonic Disorders; Humans; Levodopa; Movement Disorders; Parkinsonian Disorders

2022
Parkinsonism-Hyperpyrexia Syndrome and Dyskinesia-Hyperpyrexia Syndrome in Parkinson's Disease: Two Cases and Literature Review.
    Journal of Parkinson's disease, 2022, Volume: 12, Issue:6

    Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinson Disease; Parkinsonian Disorders; Syndrome; Tremor

2022
A Review on the Clinical Diagnosis of Multiple System Atrophy.
    Cerebellum (London, England), 2023, Volume: 22, Issue:5

    Topics: Adult; Diagnosis, Differential; Humans; Levodopa; Magnetic Resonance Imaging; Multiple System Atrophy; Parkinsonian Disorders

2023
Autopallidotomy: From Colloquial Term to Scientific Theory.
    Journal of Parkinson's disease, 2022, Volume: 12, Issue:7

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesias; Globus Pallidus; Levodopa; Parkinson Disease; Parkinsonian Disorders

2022
Food toxins and the Caribbean Parkinson plus types.
    Revue neurologique, 2019, Volume: 175, Issue:10

    Topics: Annonaceae; Caribbean Region; Dementia; Drug Resistance; Food; Guadeloupe; Humans; Levodopa; Martinique; Parkinson Disease; Parkinsonian Disorders; Teas, Herbal; West Indies

2019
Evolving concepts on bradykinesia.
    Brain : a journal of neurology, 2020, 03-01, Volume: 143, Issue:3

    Topics: Animals; Humans; Hypokinesia; Levodopa; Neural Pathways; Parkinsonian Disorders

2020
Genotype-phenotype correlations of adult-onset PLA2G6-associated Neurodegeneration: case series and literature review.
    BMC neurology, 2020, Mar-17, Volume: 20, Issue:1

    Topics: Adult; Asian People; Cohort Studies; Female; Genetic Association Studies; Group VI Phospholipases A2; High-Throughput Nucleotide Sequencing; Humans; Levodopa; Male; Middle Aged; Mutation; Neuroaxonal Dystrophies; Parkinson Disease; Parkinsonian Disorders; Phenotype

2020
Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:7

    Topics: Genotype; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Phenotype

2021
Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats

2018
Extrapontine Myelinolysis and Reversible Parkinsonism After Hyponatremia Correction in a Case of Pituitary Adenoma: Hypopituitarism as a Predisposition for Osmotic Demyelination.
    World neurosurgery, 2018, Volume: 118

    Topics: Adenoma; Demyelinating Diseases; Female; Humans; Hydrocortisone; Hyponatremia; Hypopituitarism; Levodopa; Middle Aged; Myelinolysis, Central Pontine; Parkinsonian Disorders; Pituitary Neoplasms; Saline Solution, Hypertonic

2018
Juvenile parkinsonism: Differential diagnosis, genetics, and treatment.
    Parkinsonism & related disorders, 2019, Volume: 67

    Topics: Adolescent; alpha-Synuclein; Antiparkinson Agents; Child; Child, Preschool; Deep Brain Stimulation; Diagnosis, Differential; DiGeorge Syndrome; Dystonic Disorders; Genetic Diseases, X-Linked; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Parkinsonian Disorders; Protein Deglycase DJ-1; Protein Kinases; Spinocerebellar Ataxias; Ubiquitin-Protein Ligases; Young Adult

2019
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.
    Neurotoxicity research, 2014, Volume: 25, Issue:4

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Humans; Levodopa; Mice; Motor Activity; Parkinsonian Disorders; Rats

2014
Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2014, Volume: 35, Issue:5

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Ganglionic Stimulants; Levodopa; Nicotine; Parkinsonian Disorders

2014
[Familial progressive external opthalmoplegia, parkinsonism and polyneuropathy associated with POLG1 mutation].
    Rinsho shinkeigaku = Clinical neurology, 2014, Volume: 54, Issue:5

    Topics: Aged; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Female; Gene Deletion; Genes, Dominant; Humans; Levodopa; Male; Menopause, Premature; Mitochondrial Diseases; Muscular Diseases; Mutation; Ophthalmoplegia, Chronic Progressive External; Parkinsonian Disorders; Pedigree; Polyneuropathies; Syndrome

2014
POLG1-related levodopa-responsive parkinsonism.
    Clinical neurology and neurosurgery, 2014, Volume: 126

    Topics: Aged; Antiparkinson Agents; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Female; Genotype; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinsonian Disorders; Phenotype; Treatment Outcome

2014
Peripheral nervous system involvement in Parkinson's disease: evidence and controversies.
    Parkinsonism & related disorders, 2014, Volume: 20, Issue:12

    Topics: Antiparkinson Agents; Databases, Bibliographic; Humans; Levodopa; Parkinsonian Disorders; Peripheral Nervous System Diseases

2014
Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
    Current neuropharmacology, 2016, Volume: 14, Issue:4

    Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Methylphenidate; Middle Aged; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Selegiline; Treatment Outcome

2016
mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Current neuropharmacology, 2016, Volume: 14, Issue:5

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neostriatum; Parkinsonian Disorders; Receptor, Adenosine A2A; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D2

2016
    Presse medicale (Paris, France : 1983), 2017, Volume: 46, Issue:2 Pt 1

    Topics: Antiparkinson Agents; Articulation Disorders; Corpus Striatum; Deglutition Disorders; Disease Progression; Dopamine Agonists; Dopaminergic Neurons; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Movement; Muscle Hypertonia; Parkinson Disease; Parkinsonian Disorders; Postural Balance; Sensation Disorders; Substantia Nigra; Tremor

2017
Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD.
    Parkinsonism & related disorders, 2008, Volume: 14 Suppl 2

    Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinsonian Disorders; Protein Transport; Receptors, N-Methyl-D-Aspartate; Synapses

2008
Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
    Progress in brain research, 2008, Volume: 172

    Topics: Animals; Clinical Trials as Topic; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Presynaptic Terminals; Protein Isoforms; Receptors, Dopamine; Receptors, Serotonin; Serotonin

2008
[Synthesis of monoamines by non-monoaminergic neurons: illusion or reality?].
    Journal de la Societe de biologie, 2009, Volume: 203, Issue:1

    Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain; Corpus Striatum; Dopamine; Humans; Hypothalamus; Levodopa; Nerve Tissue Proteins; Neurodegenerative Diseases; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Serotonin; Substantia Nigra; Tyrosine; Tyrosine 3-Monooxygenase

2009
Intermittent Dopaminergic stimulation causes behavioral sensitization in the addicted brain and parkinsonism.
    International review of neurobiology, 2009, Volume: 88

    Topics: Amphetamine-Related Disorders; Animals; Brain; Dopamine; Humans; Levodopa; Methamphetamine; Parkinsonian Disorders; Receptors, Dopamine D1; Signal Transduction

2009
Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment.
    Parkinsonism & related disorders, 2009, Volume: 15 Suppl 3

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinsonian Disorders; Polyneuropathies

2009
[Future standards in diagnosing Parkinson syndrome].
    Fortschritte der Neurologie-Psychiatrie, 2010, Volume: 78 Suppl 1

    Topics: Antiparkinson Agents; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Positron-Emission Tomography; Reference Standards; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2010
[Multiple system atrophy].
    Psychologie & neuropsychiatrie du vieillissement, 2010, Volume: 8, Issue:3

    Topics: Aged; Antiparkinson Agents; Atrophy; Brain; Combined Modality Therapy; Cross-Sectional Studies; Humans; Levodopa; Magnetic Resonance Imaging; Multiple System Atrophy; Neurologic Examination; Palliative Care; Parkinsonian Disorders; Physical Therapy Modalities; Prognosis; Survival Rate

2010
Exercise alleviates Parkinsonism: clinical and laboratory evidence.
    Acta neurologica Scandinavica, 2011, Volume: 123, Issue:2

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Exercise; Exercise Therapy; Humans; Levodopa; Neurotoxins; Parkinsonian Disorders; Quality of Life

2011
Levodopa and Parkinson disease--electrophysiological perspectives in animal models.
    Experimental neurology, 2011, Volume: 231, Issue:1

    Topics: Action Potentials; Animals; Female; Levodopa; Neurons; Parkinsonian Disorders; Substantia Nigra; Subthalamic Nucleus

2011
Pallidoreticular lesion in carbon monoxide intoxication by gradient echo: report of a case with parkinsonism features and review of the literature.
    Acta neurologica Taiwanica, 2012, Volume: 21, Issue:1

    Topics: Antiparkinson Agents; Carbon Monoxide Poisoning; Cerebral Cortex; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Organotechnetium Compounds; Parkinsonian Disorders; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Tropanes

2012
Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: case report and review of the literature.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6

    Topics: Adult; Diagnosis, Differential; Drug Therapy, Combination; Humans; Levodopa; Lupus Erythematosus, Systemic; Lupus Vasculitis, Central Nervous System; Male; Methylprednisolone; Neurologic Examination; Parkinsonian Disorders; Prednisolone; Recurrence

2002
The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.
    Cellular and molecular neurobiology, 2002, Volume: 22, Issue:3

    Topics: Animals; Caffeine; Disease Models, Animal; Humans; Levodopa; Memory Disorders; Neurons; Parkinsonian Disorders; Rats; Receptors, Dopamine; Receptors, Purinergic P1; Substantia Nigra

2002
Clinical features and laboratory findings for differentiating parkinsonian syndromes.
    Journal of neurology, 2002, Volume: 249 Suppl 3

    Topics: Diagnosis, Differential; Humans; Levodopa; Parkinsonian Disorders

2002
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
    Neurology, 2003, Sep-23, Volume: 61, Issue:6 Suppl 3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agonists; Drug Resistance; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Primates

2003
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
    MMW Fortschritte der Medizin, 2003, May-26, Volume: 145 Suppl 2

    Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines

2003
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Primates; Purines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine D2

2003
Translating A2A antagonist KW6002 from animal models to parkinsonian patients.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Humans; Levodopa; Macaca fascicularis; Male; Motor Activity; Neurons; Parkinsonian Disorders; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA

2003
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2).
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:6

    Topics: Antiparkinson Agents; Brain; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dystonia; Humans; Levodopa; Magnetic Resonance Imaging; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinsonian Disorders; Posture; Spinocerebellar Ataxias; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tremor

2004
Switching and combining of dopamine agonists.
    Journal of neurology, 2004, Volume: 251 Suppl 6

    Topics: Dopamine Agonists; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Parkinsonian Disorders; Treatment Outcome

2004
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
    Neurologia (Barcelona, Spain), 2005, Volume: 20, Issue:4

    Topics: Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Carbidopa; Catechols; Clinical Trials as Topic; Dopamine; Drug Therapy, Combination; Humans; Hyperhomocysteinemia; Levodopa; MPTP Poisoning; Neuroprotective Agents; Nitriles; Parkinson Disease; Parkinsonian Disorders; Rats; Treatment Outcome

2005
Parkinson's disease. Diagnosis and the initiation of therapy.
    Minerva medica, 2005, Volume: 96, Issue:3

    Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor

2005
L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.
    Journal of neurology, 2005, Volume: 252 Suppl 4

    Topics: Animals; Cell Death; Dopamine; Humans; Levodopa; Mitochondrial Diseases; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders

2005
[Atypical Parkinsonian syndromes, a challenging group of diseases].
    Duodecim; laaketieteellinen aikakauskirja, 2005, Volume: 121, Issue:16

    Topics: Brain; Diagnosis, Differential; Female; Finland; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Parkinsonian Disorders; Prognosis; Risk Factors; Severity of Illness Index; Treatment Failure

2005
The diagnosis of manganese-induced parkinsonism.
    Neurotoxicology, 2006, Volume: 27, Issue:3

    Topics: Adult; Diagnosis, Differential; Dopamine Agents; Humans; Levodopa; Male; Manganese Poisoning; Middle Aged; Parkinsonian Disorders

2006
Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    International journal of pharmaceutics, 2006, May-18, Volume: 314, Issue:2

    Topics: Alzheimer Disease; Animals; Brain; Delayed-Action Preparations; Diffusion; Disease Models, Animal; Drug Carriers; Drug Stability; Humans; Huntington Disease; Levodopa; Microspheres; Nerve Growth Factor; Neurodegenerative Diseases; Neuroprotective Agents; Parkinsonian Disorders; Polymers; Solubility

2006
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?
    Behavioural pharmacology, 2006, Volume: 17, Issue:5-6

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Dopamine Agents; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Motor Skills; Parkinsonian Disorders; Stereotyped Behavior

2006
Levodopa responsiveness in disorders with parkinsonism: a review of the literature.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Nov-15, Volume: 22, Issue:15

    Topics: Antiparkinson Agents; Education, Medical, Continuing; Humans; Levodopa; Parkinsonian Disorders

2007
[Lewy body dementia and Parkinson disease dementia].
    Presse medicale (Paris, France : 1983), 2007, Volume: 36, Issue:10 Pt 2

    Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Dementia; Diagnosis, Differential; Disease Progression; Dopamine Agents; Humans; Iatrogenic Disease; Levodopa; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Parkinsonian Disorders; Phenylcarbamates; Psychotropic Drugs; Rivastigmine; Serotonin Antagonists

2007
L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
    Parkinsonism & related disorders, 2007, Volume: 13 Suppl 3

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders

2007
Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.
    Trends in neurosciences, 2000, Volume: 23, Issue:10 Suppl

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Glutamic Acid; Humans; Levodopa; Models, Neurological; Neurons, Efferent; Parkinsonian Disorders; Phosphotransferases; Receptors, Dopamine; Receptors, Glutamate; Signal Transduction

2000
[Treatment of Parkinsonism: collaboration between the physician and the neurologist].
    Revue medicale de la Suisse romande, 2000, Volume: 120, Issue:9

    Topics: Aged; Antiparkinson Agents; Diagnosis, Differential; Drug Tolerance; Humans; Levodopa; Movement Disorders; Parkinsonian Disorders; Patient Care Team

2000
Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management.
    Alternative medicine review : a journal of clinical therapeutic, 2000, Volume: 5, Issue:6

    Topics: Disease Progression; Electron Transport; Humans; Levodopa; Mitochondria; Neurodegenerative Diseases; Oxidation-Reduction; Parkinson Disease, Secondary; Parkinsonian Disorders

2000
Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
    Neurology, 2000, Volume: 55, Issue:11 Suppl 4

    Topics: Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Parkinsonian Disorders

2000
Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials.
    Neurology, 2000, Volume: 55, Issue:11 Suppl 4

    Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinsonian Disorders; Tolcapone

2000
Parkinsonian symptoms as an initial manifestation in a Japanese patient with acquired immunodeficiency syndrome and Toxoplasma infection.
    Internal medicine (Tokyo, Japan), 2000, Volume: 39, Issue:12

    Topics: AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Carbidopa; Corpus Striatum; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parietal Lobe; Parkinsonian Disorders; Pyrimethamine; Syphilis; Toxoplasmosis, Cerebral

2000
[Physiopathology of parkinsonism and dyskinesias: lessons from surgical observations]].
    Neurologia (Barcelona, Spain), 2001, Volume: 16, Issue:1

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Dyskinesias; Globus Pallidus; Humans; Levodopa; Models, Animal; Models, Neurological; Motor Skills; Neurons; Parkinsonian Disorders; Subthalamic Nucleus; Thalamus

2001
[Parkinson disease: diagnostic and therapeutic criteria].
    Presse medicale (Paris, France : 1983), 2001, Mar-03, Volume: 30, Issue:8

    Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Female; Globus Pallidus; Humans; Indoles; Levodopa; Lewy Body Disease; Lisuride; Male; Mental Status Schedule; Neurosurgery; Parkinson Disease; Parkinsonian Disorders; Piribedil; Psychiatric Status Rating Scales; Serotonin Receptor Agonists; Stereotaxic Techniques; Supranuclear Palsy, Progressive; Surveys and Questionnaires; Thalamus

2001
Dystonia and parkinsonism.
    Parkinsonism & related disorders, 2001, Volume: 8, Issue:2

    Topics: Antiparkinson Agents; Dystonia; Humans; Levodopa; Parkinsonian Disorders; Syndrome

2001
Neurodegeneration, parkinsonian syndromes and autonomic failure.
    Autonomic neuroscience : basic & clinical, 2002, Feb-28, Volume: 96, Issue:1

    Topics: Autonomic Nervous System Diseases; Brain; Cardiovascular Physiological Phenomena; Diagnosis, Differential; Humans; Levodopa; Multiple System Atrophy; Parkinsonian Disorders; Shy-Drager Syndrome; Sympathetic Nervous System

2002

Trials

12 trial(s) available for levodopa and Parkinsonian Disorders

ArticleYear
Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients.
    Acta neurologica Scandinavica, 2014, Volume: 129, Issue:1

    Topics: Action Potentials; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Neural Conduction; Parkinsonian Disorders; Peripheral Nervous System Diseases; Prospective Studies; Reaction Time; Vitamin B 12; Vitamin B 12 Deficiency

2014
Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?
    Movement disorders : official journal of the Movement Disorder Society, 2008, Sep-15, Volume: 23, Issue:12

    Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Pain Threshold; Parkinsonian Disorders; Severity of Illness Index; Time Factors

2008
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Oct-15, Volume: 23, Issue:13

    Topics: Aged; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Dyskinesias; Excitatory Amino Acid Antagonists; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Piperidines; Severity of Illness Index

2008
Longitudinal study of the levodopa motor response in Parkinson's disease: relationship between cognitive decline and motor function.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Dec-15, Volume: 24, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cognition Disorders; Dementia; Disability Evaluation; Dyskinesias; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinsonian Disorders; Statistics, Nonparametric

2009
Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:4

    Topics: Adult; Aged; Animals; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Macaca; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Simvastatin

2013
The dopamine transporter: importance in Parkinson's disease.
    Annals of neurology, 2004, Volume: 55, Issue:6

    Topics: Aged; Analysis of Variance; Blood Pressure; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Routes; Drug Synergism; Dyskinesias; Emotions; Female; Heart Rate; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Methylphenidate; Middle Aged; Motor Activity; Nerve Tissue Proteins; Parkinson Disease; Parkinsonian Disorders; Psychomotor Performance; Time Factors; Walking

2004
Benign tremulous parkinsonism.
    Archives of neurology, 2006, Volume: 63, Issue:3

    Topics: Adult; Aged; Antiparkinson Agents; Essential Tremor; Family Health; Female; Humans; Levodopa; Longitudinal Studies; Male; Medical Records Systems, Computerized; Middle Aged; Parkinsonian Disorders; Treatment Outcome

2006
Laboratory and clinical investigations of the region of the rostral brainstem in motor control.
    Supplements to Clinical neurophysiology, 2006, Volume: 58

    Topics: Animals; Antiparkinson Agents; Bicuculline; Deep Brain Stimulation; Dose-Response Relationship, Radiation; Female; GABA Antagonists; Humans; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Retrospective Studies

2006
L-Dopa infusion does not improve explicit sequence learning in Parkinson's disease.
    Parkinsonism & related disorders, 2007, Volume: 13, Issue:3

    Topics: Analysis of Variance; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinsonian Disorders; Serial Learning; Severity of Illness Index

2007
Acute challenge with apomorphine and levodopa in Parkinsonism.
    European neurology, 2000, Volume: 43, Issue:2

    Topics: Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Sensitivity and Specificity

2000
CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.
    Parkinsonism & related disorders, 2001, Volume: 8, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Diagnosis, Differential; Discriminant Analysis; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Nerve Degeneration; Neurofilament Proteins; Parkinsonian Disorders; Spinal Puncture; Supranuclear Palsy, Progressive

2001
Effect of levodopa on orthostatic and postprandial hypotension in elderly Parkinsonian patients.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2001, Volume: 56, Issue:12

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System; Benserazide; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypotension; Hypotension, Orthostatic; Levodopa; Male; Parkinsonian Disorders; Postprandial Period; Posture; Reference Values

2001

Other Studies

781 other study(ies) available for levodopa and Parkinsonian Disorders

ArticleYear
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
    Journal of medicinal chemistry, 2011, Jun-09, Volume: 54, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease Models, Animal; Dopamine Antagonists; Drug Synergism; Haloperidol; Levodopa; Mice; Mice, Inbred C57BL; Molecular Conformation; Motor Activity; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Neurotransmitter; Stereoisomerism

2011
The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.
    Neurobiology of disease, 2021, Volume: 159

    Topics: Animals; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra; Sympatholytics

2021
PLA2G6 mutations cause motor dysfunction phenotypes of young-onset dystonia-parkinsonism type 14 and can be relieved by DHA treatment in animal models.
    Experimental neurology, 2021, Volume: 346

    Topics: Animals; Docosahexaenoic Acids; Group VI Phospholipases A2; Humans; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Parkinsonian Disorders; Phenotype; Treatment Outcome; Zebrafish

2021
Additive effects of mGluR
    Naunyn-Schmiedeberg's archives of pharmacology, 2021, Volume: 394, Issue:12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bridged Bicyclo Compounds; Callithrix; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Pyridines; Receptors, Metabotropic Glutamate; Serotonin 5-HT2 Receptor Antagonists; Sulfonamides

2021
Evaluation of efficiency omega 3 fatty acid improves the behavioural phenotype and protects against oxidative stress against MPP+ induces Parkinson's disease in mice.
    Pakistan journal of pharmaceutical sciences, 2021, Volume: 34, Issue:3

    Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Behavior, Animal; Catalase; Fatty Acids, Omega-3; Freezing Reaction, Cataleptic; Frontal Lobe; Glutathione; Glutathione Peroxidase; Levodopa; Male; Mesencephalon; Mice; Open Field Test; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances

2021
How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?
    Parkinsonism & related disorders, 2021, Volume: 92

    Topics: Aged; Diagnosis, Differential; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Symptom Assessment; Time Factors; Tremor

2021
Disruption of mitochondrial complex I induces progressive parkinsonism.
    Nature, 2021, Volume: 599, Issue:7886

    Topics: Animals; Axons; Cell Death; Dendrites; Disease Models, Animal; Disease Progression; Dopamine; Dopaminergic Neurons; Electron Transport Complex I; Female; Levodopa; Male; Mice; Motor Skills; NADH Dehydrogenase; Parkinsonian Disorders; Phenotype; Substantia Nigra

2021
Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease.
    Experimental neurology, 2022, Volume: 347

    Topics: Animals; Antiparkinson Agents; Callithrix; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Ligands; Parkinsonian Disorders; Primates; Protein Structure, Secondary; Quinpirole; Receptors, Dopamine D3

2022
Modulation of dopamine tone induces frequency shifts in cortico-basal ganglia beta oscillations.
    Nature communications, 2021, 12-02, Volume: 12, Issue:1

    Topics: Action Potentials; Animals; Basal Ganglia; Beta Rhythm; Carbidopa; Cerebral Cortex; Chlorocebus aethiops; Dopamine; Electrodes, Implanted; Eye-Tracking Technology; Female; Humans; Levodopa; Magnetic Resonance Imaging; Nerve Net; Organic Chemicals; Parkinson Disease; Parkinsonian Disorders; Pupil; Stereotaxic Techniques

2021
Spinocerebellar ataxia type 3: response to levodopa infusion in two cases.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:5

    Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Machado-Joseph Disease; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders

2022
Radiation-induced Brain Calcification Leads to L-dopa-resistant Parkinsonism and Cerebellar Ataxia.
    Internal medicine (Tokyo, Japan), 2022, Dec-15, Volume: 61, Issue:24

    Topics: Brain; Calcinosis; Cerebellar Ataxia; Corpus Striatum; Female; Humans; Levodopa; Neurodegenerative Diseases; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon

2022
L-Dopa response, choreic dyskinesia, and dystonia in Perry syndrome.
    Parkinsonism & related disorders, 2022, Volume: 100

    Topics: Antiparkinson Agents; Depression; Dyskinesia, Drug-Induced; Dystonia; Dystonic Disorders; Humans; Hypoventilation; Levodopa; Parkinson Disease; Parkinsonian Disorders

2022
Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy.
    Parkinsonism & related disorders, 2022, Volume: 101

    Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Levodopa; Magnetic Resonance Imaging; Multimodal Imaging; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive

2022
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
    European journal of pharmacology, 2022, Aug-15, Volume: 929

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine Plasma Membrane Transport Proteins; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats; Sulfones

2022
A case of Lewy body disease and anaplastic astrocytoma presenting with atypical parkinsonism.
    Neuropathology : official journal of the Japanese Society of Neuropathology, 2022, Volume: 42, Issue:6

    Topics: Humans; Levodopa; Lewy Body Disease; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders

2022
Long-term efficacy of bilateral subthalamic deep brain stimulation in the parkinsonism of SCA 3: A rare case report.
    European journal of neurology, 2022, Volume: 29, Issue:8

    Topics: Deep Brain Stimulation; Humans; Levodopa; Machado-Joseph Disease; Male; Parkinsonian Disorders; Subthalamic Nucleus; Treatment Outcome

2022
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
    Neuropharmacology, 2022, 11-01, Volume: 218

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats

2022
Amino acid transporter Asc-1 (SLC7A10) expression is altered in basal ganglia in experimental Parkinsonism and L-dopa-induced dyskinesia model mice.
    Journal of chemical neuroanatomy, 2023, Volume: 127

    Topics: Amino Acid Transport System ASC; Amino Acid Transport System y+; Animals; Basal Ganglia; Dopamine; Dyskinesias; Levodopa; Mice; Parkinson Disease; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Serine

2023
Deep brain stimulation in dopa-responsive parkinsonism - Look out for red flags.
    Parkinsonism & related disorders, 2023, Volume: 110

    Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinsonian Disorders

2023
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
    Cells, 2022, 11-08, Volume: 11, Issue:22

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine; Levodopa; Macaca fascicularis; Neuroprotective Agents; Parkinsonian Disorders; Pilot Projects; Prodrugs; Receptors, N-Methyl-D-Aspartate

2022
Parkinson disease primer, part 1: diagnosis.
    Canadian family physician Medecin de famille canadien, 2023, Volume: 69, Issue:1

    Topics: Canada; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Patients

2023
Striatal Subregion-selective Dysregulated Dopamine Receptor-mediated Intracellular Signaling in a Model of DOPA-responsive Dystonia.
    Neuroscience, 2023, 05-01, Volume: 517

    Topics: Animals; Corpus Striatum; Dopamine; Dopamine Antagonists; Dystonia; Extracellular Signal-Regulated MAP Kinases; Levodopa; Mice; Parkinsonian Disorders; Receptors, Dopamine D1

2023
The Dynamics of Dopamine D
    Neuroscience bulletin, 2023, Volume: 39, Issue:9

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Receptors, Dopamine D2

2023
Hemiatrophy-hemiparkinsonism and Poland syndrome: A causative or coincidental association?
    Parkinsonism & related disorders, 2023, Volume: 110

    Topics: Atrophy; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Poland Syndrome

2023
Glycine receptor antibody associated stiff person syndrome with nigrostriatal dopamine loss and levodopa responsiveness.
    Parkinsonism & related disorders, 2023, Volume: 111

    Topics: Dopamine; Humans; Levodopa; Parkinsonian Disorders; Receptors, Glycine; Stiff-Person Syndrome

2023
7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate.
    Open biology, 2023, Volume: 13, Issue:5

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Parkinsonian Disorders; Primates; Quality of Life

2023
Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit.
    Brain : a journal of neurology, 2023, Dec-01, Volume: 146, Issue:12

    Topics: alpha-Synuclein; Animals; Cognition; Dopamine; Dopaminergic Neurons; Hippocampus; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Parkinsonian Disorders; Pramipexole; Rats

2023
Levodopa responsive asymmetric parkinsonism as clinical presentation of progranulin gene mutation.
    Journal of the neurological sciences, 2023, 08-15, Volume: 451

    Topics: Humans; Levodopa; Mutation; Parkinsonian Disorders; Phenotype; Progranulins

2023
Effect of the mGlu
    Psychopharmacology, 2023, Volume: 240, Issue:10

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Parkinsonian Disorders; Psychotic Disorders; Rats

2023
Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions.
    International journal of molecular sciences, 2023, Jul-31, Volume: 24, Issue:15

    Topics: Animals; Antiparkinson Agents; Brain Stem; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats

2023
Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia.
    Cell reports. Medicine, 2023, 10-17, Volume: 4, Issue:10

    Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders

2023
Novel RAB39B variant associated intellectual disability and levodopa-responsive young-onset parkinsonism.
    Parkinsonism & related disorders, 2023, Volume: 116

    Topics: Adult; Child; Humans; Intellectual Disability; Levodopa; Male; Mutation; Parkinson Disease; Parkinsonian Disorders

2023
Stress-induced phospho-ubiquitin formation causes parkin degradation.
    Scientific reports, 2019, 08-12, Volume: 9, Issue:1

    Topics: Animals; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell Differentiation; Cell Line, Tumor; Embryo, Mammalian; Gene Expression Regulation; Humans; Hydrogen Peroxide; Levodopa; Models, Biological; Neurons; Parkinsonian Disorders; PC12 Cells; Phosphorylation; Primary Cell Culture; Proteasome Endopeptidase Complex; Protein Kinases; Proteolysis; Rats; Ubiquitin; Ubiquitin-Protein Ligases

2019
Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
    Experimental neurology, 2019, Volume: 322

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus

2019
Cytosolic non-vesicular dopamine accumulation as the predominant mechanism for developing non-DOPA responsive parkinsonism in late-stage Huntington disease.
    Medical hypotheses, 2019, Volume: 132

    Topics: Animals; Calcium; Corpus Striatum; Disease Progression; Dopamine; Humans; Huntington Disease; Levodopa; Mitochondria; Movement; Movement Disorders; Neurotransmitter Agents; Parkinsonian Disorders

2019
Levodopa-responsive parkinsonism in a patient with corticobasal degeneration and bilateral choroid plexus xanthogranulomas.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2020, Volume: 71

    Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Choroid Plexus; Granuloma; Humans; Hydrocephalus; Levodopa; Male; Parkinsonian Disorders; Xanthomatosis

2020
Experimental study of antiparkinsonian action of the harmine hydrochloride original compound.
    Pharmacological reports : PR, 2019, Volume: 71, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catalepsy; Haloperidol; Harmine; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Rats

2019
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
    Neuropharmacology, 2020, 01-01, Volume: 162

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; GABAergic Neurons; Glutamic Acid; Levodopa; Locomotion; Male; Medial Forebrain Bundle; Mice; Mice, Knockout; Movement; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Receptors, G-Protein-Coupled; RNA, Messenger; Serotonin; Tacrine; Tremor

2020
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.
    Neurobiology of disease, 2020, Volume: 134

    Topics: Amantadine; Animals; Antiparkinson Agents; Camphanes; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Pyrazoles; Receptor, Cannabinoid, CB2

2020
Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia.
    Neuroscience, 2020, 01-01, Volume: 424

    Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Motor Disorders; Oxidopamine; Parkinsonian Disorders; Tapentadol

2020
The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson's disease in mice.
    Behavioural brain research, 2020, 02-03, Volume: 379

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Inflammation; Levodopa; Male; Mice; Mice, Inbred BALB C; Nerve Degeneration; Parkinson Disease; Parkinsonian Disorders; Sesquiterpenes

2020
Which Scale Best Detects Treatment Response of Tremor in Parkinsonism?
    Journal of Parkinson's disease, 2020, Volume: 10, Issue:1

    Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinsonian Disorders; Sensitivity and Specificity; Severity of Illness Index; Tremor

2020
Transient parkinsonism associated with acute Legionnaires' disease.
    BMJ case reports, 2020, Jan-07, Volume: 13, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Antiparkinson Agents; Carbidopa; Ciprofloxacin; Drug Combinations; Drug Therapy, Combination; Dysarthria; Humans; Legionella; Legionnaires' Disease; Levodopa; Male; Parkinsonian Disorders; Respiratory Insufficiency

2020
Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy.
    Neurobiology of disease, 2020, Volume: 137

    Topics: Animals; Brain; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Globus Pallidus; Levodopa; Male; Neostriatum; Parkinsonian Disorders; Rats, Wistar

2020
    Pharmaceutical development and technology, 2020, Volume: 25, Issue:6

    Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Brain; Drug Delivery Systems; Drug Evaluation, Preclinical; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Nanoparticles; Parkinsonian Disorders; PC12 Cells; Rats

2020
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
    Neuropharmacology, 2020, 06-15, Volume: 170

    Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; Glutamic Acid; Levodopa; Male; Nerve Net; Organ Culture Techniques; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar

2020
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
    Pharmacological reports : PR, 2020, Volume: 72, Issue:2

    Topics: Administration, Oral; Amantadine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats, Sprague-Dawley

2020
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
    Neurobiology of disease, 2020, Volume: 139

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Infusions, Intraventricular; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pilot Projects

2020
The Bologna motor and non-motor prospective study on parkinsonism at onset (BoProPark): study design and population.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020, Volume: 41, Issue:9

    Topics: Aged; Humans; Levodopa; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders; Prospective Studies

2020
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2020, 04-29, Volume: 40, Issue:18

    Topics: Aged; Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred F344; Rats, Inbred Lew; Rats, Sprague-Dawley

2020
Dopamine, a key factor of mitochondrial damage and neuronal toxicity on rotenone exposure and also parkinsonic motor dysfunction-Impact of asiaticoside with a probable vesicular involvement.
    Journal of chemical neuroanatomy, 2020, Volume: 106

    Topics: Animals; Antiparkinson Agents; bcl-2-Associated X Protein; Cell Death; Corpus Striatum; Dopamine; Dopaminergic Neurons; Levodopa; Neuronal Outgrowth; Neuroprotective Agents; Parkinsonian Disorders; PC12 Cells; Proto-Oncogene Proteins c-bcl-2; Rats; Rotenone; Triterpenes

2020
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
    The Journal of clinical investigation, 2020, 05-01, Volume: 130, Issue:5

    Topics: Amantadine; Animals; Antiparkinson Agents; CHO Cells; Corpus Striatum; Cricetulus; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Parkinson Disease; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Receptors, N-Methyl-D-Aspartate; Synaptic Potentials

2020
Synergistic action of propolis with levodopa in the management of Parkinsonism in Drosophila melanogaster.
    Journal of complementary & integrative medicine, 2020, Sep-23, Volume: 17, Issue:3

    Topics: Animals; Antioxidants; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Drug Synergism; Drug Therapy, Combination; Ethanol; Levodopa; Longevity; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Plant Extracts; Propolis; Protein Serine-Threonine Kinases

2020
Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.
    Experimental neurology, 2020, Volume: 330

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Genotype; Levodopa; Male; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinsonian Disorders; Phenotype; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred F344; Rats, Inbred Lew

2020
Deep brain stimulation-guided optogenetic rescue of parkinsonian symptoms.
    Nature communications, 2020, 05-13, Volume: 11, Issue:1

    Topics: Algorithms; Animals; Antiparkinson Agents; Deep Brain Stimulation; Disease Models, Animal; Electrophysiological Phenomena; Female; Humans; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Motor Cortex; Optogenetics; Oxidopamine; Parkinsonian Disorders; Pyramidal Cells; Somatostatin; Subthalamic Nucleus

2020
Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms.
    Medical science monitor : international medical journal of experimental and clinical research, 2020, Jun-19, Volume: 26

    Topics: Animals; Behavior, Animal; Cistanche; Cornus; Corpus Striatum; Dioscorea; Disease Models, Animal; Dopaminergic Neurons; Drugs, Chinese Herbal; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Fallopia multiflora; Forelimb; Levodopa; Medial Forebrain Bundle; Mesencephalon; Open Field Test; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rehmannia

2020
GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming.
    Neurobiology of disease, 2020, Volume: 143

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Neuronal Plasticity; Neurons; Parkinsonian Disorders; Rats; Rats, Wistar; Synaptic Transmission

2020
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
    Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders

2020
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
    Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Psychoses, Substance-Induced

2020
Caffeine reduces deficits in mechanosensation and locomotion induced by L-DOPA and protects dopaminergic neurons in a transgenic
    Pharmaceutical biology, 2020, Volume: 58, Issue:1

    Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Caenorhabditis elegans; Caffeine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Levodopa; Locomotion; Neuroprotective Agents; Parkinsonian Disorders

2020
Characteristics of Patients with Late-Stage Parkinsonism Who are Nursing Home Residents Compared with those Living at Home.
    Journal of the American Medical Directors Association, 2021, Volume: 22, Issue:2

    Topics: Cross-Sectional Studies; Humans; Levodopa; Nursing Homes; Parkinson Disease; Parkinsonian Disorders

2021
Dramatic Response to Pramipexole in Delayed-Onset Parkinsonism from Osmotic Demyelinating Syndrome.
    Tremor and other hyperkinetic movements (New York, N.Y.), 2020, 06-16, Volume: 10

    Topics: Adult; Antiparkinson Agents; Deamino Arginine Vasopressin; Demyelinating Diseases; Dystonia; Epistaxis; Hemostatics; Humans; Hyponatremia; Levodopa; Locked-In Syndrome; Male; Myelinolysis, Central Pontine; Osmotic Pressure; Parkinsonian Disorders; Postoperative Hemorrhage; Pramipexole; Pseudobulbar Palsy; Rhinoplasty; Tetrahydronaphthalenes; Thiophenes; Treatment Failure; Treatment Outcome; von Willebrand Disease, Type 1

2020
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
    Neurobiology of disease, 2020, Volume: 144

    Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Muscarinic Antagonists; Neostriatum; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Substantia Nigra; Sympatholytics

2020
The selective 5-HT
    Parkinsonism & related disorders, 2020, Volume: 78

    Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Serotonin 5-HT1 Receptor Agonists

2020
Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Movement disorders : official journal of the Movement Disorder Society, 2020, Volume: 35, Issue:10

    Topics: Atrophy; Humans; Levodopa; Multiple System Atrophy; Parkinsonian Disorders

2020
Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy.
    Brain : a journal of neurology, 2020, 12-05, Volume: 143, Issue:11

    Topics: Age of Onset; Aged; Animals; Antiparkinson Agents; Cell Line; Chromosome Aberrations; Drosophila; Electron Transport Complex III; Exome Sequencing; Female; Frameshift Mutation; Gene Knock-In Techniques; Genes, Dominant; Humans; Levodopa; Male; Mice; Middle Aged; Mitochondria; Mutation; Parkinsonian Disorders; Pedigree; Polyneuropathies

2020
Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    European journal of pharmacology, 2021, Feb-05, Volume: 892

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catechol O-Methyltransferase Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Erythrocytes; Female; Levodopa; Locomotion; Macaca fascicularis; Oxadiazoles; Parkinsonian Disorders; Time Factors

2021
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease.
    Progress in neuro-psychopharmacology & biological psychiatry, 2021, 06-08, Volume: 108

    Topics: Affect; Animals; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Ultrasonic Waves; Vocalization, Animal

2021
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:4

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats

2021
Is Levodopa Response a Valid Indicator of Parkinson's Disease?
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:4

    Topics: Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive

2021
L-DOPA regulates α-synuclein accumulation in experimental parkinsonism.
    Neuropathology and applied neurobiology, 2021, Volume: 47, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Dopamine Agents; Female; Levodopa; Macaca mulatta; Neurons; Parkinsonian Disorders

2021
D
    European journal of pharmacology, 2021, Feb-05, Volume: 892

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Bromocriptine; Chlorocebus aethiops; Disease Models, Animal; Dopamine Agonists; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2

2021
Early-onset parkinsonism in PPP2R5D-related neurodevelopmental disorder.
    European journal of medical genetics, 2021, Volume: 64, Issue:1

    Topics: Age of Onset; Antiparkinson Agents; Corpus Striatum; Female; Humans; Levodopa; Mutation, Missense; Parkinsonian Disorders; Phenotype; Protein Phosphatase 2; Young Adult

2021
Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat.
    Behavioural pharmacology, 2021, 02-01, Volume: 32, Issue:1

    Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Granisetron; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin 5-HT3 Receptor Antagonists

2021
Involvement of Autophagy in Levodopa-Induced Dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:5

    Topics: Animals; Antiparkinson Agents; Autophagy; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders

2021
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2021, 04-01, Volume: 320, Issue:4

    Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dyskinesia, Drug-Induced; Exercise Therapy; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Mice, Inbred C57BL; Motor Activity; Neuronal Plasticity; Parkinsonian Disorders; Running; Time Factors

2021
Subcortical and brainstem hemiatrophy accompanied by iron deposition in a patient with hemiparkinsonism-hemiatrophy syndrome: a case report.
    BMC neurology, 2021, Feb-03, Volume: 21, Issue:1

    Topics: Antiparkinson Agents; Atrophy; Brain; Functional Laterality; Humans; Iron; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Young Adult

2021
Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort.
    Journal of Parkinson's disease, 2021, Volume: 11, Issue:2

    Topics: Antiparkinson Agents; Diagnosis, Differential; Humans; Levodopa; Parkinsonian Disorders; Prospective Studies

2021
Levodopa affects spike and local field synchronisation in the pedunculopontine nucleus of a rat model of Parkinson's disease.
    Aging, 2021, 02-26, Volume: 13, Issue:5

    Topics: Action Potentials; Animals; Disease Models, Animal; Dopaminergic Neurons; Levodopa; Locomotion; Male; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar

2021
Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.
    Experimental neurology, 2021, Volume: 340

    Topics: Analgesics; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gamma Rhythm; Ketamine; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2021
Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.
    Neurotoxicity research, 2021, Volume: 39, Issue:3

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation Mediators; Interferon-gamma; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders

2021
GCH1 mutations in hereditary spastic paraplegia.
    Clinical genetics, 2021, Volume: 100, Issue:1

    Topics: Adult; Canada; Child; Female; GTP Cyclohydrolase; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Pedigree; Phenotype; Spastic Paraplegia, Hereditary; Twins, Monozygotic

2021
Early-Onset Parkinsonism and Early-Onset Parkinson's Disease: A Population-Based Study (2010-2015).
    Journal of Parkinson's disease, 2021, Volume: 11, Issue:3

    Topics: Adult; Age of Onset; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders

2021
A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys.
    Pharmacology, biochemistry, and behavior, 2021, Volume: 205

    Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Male; Motivation; Motor Activity; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases

2021
Pediatric autoimmune Parkinsonism and response to deep brain stimulation.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2022, Volume: 38, Issue:1

    Topics: Adolescent; Child; Deep Brain Stimulation; Female; Globus Pallidus; Humans; Levodopa; Parkinsonian Disorders; Treatment Outcome; Tremor

2022
Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:4

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders

2021
Reply to: "Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism".
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:4

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders

2021
Early suspicion of progressive supranuclear palsy using dopamine transporter imaging: an illustrative case presenting with levodopa-responsive parkinsonism.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:8

    Topics: Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive

2021
Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus.
    Neurology, 2021, 06-08, Volume: 96, Issue:23

    Topics: Aged; Aged, 80 and over; Cerebrospinal Fluid Shunts; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Hydrocephalus, Normal Pressure; Levodopa; Male; Neostriatum; Outcome Assessment, Health Care; Parkinsonian Disorders; Phenotype; Postural Balance; Tomography, Emission-Computed, Single-Photon

2021
Older-onset levodopa-responsive parkinsonism with normal DAT-SPECT and pterin hypometabolism.
    BMJ case reports, 2021, May-07, Volume: 14, Issue:5

    Topics: Adult; Aged; Dopamine Plasma Membrane Transport Proteins; GTP Cyclohydrolase; Humans; Levodopa; Parkinsonian Disorders; Pterins; Tomography, Emission-Computed, Single-Photon

2021
Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.
    Naunyn-Schmiedeberg's archives of pharmacology, 2021, Volume: 394, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Female; Levodopa; Male; Parkinsonian Disorders; Psychotic Disorders

2021
The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
    Experimental neurology, 2021, Volume: 342

    Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Growth Factor

2021
Locomotor activity and resting local field potential oscillatory rhythms of 6-OHDA mouse model of Parkinson's disease in response to acute and repeated treatments with L-dopa.
    Neuroscience letters, 2021, 08-10, Volume: 759

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Locomotion; Male; Membrane Potentials; Mice; Mice, Inbred ICR; Parkinsonian Disorders

2021
Subregion-Specific Regulation of Dopamine D1 Receptor Signaling in the Striatum: Implication for L-DOPA-Induced Dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2021, 07-28, Volume: 41, Issue:30

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Receptors, Dopamine D1; Signal Transduction

2021
Discrimination of idiopathic Parkinson's disease and vascular parkinsonism based on gait time series and the levodopa effect.
    Journal of biomechanics, 2021, 08-26, Volume: 125

    Topics: Antiparkinson Agents; Gait; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders

2021
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
    Neuropharmacology, 2021, 09-15, Volume: 196

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate Nucleus; Dyskinesia, Drug-Induced; Glial Fibrillary Acidic Protein; Interleukin-10; Interleukin-1beta; Levodopa; Microfilament Proteins; Neuroinflammatory Diseases; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Piperazines; Putamen; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Agonists; Triazoles; Tumor Necrosis Factor-alpha

2021
Pediatric Gaucher disease with intermediate type 2-3 phenotype associated with parkinsonian features and levodopa responsiveness.
    Parkinsonism & related disorders, 2021, Volume: 91

    Topics: Antiparkinson Agents; Child, Preschool; Diseases in Twins; Female; Gaucher Disease; Humans; Infant; Levodopa; Male; Parkinsonian Disorders; Phenotype; Twins

2021
Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
    Neurobiology of disease, 2017, Volume: 102

    Topics: Animals; Antiparkinson Agents; Armadillo Domain Proteins; Catechol O-Methyltransferase; Cell Adhesion Molecules; Corpus Striatum; Disease Models, Animal; Disease Susceptibility; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphoproteins; Proto-Oncogene Proteins c-fos; Serotonin; Thioredoxin Reductase 2

2017
Parkinson's patients can rely on perspective cues to perceive 3D space.
    Brain research, 2017, 05-15, Volume: 1663

    Topics: Aged; Aged, 80 and over; Cues; Depth Perception; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Photic Stimulation; Vision, Binocular; Vision, Monocular; Visual Cortex; Visual Perception

2017
A polysomnographic study in parkinsonian patients treated with intestinal levodopa infusion.
    Journal of neurology, 2017, Volume: 264, Issue:6

    Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinsonian Disorders; Polysomnography; Severity of Illness Index; Sleep Wake Disorders; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome

2017
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
    Neuropharmacology, 2017, Sep-01, Volume: 123

    Topics: Acetylcholine; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Choline O-Acetyltransferase; Colon; Gastrointestinal Transit; Inflammation; Interleukin-1beta; Levodopa; Male; Muscle, Smooth; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Synaptic Transmission; Tissue Culture Techniques; Tumor Necrosis Factor-alpha

2017
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
    Acta pharmacologica Sinica, 2017, Volume: 38, Issue:10

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline

2017
Chronic asymmetric tremor and levodopa-responsive parkinsonism due to a vein of Galen aneurysmal malformation.
    Parkinsonism & related disorders, 2017, Volume: 43

    Topics: Antiparkinson Agents; Chronic Disease; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Tremor; Vein of Galen Malformations

2017
Choreiform dyskinesias following levodopa treatment of parkinsonism due to osmotic demyelination syndrome.
    Parkinsonism & related disorders, 2017, Volume: 43

    Topics: Aged; Antiparkinson Agents; Demyelinating Diseases; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Osmosis; Parkinsonian Disorders

2017
β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 94

    Topics: Allylbenzene Derivatives; Animals; Anisoles; Antiparkinson Agents; Behavior, Animal; Benserazide; Catechol O-Methyltransferase; Corpus Striatum; Dopa Decarboxylase; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Drug Combinations; Drug Therapy, Combination; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2017
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.
    Neurobiology of disease, 2017, Volume: 108

    Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca mulatta; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Post-Synaptic Density; Protein Binding; Rabphilin-3A; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses; Tissue Culture Techniques; Vesicular Transport Proteins

2017
Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study.
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2017, Volume: 128, Issue:10

    Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Pain; Pain Measurement; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive

2017
Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
    BMC complementary and alternative medicine, 2017, Sep-06, Volume: 17, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; Gynostemma; Levodopa; Male; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Plant Extracts; Spatial Memory

2017
DNAJC12 and dopa-responsive nonprogressive parkinsonism.
    Annals of neurology, 2017, Volume: 82, Issue:4

    Topics: Adult; alpha-Synuclein; Amyloid beta-Peptides; Antiparkinson Agents; Biogenic Amines; Brain; DNA Mutational Analysis; DNA-Binding Proteins; Family Health; Female; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Phenylalanine; Repressor Proteins; Sequestosome-1 Protein; tau Proteins; Young Adult

2017
Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism.
    Experimental neurology, 2017, Volume: 298, Issue:Pt A

    Topics: Animals; Apomorphine; Basal Ganglia; Cerebral Cortex; Dose-Response Relationship, Drug; Levodopa; Male; Nerve Net; Neurons; Parkinsonian Disorders; Rats; Rats, Wistar

2017
Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice.
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:12

    Topics: Aging; Analysis of Variance; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine beta-Hydroxylase; Dopamine Plasma Membrane Transport Proteins; Dystonic Disorders; Female; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Parkinsonian Disorders; Tyrosine 3-Monooxygenase

2017
Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine.
    Behavioural pharmacology, 2017, Volume: 28, Issue:8

    Topics: Animals; Apomorphine; Area Under Curve; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relationship, Drug; Immunohistochemistry; Levodopa; Male; Methamphetamine; Motor Activity; Oxidopamine; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase

2017
Biallelic mutations in mitochondrial tryptophanyl-tRNA synthetase cause Levodopa-responsive infantile-onset Parkinsonism.
    Clinical genetics, 2018, Volume: 93, Issue:3

    Topics: Adolescent; Age of Onset; Alleles; Biopsy; DNA Mutational Analysis; Fibroblasts; Genetic Association Studies; Genotype; Humans; Levodopa; Magnetic Resonance Imaging; Male; Mutation; Parkinsonian Disorders; Phenotype; Polymorphism, Single Nucleotide; Precision Medicine; Tryptophan-tRNA Ligase

2018
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Neuropharmacology, 2018, 03-15, Volume: 131

    Topics: Adrenergic Agents; Analgesics, Opioid; Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Guinea Pigs; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Movement; Narcotic Antagonists; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Vas Deferens

2018
SPG7 with parkinsonism responsive to levodopa and dopaminergic deficit.
    Parkinsonism & related disorders, 2018, Volume: 47

    Topics: ATPases Associated with Diverse Cellular Activities; Brain; Dopamine; Dopamine Agents; Female; Humans; Levodopa; Metalloendopeptidases; Middle Aged; Organotechnetium Compounds; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Tropanes

2018
Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:9

    Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Callithrix; Disorders of Excessive Somnolence; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Parkinsonian Disorders; Serotonin Receptor Agonists; Trazodone

2018
Cortical stimulation relieves parkinsonian pathological activity in vitro.
    The European journal of neuroscience, 2019, Volume: 49, Issue:6

    Topics: Animals; Corpus Striatum; Dopamine; Levodopa; Mice; Neurons; Oxidopamine; Parkinsonian Disorders

2019
Zonisamide for DLB parkinsonism: An old drug used in a new context.
    Neurology, 2018, 02-20, Volume: 90, Issue:8

    Topics: Double-Blind Method; Humans; Levodopa; Lewy Body Disease; Parkinsonian Disorders; Zonisamide

2018
Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1.
    Physiology & behavior, 2018, 05-01, Volume: 188

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Glucagon-Like Peptide 1; Levodopa; Linagliptin; Mice; Mice, Inbred BALB C; NF-kappa B; Parkinsonian Disorders; Toll-Like Receptor 4; Transforming Growth Factor beta1

2018
Quantitative Analysis of Catecholamines in the Pink1 -/- Rat Model of Early-onset Parkinson's Disease.
    Neuroscience, 2018, 05-21, Volume: 379

    Topics: Animals; Antiparkinson Agents; Brain; Catecholamines; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Protein Kinases; Rats, Long-Evans; Rats, Transgenic; RNA, Messenger; Ultrasonics; Vocalization, Animal

2018
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Behavioural brain research, 2018, 07-16, Volume: 347

    Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors

2018
Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease.
    Experimental neurology, 2018, Volume: 304

    Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Gene Knockout Techniques; Levodopa; Mice; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinsonian Disorders; Rats

2018
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
    Behavioural brain research, 2018, 07-16, Volume: 347

    Topics: Animals; Antiparkinson Agents; Apomorphine; Arachidonic Acids; Biomarkers; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Endocannabinoids; Glycerides; Levodopa; Male; Metabolome; Metabolomics; Motor Activity; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; Rats, Sprague-Dawley

2018
Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
    Neurotoxicity research, 2018, Volume: 34, Issue:4

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation; Levodopa; Male; Nociceptive Pain; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Rats, Wistar

2018
Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease.
    Pakistan journal of pharmaceutical sciences, 2018, Volume: 31, Issue:2

    Topics: Animals; Brain; Carbidopa; Catalepsy; Chlorpromazine; Disease Models, Animal; Drug Combinations; Hydrogen-Ion Concentration; Levodopa; Parkinsonian Disorders; Rats; Water

2018
Restorative effect of l-Dopa treatment against Ochratoxin A induced neurotoxicity.
    Neurochemistry international, 2018, Volume: 118

    Topics: Animals; Antiparkinson Agents; Carcinogens; Levodopa; Male; Mice; Mice, Inbred BALB C; Motor Activity; Ochratoxins; Parkinsonian Disorders; Random Allocation; Treatment Outcome

2018
Haloperidol-induced parkinsonism is attenuated by varenicline in mice.
    Journal of basic and clinical physiology and pharmacology, 2018, Jul-26, Volume: 29, Issue:4

    Topics: Animals; Catalepsy; Disease Models, Animal; Dopamine; Female; Haloperidol; Levodopa; Male; Mice; Neurons; Parkinsonian Disorders; Varenicline

2018
Diametric neural ensemble dynamics in parkinsonian and dyskinetic states.
    Nature, 2018, Volume: 557, Issue:7704

    Topics: Animals; Calcium Signaling; Dopamine; Dyskinesias; Female; Levodopa; Male; Mice; Models, Biological; Movement; Neostriatum; Neurons; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D2

2018
Zinc and linoleic acid pre-treatment attenuates biochemical and histological changes in the midbrain of rats with rotenone-induced Parkinsonism.
    BMC neuroscience, 2018, 05-09, Volume: 19, Issue:1

    Topics: Animals; Antioxidants; Disease Models, Animal; Female; Glutathione; Levodopa; Linoleic Acid; Lipid Peroxidation; Parkinsonian Disorders; Rats, Wistar; Rotenone; Zinc

2018
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:10

    Topics: Administration, Inhalation; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Green Fluorescent Proteins; Levodopa; Mice; Mice, Transgenic; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; Rats; Sensation Disorders; Sympatholytics; Time Factors; Xenon

2018
Osmotic Demyelination Syndrome With Evolving Movement Disorders.
    JAMA neurology, 2018, 07-01, Volume: 75, Issue:7

    Topics: Acute Disease; Adult; Akinetic Mutism; Athetosis; Benserazide; Chorea; Demyelinating Diseases; Dopamine Agents; Drug Combinations; Fluid Therapy; Gastroenteritis; Humans; Hyponatremia; Levodopa; Male; Myelinolysis, Central Pontine; Parkinsonian Disorders; Saline Solution; Time Factors

2018
Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia.
    Cell reports, 2018, 06-19, Volume: 23, Issue:12

    Topics: Action Potentials; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Neurons; Optogenetics; Parkinsonian Disorders; Receptors, Dopamine

2018
Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Neuropharmacology, 2018, Volume: 138

    Topics: Amphetamine; Animals; Antiparkinson Agents; Brain; Central Nervous System Stimulants; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Functional Laterality; Levodopa; Male; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neurodegenerative Diseases; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine; Receptors, Nicotinic; RNA, Messenger

2018
Jaw tremor: a manifestation of vascular parkinsonism? - a case report.
    BMC neurology, 2018, Jun-30, Volume: 18, Issue:1

    Topics: Aged; Brain; Female; Humans; Levodopa; Parkinsonian Disorders; Tremor; Vascular Diseases

2018
Expanding the Spectrum of Dopa-Responsive Dystonia (DRD) and Proposal for New Definition: DRD, DRD-plus, and DRD Look-alike.
    Journal of Korean medical science, 2018, Jul-09, Volume: 33, Issue:28

    Topics: Carrier Proteins; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dystonic Disorders; Group VI Phospholipases A2; Humans; Levodopa; Mitochondrial Proteins; Molecular Chaperones; Parkinsonian Disorders; Proteins

2018
Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:9

    Topics: Anacardic Acids; Animals; Antiparkinson Agents; Curcumin; Cytoskeletal Proteins; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Fos-Related Antigen-2; Gene Expression Regulation; Histone Acetyltransferases; Histone Code; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Specific Pathogen-Free Organisms; Substantia Nigra; Terpenes

2018
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
    Naunyn-Schmiedeberg's archives of pharmacology, 2018, Volume: 391, Issue:12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychoses, Substance-Induced; Triazoles

2018
Modulation of Beta Bursts in the Subthalamic Nucleus Predicts Motor Performance.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2018, 10-10, Volume: 38, Issue:41

    Topics: Aged; Antiparkinson Agents; Beta Rhythm; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinsonian Disorders; Psychomotor Performance; Subthalamic Nucleus

2018
An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:10

    Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Positron-Emission Tomography; Receptors, Metabotropic Glutamate; Time Factors

2018
Severe acute colitis related to levodopa treatment.
    Pathologica, 2018, Volume: 110, Issue:1

    Topics: Acute Disease; Aged, 80 and over; Antiparkinson Agents; Colitis; Colon; Colonoscopy; Humans; Levodopa; Male; Parkinsonian Disorders; Treatment Outcome

2018
Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
    Neurochemistry international, 2018, Volume: 121

    Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Drug Interactions; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Substantia Nigra

2018
Dramatic improvement by levodopa treatment in a patient with vascular parkinsonism.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2019, Volume: 40, Issue:2

    Topics: Antiparkinson Agents; Brain; Cerebrovascular Disorders; Diagnosis, Differential; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders

2019
SPG11-related parkinsonism: Clinical profile, molecular imaging and l-dopa response.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:10

    Topics: Adult; Antiparkinson Agents; Brain; Cognition Disorders; Cohort Studies; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Mutation; Neuropsychological Tests; Organotechnetium Compounds; Parkinsonian Disorders; Proteins; Single-Blind Method; Statistics, Nonparametric; Tomography Scanners, X-Ray Computed; Tomography, Emission-Computed, Single-Photon; Tropanes; Young Adult

2018
Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson's Disease.
    Neuron, 2018, 10-10, Volume: 100, Issue:1

    Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation, Missense; Neurons; Parkinsonian Disorders; Protein Conformation

2018
Treatment response in osmotic demyelination syndrome presenting as severe parkinsonism, ptosis and gaze palsy.
    BMJ case reports, 2018, Oct-21, Volume: 2018

    Topics: Blepharoptosis; Diagnosis, Differential; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Myelinolysis, Central Pontine; Parkinsonian Disorders; Syndrome

2018
A case of Perry Syndrome responding to intestinal infusion of carbidopa/levodopa.
    Parkinsonism & related disorders, 2019, Volume: 61

    Topics: Antiparkinson Agents; Carbidopa; Depression; Drug Combinations; Female; Gels; Humans; Hypoventilation; Infusions, Parenteral; Jejunostomy; Levodopa; Middle Aged; Parkinsonian Disorders

2019
Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:12

    Topics: Aged; Antiparkinson Agents; Diabetes Complications; Diabetes Mellitus; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Parkinsonian Disorders

2018
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:11

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Time Factors; Vilazodone Hydrochloride

2018
Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation.
    BMC neuroscience, 2018, Nov-29, Volume: 19, Issue:1

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Brain-Derived Neurotrophic Factor; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Furans; Levodopa; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Quinuclidines; Random Allocation

2018
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
    Neurochemistry international, 2019, Volume: 124

    Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinsonian Disorders; Treatment Outcome; Zonisamide

2019
Differential Expression of Striatal ΔFosB mRNA and FosB mRNA After Different Levodopa Treatment Regimens in a Rat Model of Parkinson's Disease.
    Neurotoxicity research, 2019, Volume: 35, Issue:3

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Functional Laterality; Gene Expression; Levodopa; Male; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats, Sprague-Dawley; RNA, Messenger; Time Factors

2019
Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
    Neurotoxicity research, 2019, Volume: 35, Issue:3

    Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Levodopa; Liraglutide; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Random Allocation; Rats, Wistar; Rotenone; Sitagliptin Phosphate

2019
Craniocervical dystonia with levodopa-responsive parkinsonism co-segregating with a pathogenic ANO3 mutation in a Taiwanese family.
    Parkinsonism & related disorders, 2019, Volume: 62

    Topics: Anoctamins; Cervical Vertebrae; Dystonia; Female; Genetic Variation; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Pedigree; Skull; Taiwan; Young Adult

2019
Spike and Local Field Synchronization Between the Pedunculopontine Nucleus and Primary Motor Cortex in a Rat Model of Parkinson's Disease.
    Neuroscience, 2019, 04-15, Volume: 404

    Topics: Action Potentials; Animals; Disease Models, Animal; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar

2019
Striatal spreading depolarization: Possible implication in levodopa-induced dyskinetic-like behavior.
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiparkinson Agents; Corpus Striatum; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Neurons; Nitrogen Mustard Compounds; Parkinsonian Disorders; Prednisolone; Procarbazine; Rats; Rats, Wistar; Synaptic Transmission; Vincristine

2019
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
    BMC neuroscience, 2019, Feb-13, Volume: 20, Issue:1

    Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Random Allocation; Treatment Failure

2019
Fact-finding survey on diagnostic procedures and therapeutic interventions for parkinsonism accompanying dementia with Lewy bodies.
    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2019, Volume: 19, Issue:4

    Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Lewy Body Disease; Middle Aged; Muscle Rigidity; Neurologists; Parkinsonian Disorders; Physicians; Postural Balance; Psychiatry; Psychotropic Drugs; Tremor

2019
Parkinsonism Caused by Viral Encephalitis Affecting the Bilateral Substantia Nigra.
    Clinical neuroradiology, 2019, Volume: 29, Issue:3

    Topics: Acyclovir; Benserazide; Drug Combinations; Drug Therapy, Combination; Encephalitis, Viral; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Substantia Nigra; Young Adult

2019
Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.
    British journal of pharmacology, 2019, Volume: 176, Issue:13

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Lasers; Levodopa; Mice, Inbred C57BL; Optogenetics; Oxidopamine; Parkinsonian Disorders; Photic Stimulation; Substantia Nigra

2019
Baicalein enhances the effect of low dose Levodopa on the gait deficits and protects dopaminergic neurons in experimental Parkinsonism.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2019, Volume: 64

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopaminergic Neurons; Flavanones; Gait; Levodopa; Male; Mice; Neuroprotective Agents; Parkinsonian Disorders; Plant Extracts; Scutellaria baicalensis

2019
Late-onset presentation of POLG1-associated mitochondrial disease.
    BMJ case reports, 2019, Mar-31, Volume: 12, Issue:3

    Topics: Age of Onset; Aged; Antiparkinson Agents; Blepharoptosis; Disease Progression; DNA Polymerase gamma; Humans; Levodopa; Male; Mitochondrial Diseases; Ophthalmoplegia, Chronic Progressive External; Parkinsonian Disorders; Point Mutation; Treatment Outcome

2019
Multiple system atrophy mimicked by multi-organ pathology.
    Practical neurology, 2019, Volume: 19, Issue:4

    Topics: Aged; Diagnosis, Differential; Humans; Levodopa; Male; Multiple Organ Failure; Multiple System Atrophy; Parkinsonian Disorders

2019
Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:6

    Topics: Animals; Dopamine Agents; Eating; Feeding Behavior; Food Preferences; Levodopa; Long-Term Potentiation; Male; Nucleus Accumbens; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Weight Gain

2019
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:5

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Calcium Channels; Disease Models, Animal; Dyskinesia, Drug-Induced; Green Fluorescent Proteins; Levodopa; Luminescent Agents; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; RNA Interference; RNA, Small Interfering; Substantia Nigra; Tyrosine 3-Monooxygenase

2019
Brain state-dependent alterations of corticostriatal synchronized oscillations in awake and anesthetized parkinsonian rats.
    Brain research, 2019, 08-15, Volume: 1717

    Topics: Anesthesia; Animals; Basal Ganglia; Beta Rhythm; Brain; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Motor Cortex; Neural Pathways; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Wakefulness

2019
Acute parkinsonism as an unexpected consequence of pituitary adenoma resection: A case report.
    Medicine, 2019, Volume: 98, Issue:17

    Topics: Adenoma; Adult; Carbidopa; Drug Combinations; Female; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Myelinolysis, Central Pontine; Parkinsonian Disorders; Pituitary Neoplasms

2019
l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model.
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:8

    Topics: Animals; Antiparkinson Agents; Conditioning, Psychological; Disease Models, Animal; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Macaca; Parkinsonian Disorders

2019
Video-based assessments of the hind limb stepping in a mouse model of hemi-parkinsonism.
    Neuroscience research, 2020, Volume: 154

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Gait; Hindlimb; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Tyrosine 3-Monooxygenase

2020
Gait stride-to-stride variability and foot clearance pattern analysis in Idiopathic Parkinson's Disease and Vascular Parkinsonism.
    Journal of biomechanics, 2019, Jul-19, Volume: 92

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Foot; Gait Disorders, Neurologic; Humans; Kinetics; Levodopa; Longitudinal Studies; Male; Parkinsonian Disorders; Walking

2019
Residual signs of dopa-responsive dystonia with GCH1 mutation following levodopa treatment are uncommon in Korean patients.
    Parkinsonism & related disorders, 2019, Volume: 65

    Topics: Adolescent; Adult; Child; Child, Preschool; Dopamine Agents; Dystonic Disorders; Female; GTP Cyclohydrolase; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Republic of Korea; Young Adult

2019
Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease.
    Brain : a journal of neurology, 2019, Aug-01, Volume: 142, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dependovirus; Drug Evaluation, Preclinical; Female; Genes, Reporter; Genes, Synthetic; Genetic Vectors; GTP Cyclohydrolase; Humans; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Proof of Concept Study; Putamen; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Tyrosine 3-Monooxygenase

2019
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:5

    Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Treatment Outcome

2013
Parkinsonism is a late, not rare, feature of CADASIL: a study on Italian patients carrying the R1006C mutation.
    Stroke, 2013, Volume: 44, Issue:4

    Topics: Aged; Brain; CADASIL; Exons; Female; Genetic Predisposition to Disease; Humans; Italy; Leukoencephalopathies; Levodopa; Magnetic Resonance Imaging; Male; Mutation; Parkinsonian Disorders; Receptor, Notch3; Receptors, Notch; Tomography, Emission-Computed, Single-Photon

2013
Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Archives of pharmacal research, 2013, Volume: 36, Issue:6

    Topics: Animals; Antiparkinson Agents; Berberine; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Levodopa; Male; Neurons; Neurotoxicity Syndromes; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors

2013
Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Neuroscience, 2013, Jul-23, Volume: 243

    Topics: Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Physical Conditioning, Animal

2013
The effect of dopamine on MPTP-induced rotarod disability.
    Neuroscience letters, 2013, May-24, Volume: 543

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Receptors, Dopamine D1; Rotarod Performance Test; Time Factors

2013
Transcortical motor aphasia and unilateral parkinsonism in a case of hyperostosis frontalis.
    Neurology, 2013, Apr-16, Volume: 80, Issue:16

    Topics: Aged; Antiparkinson Agents; Aphasia, Broca; Dopamine Antagonists; Female; Functional Laterality; Handwriting; Humans; Hyperostosis Frontalis Interna; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Speech Disorders; Tiapride Hydrochloride

2013
Degradation of stored movement representations in the Parkinsonian brain and the impact of levodopa.
    Neuropsychologia, 2013, Volume: 51, Issue:7

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Brain; Female; Humans; Imaging, Three-Dimensional; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Oxygen; Parkinsonian Disorders; Photic Stimulation; Reaction Time; Severity of Illness Index

2013
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
    Molecular neurodegeneration, 2013, Apr-26, Volume: 8

    Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion; Disease Models, Animal; Immunohistochemistry; Levodopa; Mood Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Rats; Rats, Wistar

2013
The K(V)7.2/3 preferring channel opener ICA 27243 attenuates L-DOPA-induced dyskinesia in hemiparkinsonian rats.
    Neuroscience letters, 2013, Jun-17, Volume: 545

    Topics: Animals; Benzamides; Dyskinesia, Drug-Induced; Female; Ion Channel Gating; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Levodopa; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Treatment Outcome

2013
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Neuropharmacology, 2013, Volume: 73

    Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes

2013
L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Biological psychiatry, 2014, May-01, Volume: 75, Issue:9

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Cerebral Cortex; Corpus Striatum; Dendritic Spines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Membrane Potentials; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2

2014
Transplantation of melanocytes obtained from the skin ameliorates apomorphine-induced abnormal behavior in rodent hemi-parkinsonian models.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Dopamine; Immunohistochemistry; Levodopa; Melanocytes; Mice; Monophenol Monooxygenase; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation

2013
Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism.
    Human mutation, 2013, Volume: 34, Issue:9

    Topics: Adolescent; Adult; Age of Onset; Auxilins; Child; Cognition Disorders; Consanguinity; Dystonia; Exome; Female; Genes, Recessive; Genetic Variation; Homozygote; Humans; Italy; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Pedigree; Phosphoric Monoester Hydrolases; Radiography; Sequence Analysis, DNA; Young Adult

2013
Commentary.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:9

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinsonian Disorders; Substantia Nigra

2013
Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:9

    Topics: Aged; Antiparkinson Agents; Craniocerebral Trauma; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Radiography; Substantia Nigra; Tomography Scanners, X-Ray Computed

2013
Therapeutic response to pramipexole in a patient with multiple system atrophy with predominant parkinsonism: positron emission tomography and pharmacokinetic assessments.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:15

    Topics: Antiparkinson Agents; Benzothiazoles; Brain; Comorbidity; Dose-Response Relationship, Drug; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Treatment Outcome

2013
The discriminating properties of an optoelectronic movement analysis method in patients with parkinsonism.
    Journal of motor behavior, 2013, Volume: 45, Issue:5

    Topics: Aged; Antiparkinson Agents; Diagnosis, Differential; Female; Humans; Levodopa; Linear Models; Logistic Models; Male; Middle Aged; Movement; Multiple System Atrophy; Parkinsonian Disorders; Posture; Reproducibility of Results; ROC Curve; Supranuclear Palsy, Progressive

2013
5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Neurobiology of disease, 2013, Volume: 60

    Topics: 5-Hydroxytryptophan; Adrenergic Agents; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin

2013
Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
    Experimental neurology, 2013, Volume: 250

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Synergism; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders; Pyridines; Rats; Receptor, Metabotropic Glutamate 5; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptors, Dopamine D1; Serotonin Receptor Agonists; Thiazoles

2013
Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Neurobiology of disease, 2014, Volume: 62

    Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Neural Pathways; Parkinsonian Disorders; Positron-Emission Tomography; Substantia Nigra

2014
Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine.
    Brain research, 2013, Dec-06, Volume: 1541

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Blotting, Western; Immunohistochemistry; Levodopa; Male; Molsidomine; NADPH Dehydrogenase; Neurons; Nitric Oxide Donors; Nitric Oxide Synthase Type I; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Subthalamic Nucleus

2013
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Neurobiology of disease, 2014, Volume: 62

    Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Mesencephalon; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Serotonin Receptor Agonists

2014
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
    Neuroscience research, 2013, Volume: 77, Issue:4

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists

2013
Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.
    Experimental neurology, 2013, Volume: 250

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; In Situ Hybridization; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus

2013
Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia.
    Neurobiology of disease, 2014, Volume: 62

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; Globus Pallidus; Levodopa; Macaca mulatta; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Putamen; Tachykinins

2014
D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
    Neurobiology of disease, 2014, Volume: 63

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Electrocardiography; Electroencephalography; Electromyography; Female; Levodopa; Macaca fascicularis; Macaca mulatta; Parkinsonian Disorders; Quinpirole; Sleep; Sleep Disorders, Circadian Rhythm; Telemetry; Time Factors; Wakefulness

2014
An 85-year old male with levodopa-responsive parkinsonism followed by dementia and supranuclear ophthalmoplegia caused by alzheimer-type pathology without Lewy bodies.
    Journal of Alzheimer's disease : JAD, 2014, Volume: 39, Issue:3

    Topics: Aged, 80 and over; Alzheimer Disease; Amphetamine; Dementia; Humans; Imaging, Three-Dimensional; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Radiopharmaceuticals; Supranuclear Palsy, Progressive; Tomography, Emission-Computed, Single-Photon

2014
L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.
    Neuropharmacology, 2014, Volume: 79

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Caudate Nucleus; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Levodopa; Macaca fascicularis; Male; Parkinsonian Disorders; Putamen; Receptor, Adenosine A2A; Receptor, Cannabinoid, CB1; Receptors, Dopamine D2

2014
Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
    Neuropharmacology, 2014, Volume: 79

    Topics: Animals; Antiparkinson Agents; Cell Count; Cell Survival; Dopamine Agents; Dopaminergic Neurons; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Neural Stem Cells; Neurogenesis; Neuroprotective Agents; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Selegiline

2014
Thalamic stimulation alleviates levodopa-resistant rigidity in a patient with non-Parkinson's disease parkinsonian syndrome.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2014, Volume: 21, Issue:5

    Topics: Aged; Deep Brain Stimulation; Humans; Levodopa; Male; Muscle Rigidity; Parkinsonian Disorders; Thalamus

2014
Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
    Neuropharmacology, 2014, Volume: 79

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Buspirone; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Mitogen-Activated Protein Kinase 1; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Severity of Illness Index; Signal Transduction

2014
Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study.
    Schizophrenia research, 2014, Volume: 152, Issue:2-3

    Topics: Adult; Age Factors; Aged; Chi-Square Distribution; Disease Progression; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinsonian Disorders; Predictive Value of Tests; Protein Binding; Schizophrenia; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Tropanes

2014
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
    Neurobiology of disease, 2014, Volume: 64

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Benserazide; Benzothiazoles; Corpus Striatum; Hippocampus; Levodopa; Male; Motor Activity; Neurogenesis; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Substantia Nigra; Time Factors

2014
Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Drug design, development and therapy, 2013, Volume: 7

    Topics: Animals; Antiparkinson Agents; Arrestins; Behavior, Animal; beta-Arrestins; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Dyskinesia, Drug-Induced; Female; G-Protein-Coupled Receptor Kinases; Immunohistochemistry; Levodopa; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2013
Parkinsonian syndrome and ataxia as a presenting finding of acquired hepatocerebral degeneration.
    Metabolic brain disease, 2014, Volume: 29, Issue:1

    Topics: Antiparkinson Agents; Ataxia; Atrophy; Brain; Diagnosis, Differential; Female; Hepatic Encephalopathy; Humans; Levodopa; Liver Cirrhosis, Alcoholic; Magnetic Resonance Imaging; Middle Aged; Parkinsonian Disorders; Wine

2014
Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Neurobiology of disease, 2014, Volume: 64

    Topics: Animals; Antiparkinson Agents; Dendritic Spines; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Motor Cortex; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Pyramidal Cells; Rats; Rats, Wistar; Telencephalon

2014
Asymmetric postural tremor preceding DOPA-responsive Parkinsonism - the transition disease.
    Journal of Parkinson's disease, 2014, Volume: 4, Issue:1

    Topics: Aged; Brain; Disease Progression; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Posture; Prospective Studies; Tremor

2014
Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
    Pharmacological reports : PR, 2013, Volume: 65, Issue:5

    Topics: Animals; Antioxidants; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Carbidopa; Catalase; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Glutathione Peroxidase; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Melatonin; Mice; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase

2013
The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.
    Psychopharmacology, 2014, Volume: 231, Issue:12

    Topics: Animals; Anti-Bacterial Agents; Antiparkinson Agents; Ceftriaxone; Central Nervous System Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Forelimb; Kainic Acid; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Long-Evans

2014
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
    Experimental neurology, 2014, Volume: 253

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Cannabinoid Receptor Antagonists; Cholinesterase Inhibitors; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Rimonabant; Tacrine; Time Factors; Tremor

2014
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
    Neuropharmacology, 2014, Volume: 82

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzodioxoles; Callithrix; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Mental Disorders; Methylamines; Molecular Structure; Motor Activity; Parkinsonian Disorders; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors

2014
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Neuropharmacology, 2014, Volume: 79

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Macaca fascicularis; MAP Kinase Signaling System; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger

2014
Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014, Feb-19, Volume: 34, Issue:8

    Topics: Adenoviridae; Animals; Antiparkinson Agents; Behavior, Animal; Denervation; Diphtheria Toxin; DNA, Complementary; Dyskinesia, Drug-Induced; Hydroxydopamines; Image Processing, Computer-Assisted; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neostriatum; Parasympathetic Nervous System; Parkinsonian Disorders

2014
The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
    Parkinsonism & related disorders, 2014, Volume: 20, Issue:5

    Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Time Factors; Tryptophan; Tyrosine 3-Monooxygenase

2014
Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
    BMC complementary and alternative medicine, 2014, Mar-20, Volume: 14

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Gastrodia; Levodopa; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos

2014
Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets.
    Journal of pharmacological sciences, 2014, Volume: 124, Issue:4

    Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Drug Synergism; Dyskinesias; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Purines

2014
Walther Birkmayer, Co-describer of L-Dopa, and his Nazi connections: victim or perpetrator?
    Journal of the history of the neurosciences, 2014, Volume: 23, Issue:2

    Topics: Austria; History, 20th Century; Humans; Levodopa; National Socialism; Neurology; Nobel Prize; Parkinsonian Disorders; Pharmacology; World War II

2014
Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys.
    Molecular neurobiology, 2014, Volume: 50, Issue:3

    Topics: Animals; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Levodopa; Macaca fascicularis; Male; Parkinsonian Disorders; Phosphorylation; Putamen; Receptors, Dopamine; Signal Transduction

2014
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
    Zebrafish, 2014, Volume: 11, Issue:3

    Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, Animal; Drug Combinations; Levodopa; Minocycline; Motor Activity; Oxidopamine; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Sympatholytics; Vitamin E; Zebrafish; Zebrafish Proteins

2014
Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson's disease model.
    International journal of molecular sciences, 2014, Apr-09, Volume: 15, Issue:4

    Topics: Aluminum; Animals; Cell Line; Cell Survival; Homovanillic Acid; Hydroxides; Levodopa; Nanocomposites; Nanoconjugates; Nanoparticles; Parkinsonian Disorders; PC12 Cells; Rats; Zinc

2014
Effects of gypenosides on anxiety disorders in MPTP-lesioned mouse model of Parkinson's disease.
    Brain research, 2014, Jun-03, Volume: 1567

    Topics: Animals; Anti-Anxiety Agents; Antiparkinson Agents; Anxiety Disorders; Behavior, Animal; Brain; Dopamine; Dopaminergic Neurons; Ethanol; Gynostemma; Levodopa; Male; Maze Learning; Mice, Inbred C57BL; Neuroprotective Agents; Neuropsychological Tests; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Serotonin; Water

2014
Noradrenergic terminals regulate L-DOPA-derived dopamine extracellular levels in a region-dependent manner in Parkinsonian rats.
    CNS neuroscience & therapeutics, 2014, Volume: 20, Issue:7

    Topics: Adrenergic Neurons; Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Extracellular Fluid; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2014
Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
    Biological psychiatry, 2015, Jan-15, Volume: 77, Issue:2

    Topics: Animals; Antiparkinson Agents; Butadienes; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Mice, Knockout; Neuronal Plasticity; Neurons; Nitriles; Oxidopamine; Parkinsonian Disorders; Protein Kinase Inhibitors; ras-GRF1; Tissue Culture Techniques

2015
Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome.
    Neurology, 2014, Jun-17, Volume: 82, Issue:24

    Topics: Antiparkinson Agents; Epilepsies, Myoclonic; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinsonian Disorders; Sensation Disorders; Statistics, Nonparametric; Videotape Recording

2014
Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
    Biological psychiatry, 2015, Jan-15, Volume: 77, Issue:2

    Topics: Acetylation; Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Endorphins; Histones; Immunohistochemistry; Kv Channel-Interacting Proteins; Levodopa; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, AMPA; Repressor Proteins; Rotarod Performance Test

2015
NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
    Neuropharmacology, 2014, Volume: 85

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Extracellular Space; Functional Laterality; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus

2014
Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
    Life sciences, 2014, Aug-06, Volume: 110, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechol O-Methyltransferase; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Male; Methylation; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Parkinsonian Disorders; Time Factors

2014
RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Neurobiology of disease, 2014, Volume: 70

    Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Gene Expression; Genetic Therapy; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RGS Proteins; RNA, Messenger; Up-Regulation

2014
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism.
    Brain structure & function, 2015, Volume: 220, Issue:5

    Topics: Animals; Basal Ganglia; Cannabinoids; Levodopa; Macaca; Male; Neurons; Parkinsonian Disorders; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2

2015
Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014, Jul-02, Volume: 34, Issue:27

    Topics: Animals; Benserazide; Cholinergic Neurons; Diphtheria Toxin; Drug Combinations; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Muscle Tonus; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Polysomnography; Recombinant Fusion Proteins; Sleep Deprivation; Sleep Disorders, Intrinsic; Sleep, REM; Urotensins; Wakefulness

2014
Cortico-striatal-thalamic network functional connectivity in hemiparkinsonism.
    Neurobiology of aging, 2014, Volume: 35, Issue:11

    Topics: Aged; Corpus Striatum; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinsonian Disorders; Temporal Lobe; Thalamus

2014
[Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
    Eksperimental'naia i klinicheskaia farmakologiia, 2014, Volume: 77, Issue:5

    Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats

2014
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
    Progress in neuro-psychopharmacology & biological psychiatry, 2015, Jan-02, Volume: 56

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Homovanillic Acid; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Protein Binding; Pyridines; Serotonin

2015
l-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via β-adrenergic receptors.
    Experimental neurology, 2014, Volume: 261

    Topics: Animals; Antiparkinson Agents; Benzazepines; Dentate Gyrus; Disease Models, Animal; Dopamine; Dopamine Antagonists; Electric Stimulation; Functional Laterality; Levodopa; Long-Term Synaptic Depression; Male; Microdialysis; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Sulpiride

2014
Functional correlates of exaggerated oscillatory activity in basal ganglia output in hemiparkinsonian rats.
    Experimental neurology, 2014, Volume: 261

    Topics: Action Potentials; Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Brain Waves; Disease Models, Animal; Dopamine Antagonists; Functional Laterality; Levodopa; Male; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyridines; Rats; Rats, Long-Evans; Salicylamides; Serotonin Antagonists; Substantia Nigra

2014
Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014, Aug-27, Volume: 34, Issue:35

    Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Antiparkinson Agents; Blotting, Western; Disease Models, Animal; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction

2014
A new quantitative rating scale for dyskinesia in nonhuman primates.
    Behavioural pharmacology, 2015, Volume: 26, Issue:1-2

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Macaca mulatta; Male; Observer Variation; Parkinsonian Disorders; Reproducibility of Results; Severity of Illness Index; Video Recording

2015
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.
    Neurobiology of disease, 2014, Volume: 71

    Topics: Animals; Animals, Newborn; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Functional Laterality; Green Fluorescent Proteins; In Vitro Techniques; Levodopa; Mice; Mice, Transgenic; Neural Pathways; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Purinergic Agents; Receptor, Adenosine A2A; Receptors, Dopamine D1

2014
Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:13

    Topics: Aged; Aged, 80 and over; Brain; Carbon Isotopes; Dopamine Agents; Family Health; Fluorodeoxyglucose F18; Humans; Levodopa; Middle Aged; Molecular Chaperones; Mutation; Parkinsonian Disorders; Positron-Emission Tomography; Tetrabenazine

2014
Dopamine signaling leads to loss of Polycomb repression and aberrant gene activation in experimental parkinsonism.
    PLoS genetics, 2014, Volume: 10, Issue:9

    Topics: Animals; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Gene Expression Regulation; Genetic Loci; Histones; Levodopa; Mice; Mice, Knockout; Parkinsonian Disorders; Phosphorylation; Polycomb-Group Proteins; Protein Binding; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Messenger; Signal Transduction; Transcriptional Activation

2014
Older treatment may be best overall for treating new Parkinson's.
    Harvard men's health watch, 2014, Volume: 19, Issue:2

    Topics: Antiparkinson Agents; Controlled Clinical Trials as Topic; Humans; Levodopa; Male; Parkinsonian Disorders; Psychomotor Performance; Task Performance and Analysis

2014
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
    Behavioural pharmacology, 2015, Volume: 26, Issue:1-2

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Species Specificity

2015
Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2015, Volume: 122, Issue:6

    Topics: Acetamides; Animals; Brain; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyrrolidinones; Rats, Sprague-Dawley

2015
New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease.
    Neurogastroenterology and motility, 2014, Volume: 26, Issue:12

    Topics: Animals; Antiparkinson Agents; Brain; Constipation; Gastrointestinal Transit; Ghrelin; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2014
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
    Molecular neurobiology, 2015, Volume: 52, Issue:3

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Corpus Striatum; Dimerization; Dominance, Cerebral; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Gene Expression Regulation; Levodopa; Macaca fascicularis; Male; Oxidopamine; Parkinsonian Disorders; Putamen; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D3

2015
Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease.
    Neuroscience letters, 2015, Jan-12, Volume: 585

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Green Fluorescent Proteins; Levodopa; Mice, Mutant Strains; Motor Activity; Parkinsonian Disorders; Receptors, Dopamine D3

2015
Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.
    Neurobiology of disease, 2015, Volume: 74

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Dyskinesia Agents; Cell Death; Cytosol; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Levodopa; Mesencephalon; Mice, Inbred C57BL; Mice, Transgenic; Motor Skills; Movement Disorders; Oxidative Stress; Parkinsonian Disorders; Vesicular Monoamine Transport Proteins

2015
L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Pharmacology, biochemistry, and behavior, 2014, Volume: 127

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Random Allocation

2014
Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?
    Neurochemistry international, 2014, Volume: 79

    Topics: Animals; Antiparkinson Agents; Caudate Nucleus; Cyclic AMP; Cyclic GMP; Down-Regulation; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Putamen; Rats; Rats, Wistar

2014
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
    Neurobiology of disease, 2015, Volume: 74

    Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; PPAR gamma; Rats, Sprague-Dawley; Rats, Wistar; Rosiglitazone; Thiazolidinediones

2015
Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Journal of pineal research, 2015, Volume: 58, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopaminergic Neurons; Drug Synergism; Levodopa; Male; Melatonin; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra

2015
Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior.
    Neuroscience, 2015, Apr-02, Volume: 290

    Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dopamine Agents; Levodopa; Mice, Inbred C57BL; Motor Activity; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D2; Synapses; Tissue Culture Techniques

2015
Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesion.
    Neuroscience, 2015, Apr-02, Volume: 290

    Topics: Animals; Antiparkinson Agents; Astrocytes; Carbidopa; Corpus Striatum; Gliosis; Levodopa; Male; Maze Learning; Memory Disorders; Memory, Short-Term; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Prefrontal Cortex; Rats, Wistar; Spatial Memory

2015
The NR2B antagonist, ifenprodil, corrects the l-DOPA-induced deficit of bilateral movement and reduces c-Fos expression in the subthalamic nucleus of hemiparkinsonian rats.
    Neuroscience research, 2015, Volume: 96

    Topics: Animals; Antiparkinson Agents; Brain; Forelimb; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Subthalamic Nucleus

2015
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
    Neuropharmacology, 2015, Volume: 95

    Topics: Aminobutyrates; Animals; Antiparkinson Agents; Catalepsy; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Haloperidol; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphinic Acids; Picolinic Acids; Random Allocation; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate

2015
Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Behavioural brain research, 2015, Jun-01, Volume: 286

    Topics: Animals; Anti-Dyskinesia Agents; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Phosphatidylethanolamines; Plasmalogens

2015
Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2015, Volume: 36, Issue:8

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Male; MAP Kinase Signaling System; Oncogene Proteins v-fos; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Simvastatin; Time Factors

2015
Deep brain stimulation of different pedunculopontine targets in a novel rodent model of parkinsonism.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015, Mar-25, Volume: 35, Issue:12

    Topics: Animals; Cell Survival; Cholinergic Neurons; Deep Brain Stimulation; Disease Models, Animal; Dopaminergic Neurons; Gait; Ibotenic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Postural Balance; Rats

2015
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
    Neuroscience, 2015, Jun-04, Volume: 295

    Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Protein Binding; Receptors, Nicotinic

2015
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
    Neuropharmacology, 2015, Volume: 95

    Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Clonidine; Dyskinesia, Drug-Induced; Imidazoles; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2

2015
Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
    Neuropharmacology, 2015, Volume: 95

    Topics: Animals; Antiparkinson Agents; Anxiety; Benzothiazoles; Depression; Hippocampus; Levodopa; Male; Mice, Inbred C57BL; Neurogenesis; Neurons; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation

2015
Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.
    Journal of neurochemistry, 2015, Volume: 134, Issue:2

    Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Motor Activity; Parkinsonian Disorders; Propranolol; Rats; Rats, Sprague-Dawley

2015
Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    BMC neuroscience, 2015, Apr-21, Volume: 16

    Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ethanol; Gynostemma; Levodopa; Locomotion; Male; MAP Kinase Signaling System; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Solvents

2015
Subthalamic nucleus activity in the awake hemiparkinsonian rat: relationships with motor and cognitive networks.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015, Apr-29, Volume: 35, Issue:17

    Topics: Action Potentials; Adrenergic Agents; Animals; Antiparkinson Agents; Benzazepines; Cognition Disorders; Disease Models, Animal; Dopamine Antagonists; Evoked Potentials; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Long-Evans; Subthalamic Nucleus; Time Factors; Tyrosine 3-Monooxygenase; Wakefulness

2015
Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Journal of neurosurgery, 2015, Volume: 123, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca; Parkinsonian Disorders; Receptors, Glutamate; Subthalamic Nucleus

2015
Similar L-dopa-stimulated motor activity in mice with adult-onset 6-hydroxydopamine-induced symmetric dopamine denervation and in transcription factor Pitx3 null mice with perinatal-onset symmetric dopamine denervation.
    Brain research, 2015, Jul-30, Volume: 1615

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Homeodomain Proteins; Levodopa; Male; Mice; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Transcription Factors

2015
Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
    Journal of neurochemistry, 2015, Volume: 134, Issue:4

    Topics: Adenine; Animals; Drug Delivery Systems; Drug Synergism; Levodopa; Male; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyridines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Rotation; Treatment Outcome; Xanthines

2015
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
    Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2015, Jul-05, Volume: 370, Issue:1672

    Topics: Animals; Calbindins; Cyclooxygenase 2; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Nitric Oxide; Nitric Oxide Synthase; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar

2015
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.
    Neuropharmacology, 2015, Volume: 97

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger

2015
Dissociative disorder manifesting for underlying adolescent hemi-parkinsonism: New chronology for old mummies.
    Asian journal of psychiatry, 2015, Volume: 16

    Topics: Adult; Age of Onset; Antiparkinson Agents; Carbidopa; Dissociative Disorders; Drug Combinations; Female; Humans; Levodopa; Parkinsonian Disorders; Young Adult

2015
The 5-HT4 Agonist Prucalopride Stimulates L-DOPA-Induced Dopamine Release in Restricted Brain Regions of the Hemiparkinsonian Rat In Vivo.
    CNS neuroscience & therapeutics, 2015, Volume: 21, Issue:9

    Topics: Animals; Benzofurans; Brain; Dopamine; Dopamine Agents; Functional Laterality; Indoles; Levodopa; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats; Serotonin 5-HT4 Receptor Agonists; Serotonin 5-HT4 Receptor Antagonists; Sulfonamides

2015
Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
    Neuroscience, 2015, Dec-03, Volume: 310

    Topics: AIDS-Related Complex; Animals; Benzazepines; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Medial Forebrain Bundle; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Synaptic Transmission

2015
Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates.
    Neuroscience bulletin, 2015, Volume: 31, Issue:6

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Fibroblasts; Globus Pallidus; Levodopa; Macaca mulatta; Parkinsonian Disorders

2015
Delayed chorea after recovery from severe akinetic-rigid parkinsonism caused by extrapontine myelinolysis.
    Journal of the neurological sciences, 2015, Nov-15, Volume: 358, Issue:1-2

    Topics: Carbidopa; Chorea; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Myelinolysis, Central Pontine; Parkinsonian Disorders

2015
Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
    Neurotoxicity research, 2016, Volume: 29, Issue:1

    Topics: Adrenergic Agents; Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Catalase; Disease Models, Animal; Dyskinesia, Drug-Induced; Extremities; Female; Glutathione; Levodopa; Male; Movement; Oleanolic Acid; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric

2016
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015, Oct-14, Volume: 35, Issue:41

    Topics: Adrenergic Agents; Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligodeoxyribonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Radiopharmaceuticals; Receptors, G-Protein-Coupled; Stereotyped Behavior; Synaptic Transmission; Time Factors; Tyrosine 3-Monooxygenase

2015
Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.
    Cerebral cortex (New York, N.Y. : 1991), 2017, 01-01, Volume: 27, Issue:1

    Topics: Animals; Corpus Striatum; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Mice; Mice, Knockout; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D3

2017
Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder.
    Journal of inherited metabolic disease, 2016, Volume: 39, Issue:2

    Topics: Brain; Brain Diseases; Carbidopa; Child; Dopamine; Humans; Levodopa; Male; Parkinsonian Disorders; Polymorphism, Single Nucleotide; Serotonin

2016
Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015, Nov-11, Volume: 35, Issue:45

    Topics: Amino Acid Transport Systems, Acidic; Animals; Circadian Rhythm; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Motor Skills Disorders; Parkinsonian Disorders

2015
α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:14

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nicotinic Agonists; Parkinsonian Disorders; Saimiri; Substantia Nigra

2015
Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
    Neurobiology of disease, 2016, Volume: 86

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzazepines; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Gamma Rhythm; Levodopa; Male; Motor Activity; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists

2016
Bridging the Gap: Muscarinic M4 Receptors Promote Striatal Plasticity in Health and Disease.
    Neuron, 2015, Nov-18, Volume: 88, Issue:4

    Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Neostriatum; Neuronal Plasticity; Parkinsonian Disorders; Receptor, Muscarinic M4; RGS Proteins

2015
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
    Neuron, 2015, Nov-18, Volume: 88, Issue:4

    Topics: Allosteric Regulation; Animals; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Macaca mulatta; Mice; Mice, Transgenic; Neostriatum; Neuronal Plasticity; Neurons; Parkinsonian Disorders; Receptor, Muscarinic M4; RGS Proteins; Signal Transduction

2015
Levodopa-Induced Motor and Dopamine Receptor Changes in Caenorhabditis elegans Overexpressing Human Alpha-Synuclein.
    Neuro-degenerative diseases, 2016, Volume: 16, Issue:3-4

    Topics: Actigraphy; alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Caenorhabditis elegans; Dyskinesia, Drug-Induced; Humans; Levodopa; Microscopy, Confocal; Motor Activity; Motor Neurons; Parkinsonian Disorders; Pattern Recognition, Automated; Receptors, Dopamine

2016
A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea.
    Parkinsonism & related disorders, 2016, Volume: 22

    Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Brain; Chorea; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Spinocerebellar Ataxias; TATA-Box Binding Protein; Trinucleotide Repeats

2016
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.
    Neurobiology of disease, 2016, Volume: 86

    Topics: Animals; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neuronal Plasticity; Neurons; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Wistar; Serotonin Receptor Agonists; Synapses; Synaptic Transmission; TOR Serine-Threonine Kinases

2016
Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.
    Neurobiology of disease, 2016, Volume: 87

    Topics: Amino Acid Transport Systems, Acidic; Animals; Antiparkinson Agents; Cell Count; Cell Size; Choline O-Acetyltransferase; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Ribosomal Protein S6; Vesicular Acetylcholine Transport Proteins

2016
Coherence of neuronal firing of the entopeduncular nucleus with motor cortex oscillatory activity in the 6-OHDA rat model of Parkinson's disease with levodopa-induced dyskinesias.
    Experimental brain research, 2016, Volume: 234, Issue:4

    Topics: Action Potentials; Animals; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2016
CART modulates the effects of levodopa in rat model of Parkinson's disease.
    Behavioural brain research, 2016, Mar-15, Volume: 301

    Topics: Animals; Antibodies; Antiparkinson Agents; Apomorphine; Brain; Dopamine Agonists; Dose-Response Relationship, Drug; Fluorescent Antibody Technique; Levodopa; Male; Movement; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Rotarod Performance Test; Tyrosine 3-Monooxygenase

2016
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    Neuropharmacology, 2016, Volume: 105

    Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists

2016
p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism.
    Proceedings of the National Academy of Sciences of the United States of America, 2016, Feb-02, Volume: 113, Issue:5

    Topics: Animals; Annexin A2; Dyskinesias; Levodopa; Mice; Mice, Knockout; Parkinsonian Disorders; S100 Proteins

2016
Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.
    Pharmacology, biochemistry, and behavior, 2016, Volume: 142

    Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Dopamine; Dyskinesias; Levodopa; Male; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins

2016
Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
    Neurobiology of disease, 2016, Volume: 89

    Topics: Action Potentials; Animals; Brain; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesia, Drug-Induced; GABAergic Neurons; Levodopa; Neurons; Oxidopamine; Parkinsonian Disorders; Pars Reticulata; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus

2016
Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
    Neurobiology of disease, 2016, Volume: 89

    Topics: Animals; Antigens, Differentiation; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; RNA, Messenger; Substantia Nigra

2016
Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Animals; Dyskinesia, Drug-Induced; Female; Levodopa; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate

2016
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
    Neuroscience, 2016, Jun-02, Volume: 324

    Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats, Wistar; RNA, Messenger; Tyrosine 3-Monooxygenase

2016
β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.
    Clinical and experimental pharmacology & physiology, 2016, Volume: 43, Issue:6

    Topics: Allylbenzene Derivatives; Animals; Anisoles; ATP Binding Cassette Transporter, Subfamily B; Blood-Brain Barrier; Corpus Striatum; Dopamine; Drug Therapy, Combination; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Tight Junction Proteins

2016
Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
    Scientific reports, 2016, Mar-21, Volume: 6

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Cyclic AMP-Dependent Protein Kinases; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Glycogen Synthase Kinase 3 beta; Levodopa; Mitogen-Activated Protein Kinase 3; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Rats; Receptors, Dopamine D1; tau Proteins; Thiadiazoles; Tyrosine 3-Monooxygenase

2016
Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis.
    Neuropharmacology, 2016, Volume: 107

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dyskinesia, Drug-Induced; Female; Ibuprofen; Levodopa; Neovascularization, Physiologic; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Piroxicam; Random Allocation; Rats; Substantia Nigra; Time Factors

2016
Parkinsonism and cognitive impairment due to a giant frontal arachnoid cyst and improving after shunting.
    Acta neurologica Belgica, 2017, Volume: 117, Issue:1

    Topics: Aged; Antiparkinson Agents; Arachnoid Cysts; Cerebrospinal Fluid Shunts; Cognition Disorders; Female; Humans; Levodopa; Mental Status Schedule; Parkinsonian Disorders; Postoperative Complications; Tomography Scanners, X-Ray Computed

2017
Mystery Case: Parkinsonism in a diabetic uremic patient.
    Neurology, 2016, 05-31, Volume: 86, Issue:22

    Topics: Aged; Antiparkinson Agents; Basal Ganglia; Diabetes Mellitus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Renal Dialysis; Steroids

2016
L-DOPA treatment in MPTP-mouse model of Parkinson's disease potentiates homocysteine accumulation in substantia nigra.
    Neuroscience letters, 2016, 08-15, Volume: 628

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Homocysteine; Levodopa; Male; Mice; Motor Activity; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase

2016
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.
    Neurobiology of disease, 2016, Volume: 94

    Topics: Animals; Anti-Dyskinesia Agents; Arachidonic Acids; Brain; Cannabidiol; Capsaicin; Cyclooxygenase 2; Dyskinesia, Drug-Induced; Endocannabinoids; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice, Inbred C57BL; NF-kappa B; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; PPAR gamma; Receptor, Cannabinoid, CB1; TRPV Cation Channels; Tyrosine 3-Monooxygenase

2016
Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.
    Neuropharmacology, 2016, Volume: 110, Issue:Pt A

    Topics: Animals; Dopamine Plasma Membrane Transport Proteins; Levodopa; Male; Norepinephrine Plasma Membrane Transport Proteins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins

2016
Facial tremors in patients with and without parkinsonism.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2016, Volume: 37, Issue:12

    Topics: Aged; Aged, 80 and over; Dopamine Agents; Face; Female; Humans; Levodopa; Male; Parkinsonian Disorders; Retrospective Studies; Sensitivity and Specificity; Tremor

2016
Small (autonomic) and large fiber neuropathy in Parkinson disease and parkinsonism.
    BMC neurology, 2016, Aug-17, Volume: 16

    Topics: Age Factors; Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Autonomic Pathways; Diabetes Complications; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Neural Conduction; Neuromuscular Junction; Parkinson Disease; Parkinsonian Disorders; Peripheral Nervous System Diseases; Skin

2016
Medication use in people with late stage Parkinson's disease and parkinsonism living at home and in institutional care in north-east England: A balance of symptoms and side-effects?
    Parkinsonism & related disorders, 2016, Volume: 32

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; England; Female; Home Care Services; Humans; Levodopa; Male; Nursing Homes; Parkinson Disease; Parkinsonian Disorders; Postural Balance; Quality of Life; Retrospective Studies; Sensation Disorders

2016
The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2016, 09-21, Volume: 36, Issue:38

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agents; GABA Agents; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Motor Cortex; Movement; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Signal Transduction; Sympatholytics; Tardive Dyskinesia

2016
Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits.
    Acta neurobiologiae experimentalis, 2016, Volume: 76, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drinking; Drug Administration Schedule; Drug Delivery Systems; Eating; Female; Injections, Intramuscular; Levodopa; Neurotoxins; Parkinsonian Disorders; Severity of Illness Index; Swine; Swine, Miniature; Time Factors

2016
Beneficial anti-Parkinson effects of camel milk in Chlorpromazineinduced animal model: Behavioural and histopathological study.
    Pakistan journal of pharmaceutical sciences, 2016, Volume: 29, Issue:5

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain; Camelus; Carbidopa; Catalepsy; Chlorpromazine; Drug Combinations; Female; Levodopa; Male; Milk; Parkinsonian Disorders; Rats, Wistar; Time Factors

2016
Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug l-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats.
    Pharmacological reports : PR, 2017, Volume: 69, Issue:1

    Topics: Animals; Antiparkinson Agents; Blood Pressure; Levodopa; Male; Molsidomine; Nitric Oxide Donors; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar

2017
Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.
    Neuroscience, 2017, 01-06, Volume: 340

    Topics: Animals; Antiparkinson Agents; Calcineurin; Calcium Ionophores; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Glutamic Acid; Ionomycin; Levodopa; Male; MAP Kinase Signaling System; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate

2017
Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Neuroscience, 2016, Dec-17, Volume: 339

    Topics: Animals; Antiparkinson Agents; Avoidance Learning; Corpus Striatum; Dioxoles; Dopamine; Dose-Response Relationship, Drug; Levodopa; Lignans; Male; Memory; Memory Disorders; Mice, Inbred C57BL; Motor Activity; Nootropic Agents; Parkinsonian Disorders; RNA, Messenger; Substantia Nigra

2016
Pallidal Deep Brain Stimulation for the Treatment of Levodopa-Responsive Juvenile Dystonia and Parkinsonism Secondary to SPG11 Mutation.
    JAMA neurology, 2017, 01-01, Volume: 74, Issue:1

    Topics: Action Potentials; Antiparkinson Agents; Deep Brain Stimulation; Dystonia; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Mutation; Neurons; Parkinsonian Disorders; Proteins; Treatment Outcome; Young Adult

2017
Novel compound heterozygous synaptojanin-1 mutation causes l-dopa-responsive dystonia-parkinsonism syndrome.
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:3

    Topics: Antiparkinson Agents; Corpus Striatum; Dystonic Disorders; Humans; Levodopa; Male; Mutation; Nerve Tissue Proteins; Parkinsonian Disorders; Pedigree; Phosphoric Monoester Hydrolases; Tomography, Emission-Computed, Single-Photon

2017
Three Cases of Levodopa-Resistant Parkinsonism After Radiation Therapy.
    The American journal of case reports, 2016, Dec-02, Volume: 17

    Topics: Adult; Aged; Antiparkinson Agents; Brain Neoplasms; Child; Drug Resistance; Female; Humans; Leukoencephalopathies; Levodopa; Male; Parkinsonian Disorders; Radiotherapy, Adjuvant; Treatment Failure

2016
Octogenarian parkinsonism - Clinicopathological observations.
    Parkinsonism & related disorders, 2017, Volume: 37

    Topics: Aged, 80 and over; Aging; Antiparkinson Agents; Autopsy; Brain; Disease Progression; Female; Humans; Levodopa; Longitudinal Studies; Male; Parkinsonian Disorders

2017
The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
    Psychopharmacology, 2017, Volume: 234, Issue:6

    Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mianserin; Mirtazapine; Motor Activity; MPTP Poisoning; Parkinsonian Disorders; Psychoses, Substance-Induced

2017
Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism.
    Experimental neurology, 2017, Volume: 292

    Topics: Animals; Corpus Striatum; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine; Levodopa; Male; Medial Forebrain Bundle; Parkinsonian Disorders; Rats, Sprague-Dawley; Substantia Nigra

2017
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:4

    Topics: Animals; Antiparkinson Agents; Channelrhodopsins; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; Sympatholytics

2017
Anti-Parkinsonian L-Dopa can also act as anti-systemic amyloidosis-A mechanistic exploration.
    International journal of biological macromolecules, 2017, Volume: 99

    Topics: Amyloidosis; Cell Line, Tumor; Cell Survival; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Levodopa; Molecular Docking Simulation; Muramidase; Parkinsonian Disorders; Protein Multimerization; Protein Structure, Secondary

2017
Dysregulation of BET proteins in levodopa-induced dyskinesia.
    Neurobiology of disease, 2017, Volume: 102

    Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Domains; Proteins; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Triazoles

2017
Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter.
    Synapse (New York, N.Y.), 2008, Volume: 62, Issue:8

    Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Denervation; Desipramine; Disease Models, Animal; Dopamine; Extracellular Matrix; Levodopa; Male; Microdialysis; Neurons; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Synapses; Synaptic Transmission

2008
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
    Psychopharmacology, 2008, Volume: 199, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Hydroxyindoleacetic Acid; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Motor Skills; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, N-Methyl-D-Aspartate; Serotonin; Serotonin Receptor Agonists; Stereotyped Behavior

2008
6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
    Neuropharmacology, 2008, Volume: 55, Issue:5

    Topics: 1-Methyl-3-isobutylxanthine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Cyclic AMP; Disease Models, Animal; Dopamine Agents; Functional Laterality; gamma-Aminobutyric Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Receptors, Dopamine D1; Substantia Nigra; Time Factors; Tritium

2008
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
    Behavioural brain research, 2008, Dec-01, Volume: 194, Issue:1

    Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase

2008
Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, Jul-23, Volume: 28, Issue:30

    Topics: Action Potentials; Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Female; Levodopa; Macaca mulatta; Neurons; Parkinsonian Disorders

2008
Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
    Neuroscience, 2008, Sep-22, Volume: 156, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Corpus Striatum; Corticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Encephalitis; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Levodopa; Male; Medial Forebrain Bundle; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Sympatholytics; Up-Regulation

2008
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Neurobiology of aging, 2010, Volume: 31, Issue:6

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Antipsychotic Agents; Benzazepines; Berberine; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Dyskinesias; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Serotonin Receptor Agonists; Transfection; Tritium

2010
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
    The European journal of neuroscience, 2008, Volume: 28, Issue:5

    Topics: Animals; Animals, Newborn; Brain; Cerebral Cortex; Cyclic AMP; Cyclic GMP; Dopamine; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphorylation; Purinones; Rats; Rats, Sprague-Dawley; Second Messenger Systems; Substantia Nigra; Sympatholytics; Synaptic Transmission

2008
Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
    Brain research, 2008, Oct-21, Volume: 1236

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Female; Functional Laterality; Gene Expression; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Synaptotagmins; Time Factors

2008
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
    Neurobiology of disease, 2008, Volume: 32, Issue:3

    Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Catechols; Corpus Striatum; Dynorphins; Electron Transport Complex IV; Enkephalins; Gene Expression; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Nitriles; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Subthalamus

2008
Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
    Journal of neurochemistry, 2008, Volume: 107, Issue:2

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Interactions; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor-Like Protein Tyrosine Phosphatases, Class 5; RNA, Messenger; Up-Regulation

2008
Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
    Behavioural brain research, 2009, Jan-30, Volume: 197, Issue:1

    Topics: Administration, Oral; Analysis of Variance; Animals; Creatine; Dietary Supplements; Disease Models, Animal; Dyskinesia, Drug-Induced; Energy Metabolism; Enkephalins; Female; In Vitro Techniques; Levodopa; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Phosphocreatine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Statistics, Nonparametric

2009
Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
    Neuropharmacology, 2008, Volume: 55, Issue:8

    Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Levodopa; Mitochondria; NAD; Neurons; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Psychomotor Performance; Rats; Rotenone; Spectrophotometry; Ubiquinone; Ultrasonography; Vitamins

2008
Levodopa affects functional brain networks in Parkinsonian resting tremor.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-15, Volume: 24, Issue:1

    Topics: Antiparkinson Agents; Brain; Brain Mapping; Cerebellum; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Nerve Net; Parietal Lobe; Parkinsonian Disorders; Somatosensory Cortex; Thalamus; Tremor

2009
Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia.
    Proceedings of the National Academy of Sciences of the United States of America, 2008, Oct-14, Volume: 105, Issue:41

    Topics: Animals; Axonal Transport; Dementia; Disease Models, Animal; Frontal Lobe; Humans; Levodopa; Mice; Mice, Transgenic; Motor Skills Disorders; Mutation, Missense; Parkinsonian Disorders; Phenotype; Sciatic Nerve; Substantia Nigra; tau Proteins; Temporal Lobe

2008
Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
    European journal of pharmacology, 2008, Dec-03, Volume: 599, Issue:1-3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Biperiden; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Female; Levodopa; Macaca nemestrina; Muscarinic Antagonists; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Tetrahydronaphthalenes; Thiophenes

2008
Parkinsonism during cyclosporine treatment in liver transplantation: an unusual case report.
    Transplantation proceedings, 2008, Volume: 40, Issue:8

    Topics: Adult; Cyclosporine; Hepatitis C; Humans; Immunosuppressive Agents; Levodopa; Liver Cirrhosis; Liver Transplantation; Male; Parkinsonian Disorders; Treatment Outcome

2008
Pseudo-orthostatic and resting leg tremor in a large Spanish family with homozygous truncating parkin mutation.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-15, Volume: 24, Issue:1

    Topics: Adult; Age of Onset; Antiparkinson Agents; Codon, Nonsense; Consanguinity; DNA Mutational Analysis; Exons; Female; Genotype; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Spain; Tremor; Ubiquitin-Protein Ligases

2009
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Brain : a journal of neurology, 2008, Volume: 131, Issue:Pt 12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Treatment Outcome

2008
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
    Journal of neurochemistry, 2008, Volume: 107, Issue:6

    Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Motor Activity; Narcotic Antagonists; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Substantia Nigra; Thalamus; Time Factors

2008
[Case of a 30-year history of PARK6 --findings from functional imaging of the brain].
    Rinsho shinkeigaku = Clinical neurology, 2008, Volume: 48, Issue:9

    Topics: Antiparkinson Agents; Benzothiazoles; Diagnostic Imaging; Female; Humans; Levodopa; Middle Aged; Mutation, Missense; Parkinsonian Disorders; Pramipexole; Protein Kinases; Receptors, Dopamine D2; Time Factors

2008
Should 3,4-dihydroxy-L-phenylalanine be used routinely in vascular Parkinson?
    Journal of the American Geriatrics Society, 2008, Volume: 56, Issue:10

    Topics: Aged, 80 and over; Antiparkinson Agents; Humans; Levodopa; Male; Parkinsonian Disorders; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon

2008
Clinical features of dystonia in atypical parkinsonism.
    Arquivos de neuro-psiquiatria, 2008, Volume: 66, Issue:4

    Topics: Adult; Aged; Antiparkinson Agents; Cerebral Cortex; Dystonia; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Nerve Degeneration; Parkinsonian Disorders; Supranuclear Palsy, Progressive

2008
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
    Journal of neuroscience research, 2009, May-15, Volume: 87, Issue:7

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists

2009
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Neurobiology of disease, 2009, Volume: 35, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger

2009
Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
    Journal of neuroscience methods, 2009, Apr-15, Volume: 178, Issue:2

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Caffeine; Catalepsy; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glutathione; Haloperidol; Levodopa; Male; Mice; Motor Activity; Parkinsonian Disorders; Posture; Superoxide Dismutase; Swimming

2009
Deep brain stimulation of the globus pallidus internus in the parkinsonian primate: local entrainment and suppression of low-frequency oscillations.
    Journal of neurophysiology, 2009, Volume: 101, Issue:4

    Topics: Action Potentials; Algorithms; Animals; Antiparkinson Agents; Deep Brain Stimulation; Disease Models, Animal; Elbow; Electric Stimulation; Female; Globus Pallidus; Levodopa; Macaca fascicularis; Neural Inhibition; Neurons; Parkinsonian Disorders; Periodicity; Time Factors

2009
L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
    Neuroreport, 2009, Feb-18, Volume: 20, Issue:3

    Topics: Animals; Brain; Brain Chemistry; Corpus Striatum; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Movement Disorders; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Serotonin; Sympatholytics; Tryptophan Hydroxylase

2009
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Parkinsonism & related disorders, 2009, Volume: 15, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Organic Chemicals; Ovariectomy; Parkinsonian Disorders; Serotonin Receptor Agonists

2009
De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat.
    Neurobiology of disease, 2009, Volume: 34, Issue:2

    Topics: Animals; Cell Proliferation; Corpus Striatum; Dopamine Agents; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation; In Situ Hybridization; Levodopa; Male; Nerve Regeneration; Neurogenesis; Neuronal Plasticity; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger

2009
Metabotropic glutamate receptor II in the brains of Parkinsonian patients.
    Journal of neuropathology and experimental neurology, 2009, Volume: 68, Issue:4

    Topics: Aged; Aged, 80 and over; Amino Acids; Antiparkinson Agents; Brain; Cocaine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Parkinsonian Disorders; Postmortem Changes; Radioligand Assay; Receptors, Metabotropic Glutamate; Tritium; Xanthenes

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopamine; Electric Stimulation Therapy; Electrodes, Implanted; Electrophysiological Phenomena; Humans; Levodopa; Locomotion; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Cortex; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Spinal Cord

2009
Cyclosporine-induced parkinsonism.
    Journal of neurology, 2009, Volume: 256, Issue:4

    Topics: Antiparkinson Agents; Brain; Carbidopa; Cyclosporine; Fatal Outcome; Hematoma, Subdural; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Stem Cell Transplantation

2009
Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2009, Apr-15, Volume: 29, Issue:15

    Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Receptors, Dopamine D1; Receptors, Dopamine D3

2009
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
    Experimental neurology, 2009, Volume: 219, Issue:1

    Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Sympatholytics

2009
Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats.
    The Journal of comparative neurology, 2009, Jul-01, Volume: 515, Issue:1

    Topics: Animals; Antiparkinson Agents; Brain; Brain Tissue Transplantation; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Graft Survival; Levodopa; Male; Neurons; Parkinsonian Disorders; Rats; Rats, Inbred F344; Treatment Outcome

2009
Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism.
    Experimental neurology, 2009, Volume: 219, Issue:1

    Topics: Animals; Antiparkinson Agents; Cell Count; Disease Models, Animal; Forelimb; Hypokinesia; Lameness, Animal; Levodopa; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurologic Examination; Parkinsonian Disorders; Predictive Value of Tests; Sensitivity and Specificity; Substantia Nigra

2009
Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats.
    Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:7

    Topics: Animals; Antiparkinson Agents; Benzylamines; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Levodopa; Male; Movement; Neurotoxins; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Recovery of Function; Synaptic Transmission; Time; Treatment Outcome

2009
D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
    Neurobiology of disease, 2009, Volume: 35, Issue:3

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2

2009
The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.
    Neurobiology of disease, 2009, Volume: 35, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blood-Brain Barrier; Brain; Dyskinesia, Drug-Induced; Gadolinium DTPA; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Time Factors

2009
Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Biological psychiatry, 2009, Sep-15, Volume: 66, Issue:6

    Topics: Acetylation; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; Gene Expression Regulation; Histones; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2; Statistics as Topic; Tyrosine 3-Monooxygenase

2009
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Neuropharmacology, 2010, Volume: 58, Issue:1

    Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors

2010
Evaluation of the effects of deep brain stimulation of the subthalamic nucleus and levodopa treatment on parkinsonian voice using perturbation, nonlinear dynamic, and perceptual analysis.
    Folia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP), 2009, Volume: 61, Issue:4

    Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Nonlinear Dynamics; Parkinsonian Disorders; Phonation; Phonetics; Speech Production Measurement; Subthalamic Nucleus; Treatment Outcome; Voice; Voice Disorders

2009
Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:12

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aminoacetonitrile; Animals; Antiparkinson Agents; Basal Ganglia; Benzazepines; Bromocriptine; Disease Models, Animal; Dopamine Agents; Dopamine D2 Receptor Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Levodopa; Neovascularization, Pathologic; Oxidopamine; Parkinsonian Disorders; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides

2009
Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.
    Neurobiology of disease, 2009, Volume: 36, Issue:1

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Electron Transport Complex IV; Gene Expression Regulation; Levodopa; Male; Nerve Net; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Protein Subunits; Rats; Rats, Wistar; RNA, Messenger

2009
Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia.
    Science signaling, 2009, Jul-21, Volume: 2, Issue:80

    Topics: Animals; Antiparkinson Agents; Carrier Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Parkinsonian Disorders; Phosphotransferases (Alcohol Group Acceptor); Proteins; Receptors, Dopamine D1; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors

2009
Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.
    Neuroreport, 2009, Sep-23, Volume: 20, Issue:14

    Topics: Adrenergic Agents; Animals; Benzazepines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors

2009
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
    Psychopharmacology, 2009, Volume: 206, Issue:2

    Topics: Animals; Antiparkinson Agents; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Homer Scaffolding Proteins; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase

2009
Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents.
    The European journal of neuroscience, 2009, Volume: 30, Issue:3

    Topics: Animals; Corpus Striatum; Dendrites; Dopamine; Dopamine Agents; Fluorescent Antibody Technique; Glutamine; Haplorhini; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Microscopy, Electron, Transmission; Neurons, Afferent; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, G-Protein-Coupled

2009
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Neuropharmacology, 2010, Volume: 58, Issue:2

    Topics: Animals; Antiparkinson Agents; Benzopyrans; Disability Evaluation; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Hypokinesia; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Time Factors; Treatment Outcome

2010
Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.
    Neurotoxicity research, 2010, Volume: 17, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Female; Hydroxyindoleacetic Acid; Hydroxyl Radical; Injections, Intraventricular; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Sympatholytics; Time Factors

2010
Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Journal of neurochemistry, 2009, Volume: 111, Issue:4

    Topics: Animals; Antiparkinson Agents; bcl-2-Associated X Protein; Benzothiazoles; Cell Count; Disease Models, Animal; Dopamine; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Glutathione; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Statistics, Nonparametric; Substantia Nigra; Tyrosine 3-Monooxygenase

2009
Hemibody mirror movements in hemiparkinsonism-hemiatrophy syndrome.
    Journal of the neurological sciences, 2009, Dec-15, Volume: 287, Issue:1-2

    Topics: Antiparkinson Agents; Arm; Electromyography; Facial Muscles; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Contraction; Muscle, Skeletal; Muscular Atrophy; Parkinsonian Disorders; Peripheral Nervous System Diseases; Syndrome; Treatment Outcome

2009
The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Synapse (New York, N.Y.), 2010, Volume: 64, Issue:2

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebrospinal Fluid; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Plasma; Propranolol; Random Allocation; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Tetralones

2010
Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents.
    Journal of pineal research, 2009, Volume: 47, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ascorbic Acid; Brain; Central Nervous System Depressants; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Ferrous Compounds; Levodopa; Male; Melatonin; Mice; Mice, Inbred BALB C; Oxidopamine; Parkinsonian Disorders

2009
The effect of levodopa treatment on cerebral hemodynamics in patients with Parkinson's disease: serial transcranial Doppler studies.
    Parkinsonism & related disorders, 2010, Volume: 16, Issue:3

    Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Female; Hemodynamics; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Prospective Studies; Retrospective Studies; Statistics, Nonparametric; Ultrasonography, Doppler, Transcranial

2010
Conjugal Parkinsonism and Parkinson disease: a case series with environmental risk factor analysis.
    Parkinsonism & related disorders, 2010, Volume: 16, Issue:3

    Topics: Age of Onset; Aged; Cognition Disorders; Disease Progression; Environment; Environmental Exposure; Female; Humans; Levodopa; Male; Marriage; Middle Aged; Parkinsonian Disorders; Retrospective Studies; Risk Assessment; Risk Factors; Surveys and Questionnaires

2010
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.
    Synapse (New York, N.Y.), 2010, Volume: 64, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Membrane; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Neostriatum; Neurons; Parkinsonian Disorders; Receptors, AMPA; Synapses; Synaptic Vesicles

2010
Cavernous hemangioma: a rare cause for secondary parkinsonism: a case report.
    The International journal of neuroscience, 2009, Volume: 119, Issue:11

    Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Carbidopa; Female; Globus Pallidus; Hemangioma, Cavernous, Central Nervous System; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Putamen; Tomography, X-Ray Computed; Treatment Failure

2009
Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
    Brain research, 2010, Jan-14, Volume: 1309

    Topics: Administration, Oral; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dopa Decarboxylase; Dopamine; Drug Combinations; Drug Synergism; Encephalitis Virus, Japanese; Encephalitis, Japanese; Enzyme Inhibitors; Levodopa; Nitriles; Parkinsonian Disorders; Rats; Rats, Inbred F344; Treatment Outcome

2010
HIV-associated Parkinsonism with levodopa-induced dyskinesia and response to highly-active antiretroviral therapy.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Dec-15, Volume: 24, Issue:16

    Topics: Adult; Akathisia, Drug-Induced; Antiparkinson Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Tropanes

2009
L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation.
    Neurochemistry international, 2010, Volume: 56, Issue:2

    Topics: Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Electrochemistry; Levodopa; Male; Mice; Mice, Inbred BALB C; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2010
Sustained dopaminergic response of parkinsonism and depression in POLG-associated parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Jan-30, Volume: 25, Issue:2

    Topics: Affect; Depression; DNA Polymerase gamma; DNA-Directed DNA Polymerase; Dopamine Agents; Female; Humans; Indoles; Levodopa; Middle Aged; Parkinsonian Disorders; Radionuclide Imaging; Treatment Outcome

2010
Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Dec-29, Volume: 106, Issue:52

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Corpus Striatum; Dopamine; Female; Gene Expression; Gene Expression Profiling; Humans; In Vitro Techniques; Leupeptins; Levodopa; Models, Neurological; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Presynaptic Terminals; rab3 GTP-Binding Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Synaptic Vesicles; Ventral Tegmental Area

2009
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Apr-16, Volume: 34, Issue:3

    Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Ergolines; Female; Glycogen Synthase Kinase 3; Levodopa; Macaca fascicularis; Oncogene Protein v-akt; Parkinsonian Disorders; Phosphorylation; Piperidines; Serine; Signal Transduction; Statistics as Topic

2010
Behavioral and electrophysiological effects of 5-HT in globus pallidus of 6-hydroxydopamine lesioned rats.
    Journal of neuroscience research, 2010, May-15, Volume: 88, Issue:7

    Topics: Action Potentials; Animals; Behavior, Animal; Dopamine Agents; Drug Combinations; Functional Laterality; Globus Pallidus; Levodopa; Male; Microinjections; Neural Inhibition; Neurons; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin

2010
Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.
    Neurobiology of aging, 2011, Volume: 32, Issue:7

    Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Cohort Studies; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Humans; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Up-Regulation

2011
Frequency-velocity mismatch: a fundamental abnormality in parkinsonian gait.
    Journal of neurophysiology, 2010, Volume: 103, Issue:3

    Topics: Acoustic Stimulation; Aged; Algorithms; Antiparkinson Agents; Biomechanical Phenomena; Feedback, Physiological; Female; Foot; Gait; Gait Disorders, Neurologic; Humans; In Vitro Techniques; Levodopa; Male; Middle Aged; Models, Neurological; Movement; Parkinsonian Disorders; Walking

2010
Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
    Neurobiology of disease, 2010, Volume: 38, Issue:1

    Topics: Animals; Behavior, Animal; Biomarkers; Corpus Striatum; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gait Disorders, Neurologic; Infusion Pumps, Implantable; Levodopa; Locomotion; Male; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Signal Transduction; Thionucleotides

2010
Levodopa-induced dyskinesias in spinocerebellar ataxia type 2.
    Archives of neurology, 2010, Volume: 67, Issue:1

    Topics: Antiparkinson Agents; Atrophy; Depressive Disorder; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinsonian Disorders; Rhombencephalon; Spinocerebellar Ataxias

2010
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
    Neuropharmacology, 2010, Volume: 58, Issue:7

    Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinsonian Disorders; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome

2010
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
    Neuropharmacology, 2010, Volume: 58, Issue:7

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Time Factors

2010
Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.
    Neurobiology of disease, 2010, Volume: 38, Issue:1

    Topics: 5,7-Dihydroxytryptamine; Animals; Antiparkinson Agents; Brain; Citalopram; Cobra Neurotoxin Proteins; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Extracellular Fluid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Raphe Nuclei; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Sympatholytics; Synaptic Transmission

2010
Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
    Experimental neurology, 2010, Volume: 223, Issue:2

    Topics: Amisulpride; Animals; Antiparkinson Agents; Benzimidazoles; Benzothiazoles; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neural Inhibition; Nociceptin; Opioid Peptides; Parkinsonian Disorders; Piperidines; Pramipexole; Pyridines; Reaction Time; Receptors, Dopamine D3; Sulpiride

2010
Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2010, Volume: 37, Issue:1

    Topics: Animals; Antiparkinson Agents; Behavioral Symptoms; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Hyperkinesis; Levodopa; Parkinsonian Disorders; Reproducibility of Results

2010
Familial paroxysmal exercise-induced dystonia: atypical presentation of autosomal dominant GTP-cyclohydrolase 1 deficiency.
    Developmental medicine and child neurology, 2010, Volume: 52, Issue:6

    Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Child; Codon, Nonsense; Depressive Disorder; Dystonia; Exercise; Exons; Family; Female; GTP Cyclohydrolase; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Restless Legs Syndrome

2010
Age of Parkinson's disease onset as a predictor for the development of dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Jul-15, Volume: 25, Issue:9

    Topics: Adult; Age Factors; Age of Onset; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinsonian Disorders; Predictive Value of Tests; Proportional Hazards Models; Risk Factors

2010
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
    Science translational medicine, 2010, Apr-21, Volume: 2, Issue:28

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Dose-Response Relationship, Drug; Dyskinesias; Endocytosis; G-Protein-Coupled Receptor Kinases; Gene Knockdown Techniques; Genetic Therapy; Humans; Lentivirus; Levodopa; Macaca; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Signal Transduction

2010
Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
    Journal of neural transmission. Supplementum, 2009, Issue:73

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Cell Count; Disease Models, Animal; Dopamine; Drug Interactions; Gene Expression Regulation; Homovanillic Acid; Levodopa; Male; Movement; Neurons; Neurotoxins; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time; Substantia Nigra; Tyrosine 3-Monooxygenase

2009
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
    Behavioural brain research, 2010, Nov-12, Volume: 213, Issue:1

    Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Oxidopamine; Parkinsonian Disorders; Piribedil; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotation; Time Factors

2010
Perry syndrome due to the DCTN1 G71R mutation: a distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Apr-30, Volume: 25, Issue:6

    Topics: Arginine; Behavioral Symptoms; DNA Mutational Analysis; Dopamine Agents; Dynactin Complex; Glycine; Humans; Levodopa; Male; Microtubule-Associated Proteins; Middle Aged; Neuropsychological Tests; Optic Nerve Diseases; Parkinsonian Disorders; Respiratory Insufficiency

2010
[Rapidly progressive parkinsonism that developed one year after ventriculoperitoneal shunting for idiopathic aqueductal stenosis: a case report].
    Brain and nerve = Shinkei kenkyu no shinpo, 2010, Volume: 62, Issue:5

    Topics: Acute Disease; Cerebral Aqueduct; Constriction, Pathologic; Disease Progression; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Postoperative Complications; Syndrome; Treatment Outcome; Ventriculoperitoneal Shunt

2010
Dopaminergic neuronal integrity in parkinsonism associated with liver cirrhosis.
    Neurotoxicology, 2010, Volume: 31, Issue:4

    Topics: Aged; Basal Ganglia; Dopamine Plasma Membrane Transport Proteins; Drug Resistance; Female; Humans; Levodopa; Liver Cirrhosis; Male; Middle Aged; Neurons; Parkinsonian Disorders; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tropanes

2010
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
    Brain research, 2010, Jul-16, Volume: 1344

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Medial Forebrain Bundle; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Salicylates

2010
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
    The International journal of neuroscience, 2010, Volume: 120, Issue:6

    Topics: Animals; Antiparasitic Agents; Corpus Striatum; Cyclin-Dependent Kinase 5; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Kinase Inhibitors; Purines; Random Allocation; Rats; Rats, Sprague-Dawley; Roscovitine; Severity of Illness Index; Treatment Outcome

2010
Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Jul-15, Volume: 25, Issue:9

    Topics: Adolescent; Antiparkinson Agents; Child; Dyskinesia, Drug-Induced; Female; Humans; Intranuclear Inclusion Bodies; Levodopa; Male; Neurons; Parkinsonian Disorders; Peptides; Taiwan; Ubiquitin

2010
Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.
    Neuroreport, 2010, Aug-23, Volume: 21, Issue:12

    Topics: Animals; Antiparkinson Agents; Benserazide; Biocompatible Materials; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Synergism; Dyskinesia, Drug-Induced; Female; Lameness, Animal; Levodopa; Microspheres; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome

2010
Juvenile levodopa-responsive Parkinsonism with early orobuccolingual dyskinesias and cognitive impairment.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Sep-15, Volume: 25, Issue:12

    Topics: Adolescent; Brain; Cognition Disorders; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Intranuclear Inclusion Bodies; Levodopa; Magnetic Resonance Imaging; Neurodegenerative Diseases; Parkinsonian Disorders; Young Adult

2010
Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Sep-15, Volume: 25, Issue:12

    Topics: Adult; Brain; F-Box Proteins; Female; Genetic Association Studies; Genotype; Group VI Phospholipases A2; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Proteins; Proton-Translocating ATPases

2010
Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release.
    European journal of nuclear medicine and molecular imaging, 2010, Volume: 37, Issue:12

    Topics: Animals; Benzothiazoles; Biomarkers; Brain; Dopamine; Dopamine Agonists; Levodopa; Male; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Presynaptic Terminals; Rats; Rats, Sprague-Dawley

2010
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia.
    Neurobiology of disease, 2010, Volume: 40, Issue:3

    Topics: Animals; Antiparkinson Agents; Callithrix; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Immunohistochemistry; Levodopa; Male; Neurites; Parkinsonian Disorders; Serotonin; Tryptophan Hydroxylase

2010
Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
    Cell biochemistry and biophysics, 2011, Volume: 59, Issue:1

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Nerve Fibers; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra

2011
L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
    Neurobiology of disease, 2011, Volume: 41, Issue:1

    Topics: Adenylyl Cyclases; Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; gamma-Aminobutyric Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Severity of Illness Index; Substantia Nigra; Up-Regulation

2011
Drug-induced cranial myoclonus.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Oct-15, Volume: 25, Issue:13

    Topics: Aged; Antidepressive Agents; Antiparkinson Agents; Depression; Female; Humans; Levodopa; Male; Middle Aged; Myoclonus; Parkinsonian Disorders

2010
Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.
    PloS one, 2010, Aug-23, Volume: 5, Issue:8

    Topics: Animals; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesias; Extracellular Signal-Regulated MAP Kinases; Female; Levodopa; Macaca mulatta; MAP Kinase Signaling System; Parkinsonian Disorders; ras Proteins

2010
Metabolic activity of the subthalamic nucleus in a primate model of L-dopa-unresponsive parkinsonism.
    Neurological research, 2010, Volume: 32, Issue:10

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Energy Metabolism; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Substantia Nigra; Subthalamic Nucleus

2010
Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency.
    Journal of child neurology, 2011, Volume: 26, Issue:2

    Topics: Adolescent; Adult; Child; Child, Preschool; Deficiency Diseases; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinsonian Disorders; Phenotype; Prolactin; Selegiline; Severity of Illness Index; Treatment Outcome; Tyrosine 3-Monooxygenase

2011
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Oct-15, Volume: 25, Issue:13

    Topics: Adrenergic alpha-2 Receptor Antagonists; Analysis of Variance; Animals; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinsonian Disorders; Time Factors

2010
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
    Brain research, 2010, Dec-02, Volume: 1363

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant

2010
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Nov-15, Volume: 25, Issue:15

    Topics: Age of Onset; Antiparkinson Agents; Cerebellar Ataxia; Europe; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Multiple System Atrophy; Parkinsonian Disorders; Registries; Shy-Drager Syndrome

2010
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.
    Neurobiology of aging, 2012, Volume: 33, Issue:1

    Topics: Animals; Autoradiography; Caudate Nucleus; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Cortex; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists

2012
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
    Fundamental & clinical pharmacology, 2011, Volume: 25, Issue:5

    Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Biological Assay; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Placebos; Purines; Random Allocation; Rats; Reproducibility of Results; Rotation; Sample Size; Single-Blind Method; Sympatholytics

2011
BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Neuropharmacology, 2011, Volume: 60, Issue:4

    Topics: Animals; Area Under Curve; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles

2011
The effects of chronic levodopa treatments on the neuronal firing properties of the subthalamic nucleus and substantia nigra reticulata in hemiparkinsonian rhesus monkeys.
    Experimental neurology, 2011, Volume: 228, Issue:1

    Topics: Action Potentials; Animals; Female; Levodopa; Macaca mulatta; Neurons; Parkinsonian Disorders; Substantia Nigra; Subthalamic Nucleus; Treatment Outcome

2011
Nigrostriatal dysfunction in patients with amyotrophic lateral sclerosis and parkinsonism.
    Journal of the neurological sciences, 2011, Feb-15, Volume: 301, Issue:1-2

    Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Corpus Striatum; Fluorine Radioisotopes; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Presynaptic Terminals; Putamen; Radiopharmaceuticals; Substantia Nigra; Tremor; Tropanes

2011
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
    Brain : a journal of neurology, 2011, Volume: 134, Issue:Pt 2

    Topics: Animals; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induced; Levodopa; Long-Term Synaptic Depression; Male; Microinjections; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Piperazines; Purinones; Pyrimidinones; Rats; Rats, Wistar

2011
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.
    Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:12

    Topics: Analysis of Variance; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression Profiling; Gene Expression Regulation; Levodopa; Male; Nerve Tissue Proteins; Neurotrophin 3; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinsonian Disorders; Pulsatile Flow; Rats; Rats, Sprague-Dawley; RNA, Messenger

2011
CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
    Brain research, 2011, Feb-28, Volume: 1376

    Topics: Adenosine A2 Receptor Antagonists; Animals; Blotting, Western; Brain; Caffeine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Microscopy, Electron, Transmission; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Synapses

2011
Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat.
    Neurobiology of disease, 2011, Volume: 42, Issue:1

    Topics: Animals; Conditioning, Psychological; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2011
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:12

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Time Factors

2011
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
    Parkinsonism & related disorders, 2011, Volume: 17, Issue:4

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate

2011
BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice.
    Neuroscience, 2011, Apr-28, Volume: 180

    Topics: Animals; Behavior, Animal; Brain; Cell Survival; Drug Combinations; gamma-Aminobutyric Acid; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Neuroprotective Agents; Parkinsonian Disorders

2011
Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 337, Issue:3

    Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Benzoxazines; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Molecular Targeted Therapy; Motor Activity; Oxazines; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Time Factors

2011
Decades of delayed diagnosis in 4 levodopa-responsive young-onset monogenetic parkinsonism patients.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:7

    Topics: Adult; Age of Onset; Antiparkinson Agents; Delayed Diagnosis; Diagnosis, Differential; Dystonic Disorders; Fatigue Syndrome, Chronic; Female; Gait Disorders, Neurologic; Humans; Levodopa; Parkinsonian Disorders; Time Factors; Ubiquitin-Protein Ligases; Young Adult

2011
The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:7

    Topics: Animals; Antiparkinson Agents; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Receptors, Opioid, mu

2011
The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
    Synapse (New York, N.Y.), 2011, Volume: 65, Issue:10

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Vesicular Glutamate Transport Protein 2

2011
Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    The European journal of neuroscience, 2011, Volume: 33, Issue:10

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Biogenic Amines; Brain; Cabergoline; Dopamine Agents; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Ketanserin; Levodopa; Macaca; Parkinsonian Disorders; Receptor, Serotonin, 5-HT2A

2011
Differential expression of FosB, c-Fos, and Zif268 in forebrain regions after acute or chronic L-DOPA treatment in a rat model of Parkinson's disease.
    Neuroscience letters, 2011, Jun-01, Volume: 496, Issue:2

    Topics: Acute Disease; Animals; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Levodopa; Male; Parkinsonian Disorders; Prosencephalon; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Tissue Distribution; Treatment Outcome

2011
Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys.
    Brain structure & function, 2011, Volume: 216, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colorimetry; DNA Primers; Dopamine; Dyskinesia, Drug-Induced; Fluorescent Antibody Technique; GABAergic Neurons; Globus Pallidus; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; In Situ Hybridization, Fluorescence; Levodopa; Macaca fascicularis; Male; Neurons, Efferent; Parkinsonian Disorders; Polymerase Chain Reaction; Statistics, Nonparametric; Thalamus; Vesicular Glutamate Transport Protein 1

2011
Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Journal of molecular neuroscience : MN, 2012, Volume: 46, Issue:1

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; RNA, Messenger

2012
[Levodopa-responsive parkinsonism-dystonia due to a traumatic injury of the substantia nigra].
    Neurologia (Barcelona, Spain), 2012, Volume: 27, Issue:3

    Topics: Antiparkinson Agents; Brain; Brain Injuries; Dystonia; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Substantia Nigra; Tomography, X-Ray Computed

2012
Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
    Neurobiology of disease, 2011, Volume: 43, Issue:3

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Combined Modality Therapy; Dopamine; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Recovery of Function; Serotonin; Sympatholytics

2011
Antidepressant-like properties of sarizotan in experimental Parkinsonism.
    Psychopharmacology, 2011, Volume: 218, Issue:4

    Topics: Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Benserazide; Cell Proliferation; Dentate Gyrus; Depression; Disease Models, Animal; Doublecortin Protein; Drug Combinations; Levodopa; Locomotion; Male; Organic Chemicals; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Swimming

2011
[2011: not just PRAXIS, also dopa turns 100 years old...].
    Praxis, 2011, May-11, Volume: 100, Issue:10

    Topics: Antiparkinson Agents; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Periodicals as Topic; Publishing; Switzerland

2011
A case of parkinsonism and dopa-induced severe dyskinesia associated with novel mutation in the GTP cyclohydrolase I gene.
    Parkinsonism & related disorders, 2011, Volume: 17, Issue:10

    Topics: Adult; Aged; Base Sequence; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; GTP Cyclohydrolase; Humans; Levodopa; Male; Mutation; Parkinsonian Disorders; Pedigree

2011
Endogenous morphine-like compound immunoreactivity increases in parkinsonism.
    Brain : a journal of neurology, 2011, Volume: 134, Issue:Pt 8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; alpha-Methyltyrosine; Analysis of Variance; Animals; Brain; Choline O-Acetyltransferase; Chromatography, High Pressure Liquid; Dendrites; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Functional Laterality; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Glutamate Decarboxylase; Humans; Levodopa; Macaca fascicularis; Male; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Immunoelectron; Middle Aged; Nerve Growth Factors; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Postmortem Changes; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Tandem Mass Spectrometry

2011
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.
    Brain : a journal of neurology, 2011, Volume: 134, Issue:Pt 8

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Antigens, CD; Antigens, Surface; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Blood Vessels; Blood-Brain Barrier; Brain; Bromodeoxyuridine; Cell Count; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Embryo, Mammalian; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Laminin; Levodopa; Male; Neovascularization, Pathologic; Nerve Tissue Proteins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Time Factors; Up-Regulation; Vascular Endothelial Growth Factor A

2011
Deep brain stimulation in benign tremulous parkinsonism.
    Archives of neurology, 2011, Volume: 68, Issue:8

    Topics: Adult; Aged; Cohort Studies; Deep Brain Stimulation; Disease Progression; Drug Resistance; Essential Tremor; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Patient Selection; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome; Tremor; Ventral Thalamic Nuclei

2011
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
    Neurotoxicity research, 2012, Volume: 21, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles

2012
Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
    Neuroscience letters, 2011, Sep-15, Volume: 502, Issue:2

    Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Drug Combinations; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time

2011
Parkinsonism and dropped head: dystonia, myopathy or both?
    Parkinsonism & related disorders, 2012, Volume: 18, Issue:1

    Topics: Aged; Carbidopa; Drug Combinations; Dystonic Disorders; Electromyography; Female; Head Movements; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Muscular Diseases; Parkinsonian Disorders; Retrospective Studies

2012
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
    Eksperimental'naia i klinicheskaia farmakologiia, 2011, Volume: 74, Issue:7

    Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra

2011
Experimental Models of l-DOPA-Induced Dyskinesia.
    International review of neurobiology, 2011, Volume: 98

    Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders

2011
The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study.
    PloS one, 2011, Volume: 6, Issue:9

    Topics: Amphetamine; Animals; Behavior, Animal; Dyskinesias; Electrophysiology; Female; Ibotenic Acid; Levodopa; Locus Coeruleus; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2011
Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
    Experimental neurology, 2011, Volume: 232, Issue:2

    Topics: Action Potentials; Animals; Antiparkinson Agents; Corpus Striatum; D-Aspartate Oxidase; D-Aspartic Acid; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; N-Methylaspartate; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Sympatholytics; Synapses

2011
Parkinsonism with multiple cysts in the bilateral striata.
    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2011, Volume: 11, Issue:3

    Topics: 3-Iodobenzylguanidine; Aged; Antiparkinson Agents; Antipsychotic Agents; Brain Ischemia; Delirium; Delusions; Diagnosis, Differential; Dibenzothiazepines; Dominance, Cerebral; Drug Therapy, Combination; Encephalomalacia; Hallucinations; Humans; Levodopa; Magnetic Resonance Imaging; Male; Neostriatum; Neurologic Examination; Organophosphate Poisoning; Parkinsonian Disorders; Psychoses, Substance-Induced; Quetiapine Fumarate; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2011
A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice.
    Neurobiology of disease, 2012, Volume: 45, Issue:1

    Topics: alpha-Synuclein; Animals; Brain; Dopaminergic Neurons; Levodopa; Male; Mice; Mice, Knockout; Nerve Regeneration; Parkinsonian Disorders

2012
Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
    Pharmacological reports : PR, 2011, Volume: 63, Issue:4

    Topics: Animals; Antiparkinson Agents; Buspirone; Catalepsy; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Serotonin 5-HT1 Receptor Agonists; Time Factors

2011
Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy.
    Behavioural brain research, 2012, Jan-15, Volume: 226, Issue:2

    Topics: Animals; Cell Count; Corpus Striatum; Dopamine; Gait; Humans; Levodopa; Male; Medial Forebrain Bundle; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred Strains; Substantia Nigra; Tyrosine 3-Monooxygenase

2012
Levodopa-responsive parkinsonism in probable extrapontine myelinolysis of the mesencephalon.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:12

    Topics: Adult; Antiparkinson Agents; Female; Humans; Levodopa; Mesencephalon; Myelinolysis, Central Pontine; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Tropanes

2011
Do levodopa treatments modify the morphology of the parkinsonian brain?
    Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:1

    Topics: Animals; Antiparkinson Agents; Brain; Humans; Levodopa; Parkinsonian Disorders

2012
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
    Brain research bulletin, 2012, Feb-10, Volume: 87, Issue:2-3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Electrochemistry; Exploratory Behavior; Forelimb; Functional Laterality; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Motor Activity; Motor Skills; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Sympatholytics

2012
Loss of dopaminoreceptive neuron causes L-dopa resistant parkinsonism in tauopathy.
    Neurobiology of aging, 2012, Volume: 33, Issue:10

    Topics: Animals; Antiparkinson Agents; Apoptosis; Caspase 3; Corpus Striatum; Dopaminergic Neurons; Hippocampus; Humans; Immunohistochemistry; Levodopa; Male; Mice; Mice, Transgenic; Mutation; Neurofibrils; Neuropsychological Tests; Parkinsonian Disorders; Putamen; tau Proteins; Tauopathies

2012
Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model.
    Amino acids, 2012, Volume: 43, Issue:3

    Topics: Analysis of Variance; Animals; Basal Ganglia; CD11b Antigen; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Gene Expression; Glial Fibrillary Acidic Protein; Glutathione; Heme Oxygenase-1; Levodopa; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; NF-E2-Related Factor 2; NF-kappa B; Nitric Oxide Synthase Type II; Oligopeptides; Oxidative Stress; Parkinsonian Disorders; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase

2012
Selective IGT decision-making impairment in a patient with juvenile Parkinson's disease and pathological gambling: a role for dopaminergic therapy?
    Neurocase, 2012, Volume: 18, Issue:6

    Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Compulsive Behavior; Decision Making; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Gambling; Humans; Levodopa; Matched-Pair Analysis; Neuropsychological Tests; Parkinsonian Disorders; Pramipexole; Reference Values

2012
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Jan-11, Volume: 32, Issue:2

    Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Organ Culture Techniques; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1

2012
Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
    European journal of pharmacology, 2012, May-15, Volume: 683, Issue:1-3

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Neostriatum; Nerve Tissue Proteins; Neurons; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type I; Parkinsonian Disorders; Protein Subunits; Proto-Oncogene Proteins c-fos; Random Allocation; Rats; Rats, Wistar; Receptors, AMPA; Signal Transduction

2012
Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.
    Brain : a journal of neurology, 2012, Volume: 135, Issue:Pt 6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biomarkers; Catecholamines; Dopamine Agents; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Multiple System Atrophy; Parkinsonian Disorders; Positron-Emission Tomography; Pure Autonomic Failure; ROC Curve

2012
Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.
    The Journal of pharmacy and pharmacology, 2012, Volume: 64, Issue:5

    Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Drug Synergism; Dyskinesias; Exenatide; Glucagon-Like Peptide 1; Levodopa; Lizards; Male; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Venoms

2012
The relationship between cerebral vascular disease and parkinsonism: The VADO study.
    Parkinsonism & related disorders, 2012, Volume: 18, Issue:6

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Disorders; Cohort Studies; Corpus Striatum; Cross-Sectional Studies; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon

2012
Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.
    Experimental neurology, 2012, Volume: 236, Issue:2

    Topics: Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Enkephalin, D-Penicillamine (2,5)-; Levodopa; Male; Neurons; Parkinsonian Disorders; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta

2012
Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.
    Neuropharmacology, 2012, Volume: 63, Issue:3

    Topics: Animals; Antiparkinson Agents; Autoradiography; Benserazide; Cotinine; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Receptors, Nicotinic

2012
L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients.
    Medical hypotheses, 2012, Volume: 79, Issue:2

    Topics: Animals; Brain; Dopaminergic Neurons; Humans; Levodopa; Models, Neurological; Neurodegenerative Diseases; Oxidopamine; Parkinsonian Disorders

2012
L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
    Neuroscience, 2012, Aug-30, Volume: 218

    Topics: Adrenergic Agents; Animals; Anxiety; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin

2012
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
    Neuropharmacology, 2012, Volume: 63, Issue:5

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benserazide; Biological Availability; Caudate Nucleus; Chromatography, High Pressure Liquid; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Half-Life; Levodopa; Macaca fascicularis; Metabolic Clearance Rate; Parkinsonian Disorders; Severity of Illness Index; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tissue Distribution

2012
Clinical and neuroimaging characteristics in neurodegenerative overlap syndrome.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2013, Volume: 34, Issue:6

    Topics: Aged; Aged, 80 and over; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Neuron Disease; Parkinsonian Disorders; Positron-Emission Tomography; Tremor; Tropanes

2013
Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism.
    The Journal of biological chemistry, 2012, Aug-10, Volume: 287, Issue:33

    Topics: Animals; Antiparkinson Agents; Cyclic AMP; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Levodopa; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Transgenic; Multiprotein Complexes; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders; Proteins; TOR Serine-Threonine Kinases

2012
Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease.
    Neurobiology of disease, 2012, Volume: 48, Issue:3

    Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Dopamine Agents; Dyskinesias; Electrodes, Implanted; Immunohistochemistry; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Subthalamic Nucleus

2012
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
    The European journal of neuroscience, 2012, Volume: 36, Issue:6

    Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskinesia, Drug-Induced; Fluoxetine; Levodopa; Male; Parkinsonian Disorders; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors

2012
L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function.
    Neurobiology of disease, 2012, Volume: 48, Issue:3

    Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neurons; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase

2012
DYT16: the original cases.
    Journal of neurology, neurosurgery, and psychiatry, 2012, Volume: 83, Issue:10

    Topics: Adolescent; Adult; Age of Onset; Anti-Dyskinesia Agents; Antiparkinson Agents; Baclofen; Biperiden; Botulinum Toxins; Carbidopa; Child; Child, Preschool; Cholinergic Antagonists; Drug Combinations; Drug Resistance; Dystonia; Dystonic Disorders; Female; Humans; Levodopa; Male; Middle Aged; Muscle Relaxants, Central; Mutation; Parkinsonian Disorders; Pedigree; Phenotype; RNA-Binding Proteins; Speech Disorders; Trihexyphenidyl; Young Adult

2012
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
    The European journal of neuroscience, 2012, Volume: 36, Issue:9

    Topics: Amantadine; Animals; Antiparkinson Agents; Cycloserine; Dextromethorphan; Dopamine Agents; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists

2012
MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Neuropharmacology, 2013, Volume: 66

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Putamen; Pyridines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate

2013
Clinical variability and L-Dopa responsive Parkinsonism in hereditary spastic paraplegia 11.
    Journal of neurology, 2012, Volume: 259, Issue:12

    Topics: Adult; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Spastic Paraplegia, Hereditary

2012
RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:2

    Topics: Animals; Antiparkinson Agents; Callithrix; Dyskinesia, Drug-Induced; Female; Histone Deacetylase Inhibitors; Levodopa; Parkinsonian Disorders

2013
Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain.
    Neurochemistry international, 2012, Volume: 61, Issue:7

    Topics: Animals; Behavior, Animal; Brain; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptors, Serotonin, 5-HT1

2012
New algorithm for the diagnosis of hereditary dystonia.
    Arquivos de neuro-psiquiatria, 2012, Volume: 70, Issue:9

    Topics: Algorithms; Antiparkinson Agents; Dystonic Disorders; Genetic Testing; Humans; Levodopa; Parkinsonian Disorders

2012
Gait patterns in Parkinsonian patients with or without mild cognitive impairment.
    Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:12

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Cognition Disorders; Executive Function; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Memory; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinsonian Disorders; Psychomotor Performance; Severity of Illness Index

2012
Eppendorf finalist. Striatal interneurons: causes of or cures for movement disorders?
    Science (New York, N.Y.), 2012, Oct-05, Volume: 338, Issue:6103

    Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Humans; Interneurons; Levodopa; Mice; Mice, Transgenic; Movement Disorders; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Receptors, AMPA; Receptors, Kainic Acid; Treatment Failure

2012
Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
    Neurobiology of disease, 2013, Volume: 50

    Topics: Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index

2013
Levodopa-responsive Parkinsonism following bilateral putaminal hemorrhages.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:4

    Topics: Antiparkinson Agents; Female; Functional Laterality; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Putaminal Hemorrhage; Stroke

2013
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
    Drug design, development and therapy, 2012, Volume: 6

    Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Carriers; Drug Combinations; Dyskinesia, Drug-Induced; Female; Lactic Acid; Levodopa; Microspheres; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, AMPA

2012
Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Dec-05, Volume: 32, Issue:49

    Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate

2012
Subthalamic lesion or levodopa treatment rescues giant GABAergic currents of PINK1-deficient striatum.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Dec-12, Volume: 32, Issue:50

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Electric Conductivity; Excitatory Amino Acid Agonists; Female; gamma-Aminobutyric Acid; Immunohistochemistry; Kainic Acid; Levodopa; Male; Mice; Mice, Knockout; Neurons; Parkinsonian Disorders; Patch-Clamp Techniques; Protein Kinases; Subthalamic Nucleus

2012
Drebrin immunoreactivity in the striatum of a rat model of levodopa-induced dyskinesia.
    Neuropathology : official journal of the Japanese Society of Neuropathology, 2013, Volume: 33, Issue:4

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dendritic Spines; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Microscopy, Immunoelectron; Neuropeptides; Parkinsonian Disorders; Rats; Rats, Wistar

2013
An electromyographic study of parkinsonian swallowing and its response to levodopa.
    Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:14

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Deglutition; Electromyography; Humans; Laryngeal Muscles; Levodopa; Middle Aged; Parkinsonian Disorders; Treatment Outcome

2012
A common optimization principle for motor execution in healthy subjects and parkinsonian patients.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, Jan-09, Volume: 33, Issue:2

    Topics: Acceleration; Aged; Algorithms; Antiparkinson Agents; Biomechanical Phenomena; Data Interpretation, Statistical; Deep Brain Stimulation; Executive Function; Female; Humans; Hypokinesia; Individuality; Isotonic Contraction; Levodopa; Male; Middle Aged; Models, Neurological; Motor Skills; Parkinsonian Disorders; Reaction Time

2013
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Neurobiology of disease, 2013, Volume: 54

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Blotting, Western; Dyskinesia, Drug-Induced; Immunoprecipitation; Levodopa; Male; MAP Kinase Signaling System; Oxidopamine; Parkinsonian Disorders; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Rats; Rats, Wistar; Receptors, Dopamine D1

2013
Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity.
    Helicobacter, 2013, Volume: 18, Issue:3

    Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiparkinson Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hypokinesia; Intestine, Small; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinsonian Disorders; Treatment Outcome

2013
The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
    Journal of neurochemistry, 2013, Volume: 125, Issue:2

    Topics: Animals; Antiparkinson Agents; Autoradiography; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic

2013
Levodopa-induced dyskinesia in a patient who has normal presynaptic dopaminergic neurons.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:8

    Topics: Antiparkinson Agents; Brain; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Tropanes

2013
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:8

    Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase

2013
Paradoxical response to apomorphine in a case of atypical parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:3

    Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Treatment Failure

2002
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
    Neurobiology of disease, 2002, Volume: 10, Issue:2

    Topics: Afferent Pathways; Animals; Bacterial Proteins; Behavior, Animal; Biomarkers; Brain Mapping; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Female; Image Processing, Computer-Assisted; Levodopa; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Severity of Illness Index; Substantia Nigra; Sympathectomy, Chemical; Transcription Factors

2002
Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Neuroscience, 2002, Volume: 114, Issue:1

    Topics: Animals; Behavior, Animal; Body Weight; Callithrix; Cell Count; Dopamine; Drug Interactions; Female; Glial Fibrillary Acidic Protein; Hedgehog Proteins; Immunohistochemistry; Levodopa; Male; Motor Activity; Nerve Growth Factors; Nerve Regeneration; Neurons; Parkinsonian Disorders; Recovery of Function; Substantia Nigra; Trans-Activators; Treatment Outcome; Tyrosine 3-Monooxygenase

2002
Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:4

    Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Disability Evaluation; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Multiple System Atrophy; Neurologic Examination; Parkinsonian Disorders; Reproducibility of Results

2002
Presynaptic parkinsonism in multiple system atrophy mimicking Parkinson's disease: a clinicopathological case study.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:4

    Topics: Brain; Combined Modality Therapy; Diagnosis, Differential; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Receptors, Presynaptic; Subthalamic Nucleus

2002
Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2002, Sep-15, Volume: 22, Issue:18

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Chlorocebus aethiops; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Electrodes, Implanted; Female; Globus Pallidus; Levodopa; Neurons; Organic Chemicals; Parkinsonian Disorders

2002
A site-specific mutation of tyrosine hydroxylase reduces feedback inhibition by dopamine in genetically modified cells grafted in parkinsonian rats.
    Journal of neurochemistry, 2002, Volume: 83, Issue:1

    Topics: Amino Acid Substitution; Animals; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Cells, Cultured; Coculture Techniques; Corpus Striatum; Disease Models, Animal; Dopamine; Extracellular Space; Feedback, Physiological; Female; Fibroblasts; Genetic Therapy; Graft Survival; GTP Cyclohydrolase; Levodopa; Microdialysis; Mutagenesis, Site-Directed; Parkinsonian Disorders; Rats; Rats, Inbred F344; Transduction, Genetic; Tyrosine 3-Monooxygenase

2002
Dopa-responsive parkinsonism phenotype of spinocerebellar ataxia type 2.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:5

    Topics: Aged; Atrophy; Cerebellum; Corpus Striatum; Dopamine Agonists; Genotype; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Organotechnetium Compounds; Parkinsonian Disorders; Pedigree; Pons; Radiopharmaceuticals; Spinocerebellar Ataxias; Substantia Nigra; Tomography, Emission-Computed, Single-Photon; Tropanes

2002
Restorative effects of glutamate antagonists in experimental parkinsonism.
    Amino acids, 2002, Volume: 23, Issue:1-3

    Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate

2002
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Amino acids, 2002, Volume: 23, Issue:1-3

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Sympatholytics; Transcription Factors

2002
Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
    Amino acids, 2002, Volume: 23, Issue:1-3

    Topics: Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Antipsychotic Agents; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Maze Learning; Mice; Mice, Inbred C57BL; Motor Activity; N-Methylaspartate; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Sympatholytics

2002
Systemic administration of dizocilpine maleate (MK-801) or L-dopa reverses the increases in GAD65 and GAD67 mRNA expression in the globus pallidus in a rat hemiparkinsonian model.
    Synapse (New York, N.Y.), 2002, Dec-15, Volume: 46, Issue:4

    Topics: Animals; Dizocilpine Maleate; Female; Globus Pallidus; Glutamate Decarboxylase; Injections, Subcutaneous; Isoenzymes; Levodopa; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger

2002
Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.
    Synapse (New York, N.Y.), 2002, Dec-15, Volume: 46, Issue:4

    Topics: Animals; Caffeine; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1

2002
Lesioning the thalamus for dyskinesia.
    Stereotactic and functional neurosurgery, 2001, Volume: 77, Issue:1-4

    Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulation; Haloperidol; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Reoperation; Retrospective Studies; Schizophrenia; Stereotaxic Techniques; Sulpiride; Torticollis; Treatment Outcome; Tremor; Ventral Thalamic Nuclei

2001
Growth-hormone release to clonidine and the clinical response to levodopa in parkinsonism.
    Journal of the American Geriatrics Society, 2002, Volume: 50, Issue:9

    Topics: Aged; Antiparkinson Agents; Benserazide; Clonidine; Female; Growth Hormone; Humans; Levodopa; Male; Parkinsonian Disorders

2002
Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus.
    Brain : a journal of neurology, 2002, Volume: 125, Issue:Pt 11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bicuculline; Cholinergic Fibers; Female; GABA Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Levodopa; Macaca mulatta; Male; Motor Activity; Neural Inhibition; Neural Pathways; Parkinsonian Disorders; Pons; Receptors, GABA-A; Recovery of Function; Tegmentum Mesencephali; Treatment Outcome

2002
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
    Experimental neurology, 2002, Volume: 177, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Dibenzothiazepines; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Quetiapine Fumarate; Rats; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists

2002
Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system.
    Experimental neurology, 2002, Volume: 177, Issue:1

    Topics: Animals; Corpus Striatum; Dyskinesias; Genes, fos; Injections, Intraventricular; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra

2002
Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment.
    Brain : a journal of neurology, 2002, Volume: 125, Issue:Pt 12

    Topics: Animals; Corpus Striatum; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; In Vitro Techniques; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate

2002
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
    Neuroscience, 2002, Volume: 115, Issue:4

    Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Male; Mazindol; Neostriatum; Neural Pathways; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins

2002
Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys.
    Neuroscience letters, 2002, Dec-19, Volume: 335, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dystonia; Female; Levodopa; Macaca fascicularis; Neurotoxins; Nitro Compounds; Parkinsonian Disorders; Propionates; Putamen; Striatonigral Degeneration; Substantia Nigra

2002
Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Experimental neurology, 2002, Volume: 178, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Forelimb; Homovanillic Acid; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Motor Activity; Nerve Tissue Proteins; Neuropeptides; Parkinsonian Disorders; Postural Balance; Recovery of Function; Tyrosine 3-Monooxygenase; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins; Walking

2002
Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6

    Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Cytoplasm; Drug Combinations; Indoles; Levodopa; Male; Microscopy, Immunoelectron; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Synaptic Membranes; Tyrosine 3-Monooxygenase

2002
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Motor Skills; Parkinsonian Disorders; Receptors, Cannabinoid; Receptors, Drug

2002
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinsonian Disorders; Recurrence

2002
AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
    The European journal of neuroscience, 2002, Volume: 16, Issue:11

    Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Isoquinolines; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tetrazoles

2002
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Experimental neurology, 2003, Volume: 179, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Severity of Illness Index

2003
Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism.
    Neurology, 2003, Jan-14, Volume: 60, Issue:1

    Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Electroencephalography; Humans; Levodopa; Male; Mianserin; Mirtazapine; Neuropsychological Tests; Parkinsonian Disorders; Polysomnography; REM Sleep Behavior Disorder

2003
Frequency of apraxia of eyelid opening in the general population and in patients with extrapyramidal disorders.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23 Suppl 2

    Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Apraxias; Blepharospasm; Dystonia; Eyelids; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Supranuclear Palsy, Progressive

2002
ALS-plus: 5 cases of concomitant amyotrophic lateral sclerosis and parkinsonism.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23 Suppl 2

    Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Dementia; Female; Humans; Levodopa; Male; Parkinsonian Disorders

2002
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors.
    Journal of neurochemistry, 2003, Volume: 84, Issue:4

    Topics: Acetylcholine; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Drug Therapy, Combination; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; N-Methylaspartate; Neuronal Plasticity; Parkinsonian Disorders; Potassium; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Synaptosomes

2003
Reversal of parkinsonism following liver transplantation.
    Neurology, 2003, Feb-11, Volume: 60, Issue:3

    Topics: Acute Disease; Aged; Antiparkinson Agents; Carbidopa; Disease Progression; Gait Disorders, Neurologic; Humans; Immunosuppressive Agents; Levodopa; Liver Cirrhosis; Liver Transplantation; Male; Parkinsonian Disorders; Remission Induction; Treatment Outcome; Tremor

2003
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
    Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Clonidine; Dopamine; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Guanfacine; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neurons; Parkinsonian Disorders; Prazosin; Receptors, Adrenergic, alpha-2; Synaptic Transmission; Yohimbine

2003
Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
    Journal of neurochemistry, 2003, Volume: 84, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Binding, Competitive; Chronic Disease; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Enkephalins; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Protein Precursors; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Tachykinins; Tyrosine 3-Monooxygenase

2003
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
    Journal of neurochemistry, 2003, Volume: 84, Issue:6

    Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; RNA, Messenger; Treatment Outcome

2003
Two large Polish kindreds with levodopa-responsive Parkinsonism not linked to known Parkinsonian genes and loci.
    Parkinsonism & related disorders, 2003, Volume: 9, Issue:4

    Topics: Activities of Daily Living; Adult; Age of Onset; Aged; Antiparkinson Agents; Dementia; Disease Progression; Female; Genetic Linkage; Humans; Levodopa; Male; Middle Aged; Molecular Biology; Parkinsonian Disorders; Pedigree; Phenotype; Poland; Urinary Incontinence

2003
Chemotherapy-induced parkinsonism responsive to levodopa: an underrecognized entity.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:3

    Topics: Aged; Antineoplastic Agents; Antiparkinson Agents; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Treatment Outcome

2003
Decreased striatal dopamine transporter binding in a patient with extrapontine myelinolysis.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:3

    Topics: Antiparkinson Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Hyponatremia; Isotonic Solutions; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Myelinolysis, Central Pontine; Nerve Tissue Proteins; Parkinsonian Disorders; Protein Binding; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tropanes

2003
[Current preclinical findings on substances against Parkinson's disease].
    Der Nervenarzt, 2003, Volume: 74 Suppl 1

    Topics: Animals; Antiparkinson Agents; Caenorhabditis elegans; Corpus Striatum; Dopamine Agonists; Drug Evaluation, Preclinical; Drugs, Investigational; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders

2003
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia.
    Nature neuroscience, 2003, Volume: 6, Issue:5

    Topics: Animals; Corpus Striatum; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; In Vitro Techniques; Levodopa; Male; Nerve Tissue Proteins; Neuronal Plasticity; Parkinsonian Disorders; Phosphoproteins; Phosphorylation; Rats; Rats, Wistar; Synaptic Transmission

2003
SCA2 may present as levodopa-responsive parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:4

    Topics: Adult; Aged; Alleles; Anticipation, Genetic; Antiparkinson Agents; Ataxins; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Pedigree; Phenotype; Proteins; Treatment Outcome; Trinucleotide Repeats

2003
Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats.
    Brain research, 2003, May-02, Volume: 971, Issue:1

    Topics: Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Enzyme Inhibitors; Gene Transfer, Horizontal; Genetic Vectors; Herpesvirus 1, Human; Immunohistochemistry; Levodopa; Male; Models, Animal; Motor Activity; Neurons; Parkinsonian Disorders; Phosphorylation; Piperidines; Protein Kinase C; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Time Factors

2003
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism.
    Journal of neurochemistry, 2003, Volume: 85, Issue:4

    Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Binding, Competitive; Cannabinoid Receptor Modulators; Cerebellum; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Endocannabinoids; Excitatory Postsynaptic Potentials; Fatty Acids, Unsaturated; Glutamic Acid; Glycerides; In Vitro Techniques; Levodopa; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Phospholipase D; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug

2003
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Male; Nitriles; Parkinsonian Disorders; Pulse Therapy, Drug; Substantia Nigra; Time Factors

2003
Parkin disease: a phenotypic study of a large case series.
    Brain : a journal of neurology, 2003, Volume: 126, Issue:Pt 6

    Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Dystonia; Female; Genetic Predisposition to Disease; Humans; Levodopa; Ligases; Male; Mental Disorders; Middle Aged; Mutation; Parkinsonian Disorders; Pedigree; Phenotype; Polymerase Chain Reaction; Ubiquitin-Protein Ligases

2003
Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease.
    European journal of neurology, 2003, Volume: 10, Issue:4

    Topics: Aged; Antiparkinson Agents; Female; Gait Disorders, Neurologic; Humans; Leg; Levodopa; Male; Middle Aged; Motion; Parkinsonian Disorders; Prevalence; Psychomotor Performance; Regression Analysis; Reproducibility of Results; Surveys and Questionnaires; Time Factors; Videotape Recording

2003
D3 receptors and levodopa-induced dyskinesia.
    The Lancet. Neurology, 2003, Volume: 2, Issue:7

    Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders; Piperazines; Receptors, Dopamine D2; Receptors, Dopamine D3

2003
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:8

    Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Callithrix; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Male; Parkinsonian Disorders; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, AMPA; Receptors, Dopamine; Receptors, GABA; Receptors, Histamine; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin

2003
Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:8

    Topics: Adult; Antiparkinson Agents; DNA Mutational Analysis; GTP Cyclohydrolase; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Pedigree; Point Mutation; Severity of Illness Index; Ubiquitin-Protein Ligases

2003
Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.
    Experimental neurology, 2003, Volume: 182, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Magnesium Sulfate; Motor Activity; Parkinsonian Disorders

2003
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
    Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ditiocarb; Dopamine; Drug Synergism; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Reaction Time; Recovery of Function; Selegiline; Serotonin

2003
[A patient with multiple system atrophy presenting prolonged levodopa-responsive parkinsonism and off-dystonia of the trunk].
    No to shinkei = Brain and nerve, 2003, Volume: 55, Issue:7

    Topics: Brain; Diagnosis, Differential; Dystonia; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Olivopontocerebellar Atrophies; Parkinsonian Disorders; Time Factors

2003
SCA2 and SCA3 mutations in young-onset dopa-responsive parkinsonism.
    European journal of neurology, 2003, Volume: 10, Issue:5

    Topics: Adult; Age of Onset; Female; Humans; Levodopa; Machado-Joseph Disease; Male; Middle Aged; Mutation; Parkinsonian Disorders; Spinocerebellar Ataxias; Yugoslavia

2003
Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats.
    Journal of neurochemistry, 2003, Volume: 86, Issue:6

    Topics: Animals; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Electron Transport Complex IV; Enkephalins; Entopeduncular Nucleus; Globus Pallidus; Glutamate Decarboxylase; In Situ Hybridization; Isoenzymes; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus

2003
Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa.
    Experimental neurology, 2003, Volume: 183, Issue:1

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Administration Schedule; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Time; Treatment Outcome

2003
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
    Experimental neurology, 2003, Volume: 183, Issue:1

    Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothiazoles; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles; Treatment Outcome; Tritium; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins

2003
Denervation and repeated L-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats.
    Neurobiology of disease, 2003, Volume: 14, Issue:1

    Topics: Animals; Corpus Striatum; Denervation; DNA-Binding Proteins; Enkephalins; Gene Expression Regulation; Levodopa; Male; Neural Pathways; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Transcription Factors

2003
[EXPERIENCES WITH L-DOPA IN THE THERAPY OF PARKINSONISM].
    Psychiatria et neurologia, 1963, Volume: 146

    Topics: Dihydroxyphenylalanine; Humans; Levodopa; Parkinsonian Disorders

1963
[THE EFFICACY OF L-DOPA IN PARKINSON PATIENTS WITH AND WITHOUT STEREOTACTIC BRAIN SURGERY].
    Archiv fur Psychiatrie und Nervenkrankheiten, 1964, Jun-01, Volume: 205

    Topics: Brain; Dihydroxyphenylalanine; Levodopa; Neurosurgery; Neurosurgical Procedures; Parkinsonian Disorders; Psychosurgery; Stereotaxic Techniques

1964
[ON THE CONTROL OF AKINESIA AND OTHER EXTRAPYRAMIDAL MOTOR DISORDERS WITH L-DOPA (L-DIHYDROXYPHENYLALANINE)].
    Deutsche medizinische Wochenschrift (1946), 1964, Oct-02, Volume: 89

    Topics: Chorea; Dihydroxyphenylalanine; Electromyography; Extrapyramidal Tracts; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Neurosurgery; Neurosurgical Procedures; Parkinsonian Disorders; Stereotaxic Techniques; Torticollis; Tremor

1964
[ELECTROENCEPHALOGRAMS DURING ADMINISTRATION OF L-DOPA BEFORE, IN (DEPTH LEADS AND STIMULATION EFFECTS) AND AFTER STEREOTACTIC BRAIN OPERATIONS IN PARKINSON PATIENTS].
    Acta neurovegetativa, 1964, Dec-17, Volume: 27

    Topics: Brain; Dihydroxyphenylalanine; Electroencephalography; Levodopa; Neurosurgery; Neurosurgical Procedures; Parkinsonian Disorders; Stereotaxic Techniques

1964
[ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM].
    Archiv fur Psychiatrie und Nervenkrankheiten, 1964, Dec-02, Volume: 206

    Topics: Biomedical Research; Brain; Catecholamines; Dihydroxyphenylalanine; Levodopa; Metabolism; Parkinson Disease; Parkinsonian Disorders; Pharmacology; Reserpine; Toxicology

1964
Multiple system atrophy: an update.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18 Suppl 6

    Topics: alpha-Synuclein; Animals; Brain; Clinical Trials as Topic; Humans; Inclusion Bodies; Levodopa; Multiple System Atrophy; Nerve Tissue Proteins; Neurologic Examination; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Synucleins

2003
Basal ganglia neuronal discharge in primary and secondary dystonia.
    Advances in neurology, 2004, Volume: 94

    Topics: Action Potentials; Adolescent; Adult; Aged; Carrier Proteins; Child; Dystonic Disorders; Electric Stimulation; Electrophysiology; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Chaperones; Neurons; Parkinsonian Disorders; Putamen; Treatment Outcome

2004
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Oct-08, Volume: 23, Issue:27

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists

2003
Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:10

    Topics: Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Sectional Studies; Demography; Diagnosis, Differential; Ethnicity; Europe; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurologic Examination; Outpatient Clinics, Hospital; Parkinsonian Disorders; Prevalence; Prospective Studies; Referral and Consultation; Retrospective Studies; Statistics, Nonparametric

2003
Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:10

    Topics: Aged; Antiparkinson Agents; Brain Mapping; Case-Control Studies; Demography; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Multiple System Atrophy; Parkinsonian Disorders

2003
Persistent hemiballism after subthalamotomy: the size of the lesion matters more than the location.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:10

    Topics: Antiparkinson Agents; Corpus Striatum; Dyskinesias; Female; Functional Laterality; Humans; Levodopa; Middle Aged; Neurosurgical Procedures; Parkinsonian Disorders; Postoperative Complications; Thalamus

2003
The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study.
    Chemical research in toxicology, 2003, Volume: 16, Issue:10

    Topics: 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Aromatic Amino Acid Decarboxylase Inhibitors; Body Temperature; Chromatography, High Pressure Liquid; Dopa Decarboxylase; Hydroxyindoleacetic Acid; Levodopa; Male; Mannitol; Microdialysis; Neostriatum; Parkinsonian Disorders; Perfusion; Rats; Rats, Sprague-Dawley; Salicylates; Serotonin; Time Factors

2003
A paradoxical acute effect of levodopa in de novo parkinsonian patients: worsening of some bradykinetic components.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2003, Volume: 24, Issue:3

    Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Choice Behavior; Drug Administration Schedule; Electromyography; Female; Humans; Hypokinesia; Levodopa; Male; Parkinsonian Disorders; Reaction Time

2003
Awakenings from persistent vegetative state: report of three cases with parkinsonism and brain stem lesions on MRI.
    Journal of neurology, neurosurgery, and psychiatry, 2003, Volume: 74, Issue:11

    Topics: Adolescent; Adult; Antiparkinson Agents; Brain Stem; Craniocerebral Trauma; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Persistent Vegetative State; Receptors, Dopamine; Treatment Outcome

2003
Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Synapse (New York, N.Y.), 2004, Volume: 51, Issue:2

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesias; Functional Laterality; Levodopa; Male; Motor Activity; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Subthalamic Nucleus; Time Factors

2004
Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process.
    Neuroscience research, 2003, Volume: 47, Issue:4

    Topics: Administration, Oral; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Female; Immunohistochemistry; Injections, Intraventricular; Levodopa; Mesencephalon; Nerve Degeneration; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Time Factors; Tyrosine 3-Monooxygenase

2003
Clinical and [99mTc]TRODAT-1/[123I]IBZM SPECT imaging findings in dopa-responsive dystonia.
    European neurology, 2004, Volume: 51, Issue:1

    Topics: Adult; Benzamides; Brain; Contrast Media; Diagnosis, Differential; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dystonia; Female; Humans; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Organotechnetium Compounds; Parkinsonian Disorders; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon; Tropanes

2004
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Dopamine Agents; Drug Synergism; Drug Therapy, Combination; Female; Indoles; Levetiracetam; Levodopa; Male; Parkinsonian Disorders; Piracetam

2003
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Denervation; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine; RNA, Messenger; Time; Triazoles

2003
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles

2003
Genetically modified human embryonic stem cells relieve symptomatic motor behavior in a rat model of Parkinson's disease.
    Neuroscience letters, 2003, Dec-19, Volume: 353, Issue:2

    Topics: Animals; Blotting, Western; Cells, Cultured; Disease Models, Animal; Embryo, Mammalian; Genetic Therapy; Graft Survival; GTP Cyclohydrolase; Humans; Immunohistochemistry; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Stem Cells; Transfection; Tyrosine 3-Monooxygenase

2003
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Experimental neurology, 2004, Volume: 185, Issue:1

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression; In Situ Hybridization; Indoles; Levodopa; Male; Motor Activity; Opioid Peptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Synaptic Transmission

2004
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:1

    Topics: Animals; Antiparkinson Agents; Callithrix; Carbidopa; Chlorobenzenes; Cyclobutanes; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Levodopa; Locomotion; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinsonian Disorders; Postural Balance; Stereotyped Behavior

2004
Exercise-induced dystonia as a preceding symptom of familial Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:2

    Topics: Aged; Antiparkinson Agents; Carbidopa; Disease Progression; DNA Mutational Analysis; Drug Combinations; Dystonic Disorders; Exercise; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Phenotype; Semen; Ubiquitin-Protein Ligases; Videotape Recording

2004
L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease.
    Synapse (New York, N.Y.), 2004, Volume: 52, Issue:2

    Topics: Animals; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra

2004
Parkinsonism following anterior choroidal artery stroke.
    European journal of neurology, 2004, Volume: 11, Issue:4

    Topics: Adult; Angiography; Antiparkinson Agents; Benserazide; Cerebral Infarction; Female; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Parkinsonian Disorders; Putamen; Tomography, Emission-Computed, Single-Photon

2004
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
    Experimental neurology, 2004, Volume: 187, Issue:1

    Topics: Animals; Antiparkinson Agents; Apomorphine; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phenols; Piperidines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate

2004
Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
    Experimental neurology, 2004, Volume: 187, Issue:1

    Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Heterozygote; Homozygote; Islands of Calleja; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Nucleus Accumbens; Olfactory Pathways; Oxidative Stress; Parkinsonian Disorders; Prosencephalon; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Receptor, trkB; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Tyrosine 3-Monooxygenase

2004
The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
    Behavioural brain research, 2004, May-05, Volume: 151, Issue:1-2

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Catalepsy; Chromatography, High Pressure Liquid; Dopamine; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reaction Time; Rotenone; Statistics, Nonparametric; Time Factors

2004
Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:5

    Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Corpus Callosum; Diagnosis, Differential; Electromyography; Humans; Levodopa; Magnetic Resonance Imaging; Magnetoencephalography; Middle Aged; Motor Cortex; Multiple System Atrophy; Muscle, Skeletal; Nerve Degeneration; Nerve Net; Neural Inhibition; Parkinsonian Disorders; Supranuclear Palsy, Progressive

2004
Arg(184)His mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa-responsive dystonia with parkinsonism: a case report.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:5

    Topics: Antiparkinson Agents; Arginine; Brain; Dystonia; Genes, Recessive; GTP Cyclohydrolase; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Pedigree; Phenylketonurias; Point Mutation; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon

2004
SCA2 presenting as levodopa-responsive parkinsonism in a young patient from the United Kingdom: a case report.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:5

    Topics: Adult; Alleles; Antiparkinson Agents; Ataxins; Female; Humans; Levodopa; Nerve Tissue Proteins; Parkinsonian Disorders; Phenotype; Proteins; Spinocerebellar Ataxias; Trinucleotide Repeat Expansion

2004
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2004, Jun-09, Volume: 24, Issue:23

    Topics: Animals; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Denervation; Disease Models, Animal; Disks Large Homolog 4 Protein; Enzyme Inhibitors; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Membrane Proteins; Motor Activity; Nerve Tissue Proteins; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Peptides; Phosphorylation; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Sulfonamides; Synaptic Transmission

2004
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
    Experimental neurology, 2004, Volume: 188, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzopyrans; Brain; Callithrix; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Indoles; Levodopa; Parkinsonian Disorders; Pyrroles; Receptors, Dopamine D2; Receptors, Dopamine D3

2004
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Experimental neurology, 2004, Volume: 188, Issue:2

    Topics: Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Range of Motion, Articular; Receptors, N-Methyl-D-Aspartate; Treatment Failure

2004
Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:7

    Topics: Alleles; Antiparkinson Agents; Atrophy; Brain Stem; Female; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Motor Neuron Disease; Parkinsonian Disorders; Pedigree; Phenotype; Spinocerebellar Ataxias

2004
Markedly asymmetrical parkinsonism as a leading feature of adult-onset Huntington's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:7

    Topics: Adult; Alleles; Antiparkinson Agents; Carbidopa; Cognition Disorders; Diagnosis, Differential; Drug Combinations; Humans; Huntington Disease; Levodopa; Male; Neuropsychological Tests; Parkinsonian Disorders; Pedigree; Severity of Illness Index

2004
L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Behavioural brain research, 2004, Aug-31, Volume: 153, Issue:2

    Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Corpus Striatum; Dopamine; Drug Synergism; Electron Transport Complex I; Levodopa; Male; Motor Activity; Motor Skills; Muscle Rigidity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Uncoupling Agents

2004
Case study: cerebrovascular parkinsonism with levodopa addiction.
    Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:9

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Disorders; Female; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Substance Withdrawal Syndrome; Substance-Related Disorders

2004
High titer retroviral gene transduction to neural progenitor cells for establishment of donor cells for neural transplantation to parkinsonian model rats.
    Neurologia medico-chirurgica, 2004, Volume: 44, Issue:7

    Topics: Animals; Cells, Cultured; Corpus Striatum; Fetal Tissue Transplantation; Gene Expression Regulation, Enzymologic; Gene Transfer Techniques; Humans; Levodopa; Mesencephalon; Neurons; Parkinsonian Disorders; Rats; Rats, Wistar; Retroviridae; Stem Cell Transplantation; Transduction, Genetic; Transformation, Genetic; Tyrosine 3-Monooxygenase

2004
[Increase in regional cerebral blood flow of striatum induced by low dose levodopa in a patient with hemiparkinsonism].
    Rinsho shinkeigaku = Clinical neurology, 2004, Volume: 44, Issue:7

    Topics: Antiparkinson Agents; Cerebrovascular Circulation; Corpus Striatum; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Stimulation, Chemical

2004
Chronic bilateral subthalamic deep brain stimulation in a patient with homozygous deletion in the parkin gene.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:12

    Topics: Antiparkinson Agents; Deep Brain Stimulation; Disability Evaluation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Exons; Female; Gene Deletion; Genomic Imprinting; Homozygote; Humans; Levodopa; Male; Parkinsonian Disorders; Polymerase Chain Reaction; Severity of Illness Index; Subthalamic Nucleus; Ubiquitin-Protein Ligases

2004
Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates.
    Annals of neurology, 2004, Volume: 56, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Glycine Agents; Levodopa; Macaca mulatta; Motor Activity; Parkinsonian Disorders; Pilot Projects; Psychomotor Performance; Receptors, Glycine

2004
Pathophysiology of parkinsonism due to hydrocephalus.
    Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:11

    Topics: Adult; Antiparkinson Agents; Brain Mapping; Carbidopa; Caudate Nucleus; Cerebral Ventricles; Drug Combinations; Equipment Failure; Humans; Hydrocephalus; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Neurologic Examination; Parkinsonian Disorders; Positron-Emission Tomography; Postoperative Complications; Putamen; Ventriculoperitoneal Shunt

2004
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
    Annals of neurology, 2005, Volume: 57, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Blotting, Western; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Guanosine 5'-O-(3-Thiotriphosphate); Immunohistochemistry; In Situ Hybridization; Isotopes; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Nortropanes; Parkinsonian Disorders; Phosphoproteins; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; Signal Transduction; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase

2005
[Dose levodopa decrease the right and left difference of the striatal blood flow in patients with hemiparkinsonism?].
    Rinsho shinkeigaku = Clinical neurology, 2004, Volume: 44, Issue:10

    Topics: Animals; Antiparkinson Agents; Cerebrovascular Circulation; Corpus Striatum; Humans; Levodopa; Parkinsonian Disorders

2004
Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2004, Dec-01, Volume: 24, Issue:48

    Topics: Animals; Antioxidants; Apoptosis; Brain; Cell Count; Dopamine; Dopamine Agonists; Drosophila melanogaster; Electron Transport Complex I; Insecticides; Levodopa; Locomotion; Melatonin; Nerve Degeneration; Neurons; Oxidative Stress; Parkinsonian Disorders; Phenotype; Rotenone

2004
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:4

    Topics: Adult; Antiparkinson Agents; Brazil; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Exons; Female; Follow-Up Studies; Foot; Genotype; Heterozygote; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Point Mutation; Ubiquitin-Protein Ligases

2005
Cerebral glutamate metabolism in Parkinson's disease: an in vivo dynamic (13)C NMS study in the rat.
    Experimental neurology, 2005, Volume: 191, Issue:2

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Carbon Isotopes; Disease Models, Animal; Dopamine; Glutamic Acid; Glutaminase; Glutamine; Infusions, Intravenous; Levodopa; Lipid Metabolism; Magnetic Resonance Spectroscopy; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Sodium Acetate

2005
Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats.
    Journal of controlled release : official journal of the Controlled Release Society, 2005, Feb-16, Volume: 102, Issue:3

    Topics: Animals; Biotransformation; Carbidopa; Drug Evaluation, Preclinical; Levodopa; Male; Microspheres; Parkinsonian Disorders; Rats

2005
L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain.
    Neurobiology of disease, 2005, Volume: 18, Issue:2

    Topics: Animals; Antiparkinson Agents; Arrestins; Basal Ganglia; beta-Adrenergic Receptor Kinases; Brain; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; G-Protein-Coupled Receptor Kinases; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Phosphoproteins; Phosphorylation; Protein Serine-Threonine Kinases; Receptors, G-Protein-Coupled; Up-Regulation

2005
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
    Experimental neurology, 2005, Volume: 192, Issue:1

    Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome

2005
Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.
    Psychopharmacology, 2005, Volume: 179, Issue:1

    Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Drug Synergism; Levodopa; Male; Parkinsonian Disorders; Pyridines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate

2005
Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2005, Feb-23, Volume: 25, Issue:8

    Topics: Animals; Basal Ganglia; Deoxyglucose; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Levodopa; Limbic System; Macaca fascicularis; Motor Cortex; Parkinsonian Disorders; Septal Nuclei; Somatosensory Cortex; Substantia Nigra; Subthalamic Nucleus

2005
3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2005, Feb-23, Volume: 25, Issue:8

    Topics: Animals; Antiparkinson Agents; Ataxia; Benserazide; Blindness; Corpus Striatum; Dopamine; Homeodomain Proteins; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Parkinsonian Disorders; Psychomotor Performance; Substantia Nigra; Transcription Factors

2005
Levodopa-responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:6

    Topics: Animals; Antiparkinson Agents; Central Nervous System Viral Diseases; Child, Preschool; DNA Mutational Analysis; Female; Histidine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Mice; Mutation; Parkinsonian Disorders; Rats; Treatment Outcome; Tyrosine; Tyrosine 3-Monooxygenase

2005
Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:6

    Topics: Adult; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Substantia Nigra

2005
Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism.
    Journal of neural transmission (Vienna, Austria : 1996), 2005, Volume: 112, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Chromosome Mapping; Corpus Striatum; DNA Mutational Analysis; Dopamine Plasma Membrane Transport Proteins; Female; Genetic Predisposition to Disease; Genetic Testing; Humans; Inheritance Patterns; Levodopa; Male; Middle Aged; Neural Pathways; Parkinsonian Disorders; Pedigree; Poland; Substantia Nigra; Tomography, Emission-Computed, Single-Photon

2005
Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Neuroscience, 2005, Volume: 132, Issue:2

    Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Female; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Naloxone; Narcotic Antagonists; Narcotics; Nerve Tissue Proteins; Parkinsonian Disorders; Protein Binding; Receptors, Opioid; Saimiri; Sulfur Isotopes

2005
Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration.
    Neurobiology of disease, 2005, Volume: 20, Issue:2

    Topics: Animals; Basal Ganglia; Cell Count; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; gamma-Aminobutyric Acid; Globus Pallidus; Glutamate Decarboxylase; Immunohistochemistry; Isoenzymes; Levodopa; Male; Neural Inhibition; Neurons; Parkinsonian Disorders; Saimiri; Transcriptional Activation; Up-Regulation

2005
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Experimental neurology, 2005, Volume: 194, Issue:1

    Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome

2005
Recovery from parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy.
    Metabolic brain disease, 2005, Volume: 20, Issue:1

    Topics: Anti-Bacterial Agents; Antiparkinson Agents; Benzothiazoles; Brain; Chronic Disease; Dipeptides; Evoked Potentials, Visual; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Paromomycin; Pramipexole; Recovery of Function; Thiazoles; Treatment Outcome; Vision Disorders

2005
Activation of mitochondrial ATP-sensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats.
    The international journal of neuropsychopharmacology, 2006, Volume: 9, Issue:1

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Catalepsy; Decanoic Acids; Diazoxide; Disease Models, Animal; Dopamine; Hydroxy Acids; Levodopa; Male; Motor Activity; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels; Propylamines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotenone; Substantia Nigra

2006
Different clinical and evolutional patterns in late idiopathic and vascular parkinsonism.
    Journal of neurology, 2005, Volume: 252, Issue:9

    Topics: Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Parkinsonian Disorders; Prognosis; Treatment Outcome

2005
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:7

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Kynurenic Acid; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Mixed Function Oxygenases; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors

2005
The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease.
    Neurology, 2005, Jun-14, Volume: 64, Issue:11

    Topics: Age of Onset; Brain; Diagnosis, Differential; Dopamine Agents; Energy Metabolism; Genetic Predisposition to Disease; Humans; Italy; Levodopa; Male; Middle Aged; Mitochondria; Mitochondrial Diseases; Mutation; Parkinson Disease; Parkinsonian Disorders; Phenotype; Protein Kinases; Shy-Drager Syndrome; Sympathetic Nervous System; Tomography, Emission-Computed, Single-Photon; Treatment Outcome

2005
Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:10

    Topics: Adolescent; Adult; Age of Onset; Antiparkinson Agents; Child; Chromosomes, Human, Pair 1; Dementia; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Pedigree; Pyramidal Tracts; Severity of Illness Index; Supranuclear Palsy, Progressive

2005
Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Neuropharmacology, 2005, Volume: 49, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Female; Levodopa; Macaca fascicularis; Motor Activity; Naltrexone; Narcotic Antagonists; Ovariectomy; Parkinsonian Disorders; Statistics, Nonparametric; Time Factors

2005
Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila.
    Proceedings of the National Academy of Sciences of the United States of America, 2005, Jul-19, Volume: 102, Issue:29

    Topics: Animals; Blotting, Northern; Blotting, Western; Brain; Chlorocebus aethiops; COS Cells; Dopamine; Drosophila; Drosophila Proteins; Histocytochemistry; Immunoenzyme Techniques; Immunoprecipitation; JNK Mitogen-Activated Protein Kinases; Levodopa; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Mutation; Neurons; Parkinsonian Disorders; Signal Transduction; Tyrosine 3-Monooxygenase; Ubiquitin-Protein Ligases

2005
Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism.
    The European journal of neuroscience, 2005, Volume: 22, Issue:1

    Topics: Aging; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Levodopa; Male; Nerve Tissue Proteins; Neural Pathways; Neuronal Plasticity; Parkinsonian Disorders; Phosphoprotein Phosphatases; Phosphoproteins; Phosphorylation; Presynaptic Terminals; Protein Phosphatase 1; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Substantia Nigra; Synaptic Membranes; Up-Regulation

2005
Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
    The European journal of neuroscience, 2005, Volume: 22, Issue:1

    Topics: Animals; Antiparkinson Agents; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Degeneration; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase

2005
Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:11

    Topics: Adult; Dysarthria; Dyskinesias; Electric Stimulation Therapy; Functional Laterality; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Severity of Illness Index; Subthalamic Nucleus

2005
In vivo models of multiple system atrophy.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 12

    Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Macaca fascicularis; Mice; MPTP Poisoning; Multiple System Atrophy; Oxidopamine; Parkinsonian Disorders; Point Mutation; Rats; Substantia Nigra

2005
Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
    Neuroscience, 2005, Volume: 135, Issue:2

    Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Brain; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Interactions; Female; Gene Expression; Gene Expression Regulation; In Situ Hybridization; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Isoforms; Rats; Rats, Wistar; RNA, Messenger; Rotation; Substantia Nigra; Synaptotagmins; Time Factors; Tyrosine 3-Monooxygenase

2005
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:1

    Topics: Animals; Antiparkinson Agents; Benserazide; Benzoxazoles; Corpus Striatum; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Protein Precursors; Receptors, N-Methyl-D-Aspartate; RNA, Messenger

2006
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Biological psychiatry, 2006, Jan-01, Volume: 59, Issue:1

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Proto-Oncogene Proteins c-fos; RNA, Messenger; Statistics, Nonparametric; Time Factors

2006
Oculogyric dystonic states in early-onset parkinsonism with basal ganglia calcifications.
    Neurology, 2005, Sep-13, Volume: 65, Issue:5

    Topics: Age of Onset; Antiparkinson Agents; Apomorphine; Basal Ganglia; Calcinosis; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Humans; Levodopa; Middle Aged; Ocular Motility Disorders; Oculomotor Muscles; Parkinsonian Disorders

2005
Hemiparkinsonism with a discrete lacunar infarction in the contralateral substantia nigra.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:1

    Topics: Antiparkinson Agents; Brain Stem Infarctions; Carbidopa; Cerebral Infarction; Diagnosis, Differential; Dominance, Cerebral; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Substantia Nigra; Tomography, Emission-Computed, Single-Photon

2006
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
    Neurobiology of aging, 2006, Volume: 27, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dehydroepiandrosterone; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Severity of Illness Index

2006
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia.
    Neurobiology of disease, 2006, Volume: 21, Issue:3

    Topics: Animals; Brain Tissue Transplantation; Dyskinesias; Female; Fetal Tissue Transplantation; Levodopa; Mesencephalon; Nerve Regeneration; Neurons; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2006
Dopa-responsive hemiparkinsonism due to midbrain Virchow-Robin spaces?
    Journal of neurology, 2005, Volume: 252, Issue:12

    Topics: Antiparkinson Agents; Female; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Parkinsonian Disorders; Subarachnoid Space; Tomography, Emission-Computed, Single-Photon

2005
Modulation of torsinA expression in the globus pallidus internus is associated with levodopa-induced dyskinesia in hemiparkinsonian rats.
    Neuroscience letters, 2006, Mar-20, Volume: 396, Issue:1

    Topics: Animals; Cell Count; Disease Models, Animal; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Globus Pallidus; Levodopa; Male; Molecular Chaperones; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar

2006
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
    Neurobiology of disease, 2006, Volume: 22, Issue:2

    Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Levodopa; Movement; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Selective Serotonin Reuptake Inhibitors; Substantia Nigra; Transplantation Tolerance

2006
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:5

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors

2006
Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
    Neurochemistry international, 2006, Volume: 48, Issue:5

    Topics: Aged; Aged, 80 and over; Animals; Arachidonic Acid; Cerebral Cortex; Chromatography, Gas; Dietary Fats; Disease Models, Animal; Docosahexaenoic Acids; Dopamine Agents; Dyskinesia, Drug-Induced; Fatty Acids; Fatty Acids, Unsaturated; Female; Humans; Levodopa; Lipid Metabolism; Macaca fascicularis; Male; Neurons; Parkinson Disease; Parkinsonian Disorders; Postmortem Changes; Species Specificity

2006
Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.
    Journal of neural transmission (Vienna, Austria : 1996), 2006, Volume: 113, Issue:9

    Topics: Aged; Antiparkinson Agents; Benzamides; Diagnosis, Differential; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Pyrrolidines; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed, Single-Photon; Tropanes

2006
Microelectrode recording can be a good adjunct in magnetic resonance image-directed subthalamic nucleus deep brain stimulation for parkinsonism.
    Surgical neurology, 2006, Volume: 65, Issue:3

    Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Dominance, Cerebral; Electric Stimulation Therapy; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Middle Aged; Outcome Assessment, Health Care; Parkinsonian Disorders; Retrospective Studies; Stereotaxic Techniques; Subthalamic Nucleus; Surgery, Computer-Assisted; Treatment Outcome

2006
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
    Synapse (New York, N.Y.), 2006, Jun-01, Volume: 59, Issue:7

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; Adrenergic Agents; Animals; Caffeine; Corpus Striatum; Dynorphins; Dyskinesias; Enkephalins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; RNA, Messenger

2006
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Journal of neurochemistry, 2006, Volume: 96, Issue:6

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Extracellular Fluid; Female; Levodopa; Microdialysis; Microinjections; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Serotonin; Up-Regulation

2006
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Mar-15, Volume: 26, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antiparkinson Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Disks Large Homolog 4 Protein; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Membrane Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Binding; Protein Interaction Mapping; Protein Processing, Post-Translational; Protein Structure, Tertiary; Protein Transport; Protein-Tyrosine Kinases; Psychomotor Performance; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Recombinant Fusion Proteins; Subcellular Fractions; Synapses

2006
Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
    Behavioural brain research, 2006, Jun-30, Volume: 170, Issue:2

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Time Factors

2006
Three in one: case report supporting different origins of essential and parkinsonian tremors.
    European neurology, 2006, Volume: 55, Issue:2

    Topics: Aged; Antiparkinson Agents; Antithyroid Agents; Combined Modality Therapy; Deep Brain Stimulation; Diagnosis, Differential; Essential Tremor; Female; Humans; Hyperthyroidism; Levodopa; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Tremor; Ventral Thalamic Nuclei

2006
Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:10

    Topics: Adrenergic beta-Antagonists; Aged; Anxiety Disorders; Benzodiazepines; Carbidopa; Central Nervous System Agents; Cerebellar Ataxia; Cholinesterase Inhibitors; Dopamine Agonists; Female; Fragile X Syndrome; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Tremor

2006
Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists.
    Experimental neurology, 2006, Volume: 202, Issue:1

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Functional Laterality; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors

2006
MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
    The European journal of neuroscience, 2006, Volume: 23, Issue:10

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fenfluramine; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Antagonists; Serotonin Agents

2006
MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA.
    Journal of the neurological sciences, 2006, Nov-15, Volume: 249, Issue:2

    Topics: Adult; Aged; Antiparkinson Agents; Autonomic Nervous System; Cerebellar Ataxia; Death, Sudden; Diagnostic Imaging; Drug Resistance; Female; Follow-Up Studies; Humans; Japan; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Multiple System Atrophy; Parkinsonian Disorders; Phenotype; Retrospective Studies; Vocal Cord Paralysis

2006
Dopa-responsive parkinsonism after acute subdural hematoma.
    European journal of neurology, 2006, Volume: 13, Issue:7

    Topics: Adult; Antiparkinson Agents; Female; Hematoma, Subdural, Acute; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Tomography, X-Ray Computed

2006
Levodopa can worsen tremor associated with dystonia.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:10

    Topics: Aged; Antiparkinson Agents; Carbidopa; Diagnostic Errors; Drug Combinations; Dystonia; Female; Humans; Levodopa; Neurologic Examination; Parkinsonian Disorders; Psychomotor Performance; Tremor

2006
Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques.
    NeuroImage, 2006, Nov-01, Volume: 33, Issue:2

    Topics: Animals; Brain Mapping; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Functional Laterality; Image Processing, Computer-Assisted; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Parkinsonian Disorders; Putamen; Substantia Nigra

2006
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    Biological psychiatry, 2007, Apr-01, Volume: 61, Issue:7

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; In Situ Hybridization; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Protein Precursors; Radioligand Assay; Receptors, Opioid; Regression Analysis; RNA, Messenger; Subthalamic Nucleus

2007
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Grooming; Hallucinations; Levodopa; Parkinsonian Disorders; Psychomotor Agitation; Psychotic Disorders; Statistics, Nonparametric; Stereotyped Behavior

2006
Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.
    Archives of neurology, 2006, Volume: 63, Issue:9

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dopamine Agonists; Drug Administration Routes; Drug Administration Schedule; Levodopa; Mental Disorders; Parkinsonian Disorders; Severity of Illness Index; Time Factors

2006
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Sep-13, Volume: 26, Issue:37

    Topics: Animals; Antibodies, Monoclonal; Antigens; Basal Ganglia; Biomarkers; Blood-Brain Barrier; Bromodeoxyuridine; Cell Count; Cell Proliferation; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Endothelial Cells; Female; Intermediate Filament Proteins; Levodopa; Motor Activity; Neovascularization, Pathologic; Nerve Tissue Proteins; Nestin; Oxidopamine; Parkinsonian Disorders; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Rats; Rats, Sprague-Dawley

2006
[Case of juvenile parkinsonism in pregnancy].
    Rinsho shinkeigaku = Clinical neurology, 2006, Volume: 46, Issue:6

    Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Contraindications; Dopamine Agents; Dopamine Agonists; Ergolines; Family Planning Services; Female; Humans; Infant, Newborn; Levodopa; Parkinsonian Disorders; Pramipexole; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Thiazoles

2006
Reversible Parkinsonism and T1W pallidal hyperintensities in acute liver failure.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:11

    Topics: Adult; Antiparkinson Agents; Female; Globus Pallidus; Humans; Levodopa; Liver Failure, Acute; Magnetic Resonance Imaging; Parkinson Disease, Secondary; Parkinsonian Disorders

2006
Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission.
    The European journal of neuroscience, 2006, Volume: 24, Issue:6

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Interactions; Dyskinesias; Electric Stimulation; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Functional Laterality; Levodopa; Male; Membrane Potentials; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Subthalamic Nucleus; Time Factors

2006
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Sep-27, Volume: 26, Issue:39

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Catechols; Cell Differentiation; Cell Line, Tumor; Cerebral Cortex; Corpus Striatum; Cytosol; Dopamine; Humans; Levodopa; Mice; Mice, Transgenic; Mutation, Missense; Nerve Degeneration; Neuroblastoma; Oxidation-Reduction; Parkinson Disease; Parkinsonian Disorders; Protein Conformation; Recombinant Fusion Proteins; Solubility; Transfection; Tretinoin; Tyrosine 3-Monooxygenase

2006
Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata.
    Brain research, 2006, Dec-06, Volume: 1123, Issue:1

    Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agents; Drug Administration Schedule; gamma-Aminobutyric Acid; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra

2006
T313M PINK1 mutation in an extended highly consanguineous Saudi family with early-onset Parkinson disease.
    Archives of neurology, 2006, Volume: 63, Issue:10

    Topics: Adolescent; Adult; Age of Onset; Amino Acid Substitution; Child; Child, Preschool; Consanguinity; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genetic Testing; Genotype; Homozygote; Humans; Levodopa; Male; Mutation; Parkinsonian Disorders; Pedigree; Protein Kinases; Saudi Arabia; Treatment Outcome

2006
Dopamine: from pharmacology to molecular biology and back.
    Wiener klinische Wochenschrift, 2006, Volume: 118, Issue:19-20

    Topics: Amphetamines; Animals; Antiparkinson Agents; Brain; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gene Expression Regulation; Humans; Levodopa; Locomotion; Mice; Mice, Knockout; Parkinson Disease; Parkinsonian Disorders; Receptors, G-Protein-Coupled; Signal Transduction

2006
Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Feb-15, Volume: 22, Issue:3

    Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Functional Laterality; Levodopa; Male; Multiple System Atrophy; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra

2007
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias.
    Neurobiology of disease, 2007, Volume: 25, Issue:3

    Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Combined Modality Therapy; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Levodopa; Mesencephalon; Motor Skills; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Recovery of Function; Severity of Illness Index; Sympatholytics

2007
Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Dec-27, Volume: 26, Issue:52

    Topics: Adenosine A2 Receptor Antagonists; Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders; Prosencephalon; Purines; Receptor, Adenosine A2A

2006
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
    Brain research, 2007, Feb-16, Volume: 1133, Issue:1

    Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Exploratory Behavior; Levodopa; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Sympatholytics; Triazoles

2007
Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata.
    Neuroscience, 2007, Mar-16, Volume: 145, Issue:2

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Down-Regulation; Drug Administration Schedule; Enkephalins; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Synaptic Transmission; Up-Regulation; Vesicular Inhibitory Amino Acid Transport Proteins

2007
Exercise improves efficacy of levodopa in patients with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Feb-15, Volume: 22, Issue:3

    Topics: Aged; Antiparkinson Agents; Area Under Curve; Exercise; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Severity of Illness Index; Time Factors

2007
Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism.
    Brain research bulletin, 2007, Mar-15, Volume: 71, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Benzodiazepines; Corpus Striatum; Dopamine; Dopamine Agents; Drug Interactions; Functional Laterality; Homovanillic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, AMPA

2007
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2007, Feb-07, Volume: 27, Issue:6

    Topics: Animals; Antiparkinson Agents; Benzimidazoles; Bicuculline; Drug Synergism; Drug Therapy, Combination; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Injections; Levodopa; Male; Microdialysis; Motor Activity; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Perfusion; Piperidines; Postural Balance; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Sodium Channel Blockers; Stereotaxic Techniques; Substantia Nigra; Tetrodotoxin; Thalamus

2007
[Juvenile Parkinson's disease and recurring prematurity. Case report].
    Gynecologie, obstetrique & fertilite, 2007, Volume: 35, Issue:3

    Topics: Adult; Antiparkinson Agents; Bromocriptine; Female; Humans; Infant, Newborn; Infant, Premature; Levodopa; Obstetric Labor, Premature; Parkinsonian Disorders; Pregnancy; Pregnancy Complications; Pregnancy Outcome

2007
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
    Behavioural brain research, 2007, Apr-16, Volume: 179, Issue:1

    Topics: Adrenergic Agents; Animals; Cross-Over Studies; Disease Models, Animal; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Neurotransmitter Agents; Parkinsonian Disorders; Random Allocation; Rats; Rotarod Performance Test; Serotonin Agents; Statistics, Nonparametric

2007
The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.
    Experimental neurology, 2007, Volume: 205, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Hypnotics and Sedatives; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Saimiri; Vomiting

2007
Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
    Neurobiology of disease, 2007, Volume: 26, Issue:2

    Topics: Animals; Antiparkinson Agents; Cell Compartmentation; Corpus Striatum; Cytoplasm; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Microscopy, Electron, Transmission; Neurons; Parkinsonian Disorders; Protein Transport; Receptor Aggregation; Receptors, Dopamine D1; Receptors, Dopamine D2; Up-Regulation

2007
Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling.
    Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, 2007, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Gambling; Humans; Levodopa; Parkinsonian Disorders; Pergolide; Pramipexole; Recurrence

2007
Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Apr-15, Volume: 22, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Callithrix; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Infusions, Intravenous; Levodopa; Locomotion; Male; Motor Activity; MSH Release-Inhibiting Hormone; Parkinsonian Disorders

2007
Modification of L-DOPA pharmacological activity by MAO inhibitors.
    Journal of neural transmission (Vienna, Austria : 1996), 2007, Volume: 114, Issue:6

    Topics: Animals; Basal Ganglia; Brain; Denervation; Dopamine; Drug Interactions; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra; Synaptic Transmission

2007
Nicotine induces tyrosine hydroxylase plasticity in the neurodegenerating striatum.
    Journal of neurochemistry, 2007, Volume: 102, Issue:3

    Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Axons; Corpus Striatum; Denervation; Dopamine; Down-Regulation; Levodopa; Male; Nerve Degeneration; Neuronal Plasticity; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase

2007
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.
    Neurobiology of disease, 2007, Volume: 27, Issue:1

    Topics: Afferent Pathways; Animals; Antiparkinson Agents; Aphakia; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Substantia Nigra

2007
Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys.
    Cell transplantation, 2007, Volume: 16, Issue:3

    Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Basal Ganglia; Biomarkers; Disease Progression; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Male; Parkinsonian Disorders; Placebos; Presynaptic Terminals; Saimiri; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins

2007
The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
    Neurological research, 2007, Volume: 29, Issue:3

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Functional Laterality; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred F344; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase

2007
Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time.
    Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:4

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Cross-Sectional Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Neurologic Examination; Neuropsychological Tests; Norway; Parkinson Disease; Parkinsonian Disorders; Prospective Studies; REM Sleep Behavior Disorder; Sex Factors

2008
In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias.
    Neurobiology of disease, 2007, Volume: 27, Issue:2

    Topics: Animals; Brain; Cerebrovascular Circulation; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Tetrahydronaphthalenes

2007
Amyotrophic lateral sclerosis with dementia showing clinical parkinsonism and severe degeneration of the substantia nigra: report of an autopsy case.
    Neuropathology : official journal of the Japanese Society of Neuropathology, 2007, Volume: 27, Issue:3

    Topics: Aged; Amyotrophic Lateral Sclerosis; Autopsy; Dementia; Diagnosis, Differential; Dopamine Agents; Fatal Outcome; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Parkinsonian Disorders; Substantia Nigra

2007
Fracture risk associated with parkinsonism and anti-Parkinson drugs.
    Calcified tissue international, 2007, Volume: 81, Issue:3

    Topics: Adult; Age Factors; Antiparkinson Agents; Carbidopa; Case-Control Studies; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Female; Fractures, Bone; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Risk Factors; Sex Factors; Time Factors

2007
L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
    Journal of chemical neuroanatomy, 2008, Volume: 35, Issue:1

    Topics: Adaptation, Physiological; Animals; Antiparkinson Agents; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Immunohistochemistry; Interneurons; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Phenotype; Tyrosine 3-Monooxygenase; Up-Regulation

2008
Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Nov-15, Volume: 22, Issue:15

    Topics: Adult; Aged; Antiparkinson Agents; Brain Mapping; Cerebral Cortex; Combined Modality Therapy; Deep Brain Stimulation; Female; Fluorodeoxyglucose F18; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Parkinsonian Disorders; Positron-Emission Tomography; Radiopharmaceuticals; Subthalamic Nucleus

2007
Genetic analysis of SCA 2 and 3 repeat expansions in essential tremor and atypical Parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Oct-15, Volume: 22, Issue:13

    Topics: Adult; Antiparkinson Agents; Ataxin-3; Ataxins; Cross-Sectional Studies; Diagnosis, Differential; DNA Mutational Analysis; Drug Resistance; Essential Tremor; Female; Genetic Testing; Genotype; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Multiple System Atrophy; Nerve Tissue Proteins; Neurologic Examination; Nuclear Proteins; Parkinsonian Disorders; Phenotype; Polymerase Chain Reaction; Repressor Proteins; Spinocerebellar Ataxias; Supranuclear Palsy, Progressive; Trinucleotide Repeat Expansion; Trinucleotide Repeats

2007
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
    Behavioural brain research, 2008, Jan-25, Volume: 186, Issue:2

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors

2008
Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.
    Neuroscience letters, 2007, Oct-09, Volume: 426, Issue:1

    Topics: Amino Acid Sequence; Animals; Basal Ganglia; Brain Chemistry; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Administration Schedule; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Gene Expression Regulation; Levodopa; Male; Neural Pathways; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Threonine; Time

2007
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
    Annals of neurology, 2007, Volume: 62, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Circadian Rhythm; Dyskinesia, Drug-Induced; Levodopa; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Saimiri; Substantia Nigra; Time Factors

2007
Novel pattern of levodopa-related motor fluctuations: 'paradoxical'on.
    Parkinsonism & related disorders, 2008, Volume: 14, Issue:4

    Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinsonian Disorders

2008
Transcranial sonography findings in welding-related Parkinsonism in comparison to Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Volume: 23, Issue:1

    Topics: Adult; Diagnosis, Differential; Dopamine Agonists; Drug Resistance; Echoencephalography; Humans; Levodopa; Male; Occupational Diseases; Parkinson Disease; Parkinsonian Disorders; Substantia Nigra; Ultrasonography, Doppler, Transcranial; Welding

2008
Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys.
    Synapse (New York, N.Y.), 2008, Volume: 62, Issue:2

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Benzoxazoles; Binding, Competitive; Bridged Bicyclo Compounds, Heterocyclic; Convulsants; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Flunitrazepam; GABA Modulators; Isotopes; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Binding; Radiography; Receptors, GABA; Substantia Nigra

2008
Parkinsonism in a patient with antiphospholipid syndrome--case report and literature review.
    Journal of the neurological sciences, 2008, Apr-15, Volume: 267, Issue:1-2

    Topics: Adult; Anticoagulants; Antiparkinson Agents; Antiphospholipid Syndrome; Brain; Cerebral Arteries; Corpus Striatum; Dementia, Vascular; Female; Humans; Intracranial Thrombosis; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Warfarin

2008
A novel phenotype of sporadic Creutzfeldt-Jakob disease.
    Journal of neurology, neurosurgery, and psychiatry, 2007, Volume: 78, Issue:12

    Topics: Aged; Antibodies; Antibodies, Monoclonal; Antiparkinson Agents; Blotting, Western; Brain; Codon; Creutzfeldt-Jakob Syndrome; Female; Humans; Immunohistochemistry; Levodopa; Magnetic Resonance Imaging; Methionine; Parkinsonian Disorders; Phenotype; Polymorphism, Genetic; PrPSc Proteins; Valine

2007
Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-15, Volume: 23, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Functional Laterality; Intralaminar Thalamic Nuclei; Kainic Acid; Levodopa; Macaca fascicularis; Male; Parkinsonian Disorders; Stereotaxic Techniques

2008
Are parkin patients particularly suited for deep-brain stimulation?
    Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-15, Volume: 23, Issue:5

    Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Genetic Testing; Heterozygote; Homozygote; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Treatment Outcome; Ubiquitin-Protein Ligases

2008
Marked diurnal fluctuation and rest benefit in a patient with parkin mutation.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Mar-15, Volume: 23, Issue:4

    Topics: Adult; Circadian Rhythm; Diagnosis, Differential; Dopamine; Dopamine Agonists; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinsonian Disorders; Point Mutation; Positron-Emission Tomography; Putamen; Radiopharmaceuticals; Tropanes; Ubiquitin-Protein Ligases; Videotape Recording

2008
Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
    Synapse (New York, N.Y.), 2008, Volume: 62, Issue:4

    Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; In Situ Hybridization; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor Activity-Modifying Protein 1; Receptor Activity-Modifying Proteins; RNA, Messenger

2008
Specific induction of PAG608 in cranial and spinal motor neurons of L-DOPA-treated parkinsonian rats.
    Neuroscience research, 2008, Volume: 60, Issue:4

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; DNA-Binding Proteins; Drug Interactions; Functional Laterality; Gene Expression Regulation; Levodopa; Motor Neurons; Nuclear Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Spinal Cord

2008
Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.
    Journal of neural transmission (Vienna, Austria : 1996), 2008, Volume: 115, Issue:3

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Chlorobenzenes; Corpus Striatum; Cyclobutanes; Dynorphins; Enkephalins; Gene Expression; In Situ Hybridization; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Substance P; Time

2008
Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
    Neuroscience letters, 2008, Mar-15, Volume: 433, Issue:3

    Topics: Animals; Astrocytes; Biomarkers; Calcium-Binding Proteins; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Glial Fibrillary Acidic Protein; Immunohistochemistry; Levodopa; Male; Microfilament Proteins; Microglia; Neural Pathways; Neuroglia; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Substantia Nigra

2008
Homozygous SCA 2 mutations changes phenotype and hastens progression.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-15, Volume: 23, Issue:5

    Topics: Antiparkinson Agents; Ataxins; Dementia; Disease Progression; Dyskinesias; Female; Follow-Up Studies; Homozygote; Humans; Levodopa; Male; Mutation; Nerve Tissue Proteins; Ocular Motility Disorders; Parkinsonian Disorders; Phenotype; Psychotic Disorders; Spinocerebellar Degenerations

2008
Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice.
    Journal of sleep research, 2008, Volume: 17, Issue:1

    Topics: Animals; Dopamine Agonists; Electroencephalography; Levodopa; Lisuride; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Pergolide; Polysomnography; Sleep; Wakefulness

2008
The auditory startle response in parkinsonism may reveal the extent but not type of pathology.
    Journal of neurology, 2008, Volume: 255, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Auditory Pathways; Blinking; Brain Stem; Dementia; Diagnosis, Differential; Facial Muscles; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Neck Muscles; Ocular Motility Disorders; Parkinsonian Disorders; Predictive Value of Tests; Reflex, Startle; Sensitivity and Specificity; Supranuclear Palsy, Progressive; Tauopathies

2008
[L-dopa sensitive Parkinsonism in neurocysticercosis].
    Neurologia (Barcelona, Spain), 2008, Volume: 23, Issue:2

    Topics: Adult; Anthelmintics; Cerebrospinal Fluid Pressure; Female; Fourth Ventricle; Humans; Hydrocephalus; Levodopa; Neurocysticercosis; Parkinsonian Disorders; Ventriculoperitoneal Shunt

2008
In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
    European journal of pharmacology, 2008, Apr-28, Volume: 584, Issue:2-3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adamantane; Amidines; Animals; Antiparkinson Agents; Basal Ganglia; Denervation; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Microdialysis; Oxidopamine; Parkinsonian Disorders; Perfusion; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Time Factors

2008
Primitive reflexes distinguish vascular parkinsonism from Parkinson's disease.
    Clinical neurology and neurosurgery, 2008, Volume: 110, Issue:6

    Topics: Aged; Antiparkinson Agents; Cerebrovascular Disorders; Diagnosis, Differential; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Motor Neurons; Neuropsychological Tests; Parkinson Disease; Parkinsonian Disorders; Reflex

2008
Striatal histone modifications in models of levodopa-induced dyskinesia.
    Journal of neurochemistry, 2008, Volume: 106, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Chromatin; Chromosome Aberrations; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Female; Histones; Levodopa; Macaca mulatta; Male; Methylation; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Phosphorylation; Protein Processing, Post-Translational; Species Specificity

2008
Preclinical models of Parkinson's disease.
    Current protocols in neuroscience, 2001, Volume: Chapter 9

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Injections, Intra-Arterial; Injections, Intravenous; Levodopa; Macaca fascicularis; Macaca mulatta; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Primates; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Species Specificity

2001
Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
    Current protocols in neuroscience, 2007, Volume: Chapter 9

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats; Sympatholytics

2007
Reversible parkinsonism following ventriculoperitoneal shunt in a patient with obstructive hydrocephalus secondary to intraventricular neurocysticercosis.
    Clinical neurology and neurosurgery, 2008, Volume: 110, Issue:7

    Topics: Adult; Antiparkinson Agents; Cerebral Ventricles; Humans; Hydrocephalus; Levodopa; Male; Neurocysticercosis; Parkinsonian Disorders; Ventriculoperitoneal Shunt

2008
Stroke of the substance nigra and parkinsonism as first manifestation of systemic lupus erythematosus.
    Parkinsonism & related disorders, 2008, Volume: 14, Issue:4

    Topics: Antiparkinson Agents; Female; Humans; Levodopa; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Middle Aged; Parkinsonian Disorders; Stroke; Substantia Nigra

2008
Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism.
    Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:11

    Topics: Aged; Antiparkinson Agents; Brain; Diagnosis, Differential; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Pilot Projects; Predictive Value of Tests; Severity of Illness Index; Surveys and Questionnaires; Tomography, X-Ray Computed

2008
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
    Journal of neuroinflammation, 2008, May-21, Volume: 5

    Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Drug Evaluation, Preclinical; Endotoxins; Exenatide; Glucagon-Like Peptide-1 Receptor; Levodopa; Locomotion; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Receptors, Glucagon; Substantia Nigra; Tyrosine 3-Monooxygenase; Venoms

2008
Intraocular microinjections repair experimental Parkinson's disease.
    Brain research, 2008, Jun-27, Volume: 1217

    Topics: 5-Methoxytryptamine; Animals; Antiparkinson Agents; Circadian Rhythm; Levodopa; Male; Microinjections; Motor Activity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Retina

2008
Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists.
    Bioorganic & medicinal chemistry letters, 1999, Oct-04, Volume: 9, Issue:19

    Topics: Animals; Disease Models, Animal; Imidazoles; Levodopa; Ligands; Molecular Structure; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyrazoles; Pyrroles; Rats; Receptors, N-Methyl-D-Aspartate

1999
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
    Annals of neurology, 1999, Volume: 46, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Electrophysiology; Eye Movements; Globus Pallidus; Levodopa; Macaca mulatta; Motor Activity; Neurons; Parkinsonian Disorders

1999
Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment.
    Neuroscience, 1999, Volume: 94, Issue:2

    Topics: Animals; Corpus Striatum; Denervation; Dopamine; Drug Administration Schedule; Exploratory Behavior; Female; Functional Laterality; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley

1999
Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.
    Neurobiology of disease, 1999, Volume: 6, Issue:6

    Topics: Animals; Antisense Elements (Genetics); Bacterial Proteins; Biomarkers; Cell Count; Disease Models, Animal; Dyskinesias; Enkephalins; Female; Levodopa; Neostriatum; Nerve Degeneration; Neurons; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Transcription Factors; Ventral Tegmental Area

1999
Weight gain following unilateral pallidotomy in Parkinson's disease.
    Acta neurologica Scandinavica, 2000, Volume: 101, Issue:2

    Topics: Dyskinesia, Drug-Induced; Eating; Globus Pallidus; Humans; Levodopa; Linear Models; Longitudinal Studies; Motor Activity; Neuropsychological Tests; Nutrition Assessment; Parkinsonian Disorders; Severity of Illness Index; Smell; Stereotaxic Techniques; Surveys and Questionnaires; Weight Gain

2000
Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
    Synapse (New York, N.Y.), 2000, Jun-15, Volume: 36, Issue:4

    Topics: Animals; Antiparkinson Agents; Dextromethorphan; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Riluzole; Rotation

2000
Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment.
    Neuroscience, 2000, Volume: 98, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Binding Sites; Carrier Proteins; Caudate Nucleus; Dopamine Plasma Membrane Transport Proteins; Female; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Parkinsonian Disorders; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Saimiri; Substantia Nigra

2000
Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys.
    European journal of pharmacology, 2000, Jul-07, Volume: 399, Issue:2-3

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Clozapine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders

2000
A possible association between exposure to n-hexane and parkinsonism.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2000, Volume: 21, Issue:1

    Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Electromyography; Evoked Potentials, Auditory, Brain Stem; Evoked Potentials, Somatosensory; Hexanes; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Occupational Diseases; Parkinsonian Disorders; Selegiline; Solvents

2000
The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:5

    Topics: Adult; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Male; Memantine; N-Methylaspartate; Parkinsonian Disorders; Treatment Outcome

2000
Dopamine-receptor stimulation: biobehavioral and biochemical consequences.
    Trends in neurosciences, 2000, Volume: 23, Issue:10 Suppl

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Neural Inhibition; Neuropeptides; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Receptors, Dopamine; Receptors, GABA; Receptors, Glutamate; Signal Transduction

2000
Expression of metallothionein-III mRNA and its regulation by levodopa in the basal ganglia of hemi-parkinsonian rats.
    Neuroscience letters, 2000, Oct-20, Volume: 293, Issue:1

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Levodopa; Male; Metallothionein 3; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger

2000
MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
    European journal of pharmacology, 2000, Nov-03, Volume: 407, Issue:3

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra

2000
Abnormalities of motor cortical excitability are not correlated with clinical features in atypical parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:6

    Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia Cerebrovascular Disease; Case-Control Studies; Electromyography; Evoked Potentials, Motor; Female; Humans; Levodopa; Magnetics; Magnetoencephalography; Male; Middle Aged; Motor Cortex; Multiple System Atrophy; Parkinsonian Disorders; Statistics, Nonparametric

2000
Dopa-resistant parkinsonism, oculomotor disturbances, chorea, mirror movements, dyspraxia, and dementia: the expanding clinical spectrum of hypoparathyroidism. A case report.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:6

    Topics: Aged; Antiparkinson Agents; Apraxias; Brain Diseases; Calcinosis; Chorea; Chronic Disease; Dementia; Diagnosis, Differential; Drug Tolerance; Female; Humans; Hypoparathyroidism; Levodopa; Magnetic Resonance Imaging; Oculomotor Nerve Diseases; Parkinsonian Disorders; Stereotypic Movement Disorder; Videotape Recording

2000
Occupational Mn parkinsonism: magnetic resonance imaging and clinical patterns following CaNa2-EDTA chelation.
    Neurotoxicology, 2000, Volume: 21, Issue:5

    Topics: Antiparkinson Agents; Benserazide; Brain; Chelating Agents; Edetic Acid; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Manganese Poisoning; Metals, Heavy; Middle Aged; Occupational Diseases; Occupational Exposure; Parkinsonian Disorders

2000
L-dopa-responsive infantile hypokinetic rigid parkinsonism due to tyrosine hydroxylase deficiency.
    Neurology, 2000, Dec-26, Volume: 55, Issue:12

    Topics: Humans; Infant; Levodopa; Male; Parkinsonian Disorders; Tyrosine 3-Monooxygenase

2000
Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
    European journal of pharmacology, 2001, Feb-02, Volume: 412, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Piperidines; Receptors, Dopamine D2

2001
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
    Nature medicine, 2001, Volume: 7, Issue:2

    Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Epilepsy, Tonic-Clonic; Humans; Inclusion Bodies; Levodopa; Mice; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinsonian Disorders; Prazosin; Receptors, Adrenergic, alpha-1; Shy-Drager Syndrome; Syndrome; Synucleins; Tyrosine 3-Monooxygenase

2001
The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
    Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:4

    Topics: Adrenergic Agents; Animals; Clorgyline; Corpus Striatum; Dopamine Agents; Dopamine Uptake Inhibitors; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra

2000
Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism.
    Annals of human genetics, 2000, Volume: 64, Issue:Pt 1

    Topics: Adult; Amino Acid Sequence; Child; Child, Preschool; DNA Mutational Analysis; DNA Primers; Exons; Female; Humans; Introns; Levodopa; Male; Molecular Sequence Data; Mutation, Missense; Parkinsonian Disorders; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Sequence Homology, Amino Acid; Tyrosine 3-Monooxygenase

2000
[Parkinson's disease].
    Presse medicale (Paris, France : 1983), 2001, Mar-03, Volume: 30, Issue:8

    Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Catechols; Depressive Disorder; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Follow-Up Studies; Humans; Indoles; Levodopa; Lewy Body Disease; Neuroprotective Agents; Nitriles; Parkinson Disease; Parkinsonian Disorders; Pergolide; Psychiatric Status Rating Scales; Psychotic Disorders; Time Factors

2001
New nonsense mutation in the GTP-cyclohydrolase I gene in L-DOPA responsive dystonia-parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:2

    Topics: Adult; Aged; Antiparkinson Agents; Codon, Nonsense; DNA Mutational Analysis; Dystonia; Female; Gene Expression; GTP Cyclohydrolase; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Point Mutation

2001
Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
    Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Levodopa; Male; Memantine; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Recovery of Function

2001
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Hydroxyl Radical; Levodopa; Male; Microdialysis; Nitriles; Nitrophenols; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Wistar; Tolcapone

2001
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
    Synapse (New York, N.Y.), 2001, Volume: 41, Issue:2

    Topics: Adrenergic Uptake Inhibitors; Animals; Ankle Joint; Dopamine Agents; Dopamine Antagonists; Drug Combinations; Electromyography; Haloperidol; Levodopa; Male; Muscle Contraction; Muscle Rigidity; Muscle, Skeletal; Neostriatum; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Purinergic P1; Reserpine; Triazoles

2001
Response to levodopa treatment in dopa-responsive dystonia.
    Archives of neurology, 2001, Volume: 58, Issue:6

    Topics: Adult; Antiparkinson Agents; Dopamine; Dystonia; Dystonic Disorders; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Pilot Projects

2001
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indoles; Levodopa; Neurologic Examination; Parkinsonian Disorders

2001
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2001, Volume: 22, Issue:1

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dopamine Agonists; Down-Regulation; Drug Interactions; Drug Tolerance; Dynorphins; Enkephalins; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Neostriatum; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; RNA, Messenger; Sympatholytics; Up-Regulation

2001
Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2001, Volume: 22, Issue:1

    Topics: Animals; Antiparkinson Agents; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Levodopa; Male; Motor Activity; Neostriatum; Neural Pathways; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Substantia Nigra; Sympatholytics; Triazoles

2001
Chronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6-OHDA dopamine-depleted (hemi-Parkinson analogue) rats.
    The European journal of neuroscience, 2001, Volume: 14, Issue:1

    Topics: Animals; Antiparkinson Agents; Arm; Cell Count; Drug Administration Schedule; Female; Immunohistochemistry; Levodopa; Motor Skills; Movement; Neurons; Neuropsychological Tests; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Long-Evans; Recovery of Function; Rotation; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase

2001
Levodopa prolongs life expectancy and is non-toxic to substantia nigra.
    Parkinsonism & related disorders, 2001, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cadaver; Child; Disease Progression; Dystonia; Female; Humans; Levodopa; Longevity; Male; Middle Aged; Parkinsonian Disorders; Retrospective Studies; Substantia Nigra; Survival Analysis; Tremor

2001
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
    Experimental neurology, 2001, Volume: 171, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Female; Hypokinesia; Levodopa; Male; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Posture; Receptors, Opioid, delta; Receptors, Opioid, mu

2001
Levodopa responsive Parkinsonism in adults with Angelman Syndrome.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2001, Volume: 8, Issue:5

    Topics: Adult; Angelman Syndrome; Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinsonian Disorders

2001
Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy.
    Biological psychiatry, 2001, Sep-15, Volume: 50, Issue:6

    Topics: Acute Disease; Adult; Antiparkinson Agents; Antipsychotic Agents; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Prospective Studies; Psychotic Disorders; Retrospective Studies; Substantia Nigra; Tomography, Emission-Computed; Ultrasonography

2001
Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP.
    Journal of neuroscience methods, 2001, Oct-15, Volume: 111, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Chronic Disease; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Dyskinesias; Female; Image Processing, Computer-Assisted; Levodopa; Macaca mulatta; Motor Activity; Parkinsonian Disorders; Video Recording

2001
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
    Brain research bulletin, 2001, Sep-01, Volume: 56, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Interactions; Homovanillic Acid; Hydroxyindoleacetic Acid; Hypokinesia; Immunohistochemistry; Isoquinolines; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Serotonin; Stereoisomerism; Substantia Nigra; Tetrahydroisoquinolines; Tyrosine 3-Monooxygenase

2001
LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.
    Synapse (New York, N.Y.), 2001, Volume: 42, Issue:1

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Isoquinolines; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Tetrazoles

2001
Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment.
    Neuroscience, 2001, Volume: 105, Issue:2

    Topics: Animals; Apomorphine; Chromogranins; DNA, Complementary; Dopamine Agonists; Drug Administration Schedule; Gene Expression Regulation; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Proteins; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Secretogranin II; Sympatholytics; Up-Regulation

2001
Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.
    The European journal of neuroscience, 2001, Volume: 14, Issue:7

    Topics: Animals; Bromocriptine; Denervation; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Enkephalins; Female; Gene Expression Regulation; Immunohistochemistry; Levodopa; Neostriatum; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics

2001
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.
    Neurology, 2001, Nov-27, Volume: 57, Issue:10

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dose-Response Relationship, Drug; Female; Levodopa; Macaca fascicularis; Male; Motor Skills; Organic Chemicals; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Species Specificity; Stereotyped Behavior; Substantia Nigra

2001
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Synapse (New York, N.Y.), 2002, Volume: 43, Issue:1

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Immunohistochemistry; Levodopa; Male; Motor Activity; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tachykinins; Tyrosine 3-Monooxygenase

2002
Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families.
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:6

    Topics: Adult; Age of Onset; Aged; Chromosomes, Human, Pair 1; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Female; Functional Laterality; Gait Disorders, Neurologic; Genes, Recessive; Haplotypes; Humans; Italy; Levodopa; Lod Score; Male; Middle Aged; Parkinsonian Disorders; Pedigree; Phenotype; Syndrome; Tremor; Videotape Recording

2001
Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism.
    Annals of neurology, 2001, Volume: 50, Issue:6

    Topics: Adult; Aged; Ataxins; Brain; China; Female; Fluorine Radioisotopes; Gait; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Parkinsonian Disorders; Pedigree; Proteins; Spinocerebellar Ataxias; Tomography, Emission-Computed; Trinucleotide Repeats

2001
Anticholinergic drugs: response of parkinsonism not responsive to levodopa.
    Journal of neurology, neurosurgery, and psychiatry, 2002, Volume: 72, Issue:1

    Topics: Adult; Brain Mapping; Cholinergic Antagonists; Corpus Striatum; Humans; Levodopa; Magnetic Resonance Imaging; Male; Neurons; Parkinsonian Disorders; Pyramidal Tracts; Substantia Nigra; Tomography, Emission-Computed; Trihexyphenidyl

2002
MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats.
    Brain research, 2002, Feb-01, Volume: 926, Issue:1-2

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Sympatholytics; Synaptic Transmission

2002
Toxicity of Annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadeloupe.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:1

    Topics: Annonaceae; Antiparkinson Agents; Apoptosis; Cell Culture Techniques; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Resistance; Guadeloupe; Humans; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Mesencephalon; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders

2002
Life-threatening parkinsonism induced by kava-kava.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:1

    Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Kava; Levodopa; Middle Aged; Parkinsonian Disorders; Tremor

2002
X-linked dystonia ("Lubag") presenting predominantly with parkinsonism: a more benign phenotype?
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:1

    Topics: Adult; Antiparkinson Agents; Chromosome Aberrations; Dystonic Disorders; Humans; Levodopa; Male; Parkinsonian Disorders; Phenotype; X Chromosome

2002
Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
    The European journal of neuroscience, 2001, Volume: 14, Issue:11

    Topics: Aged; Aged, 80 and over; Animals; Basal Ganglia; Binding, Competitive; Callithrix; Dopamine Agents; Female; GTP-Binding Proteins; Humans; Levodopa; Male; Middle Aged; Neurons; Parkinsonian Disorders; Receptors, Cannabinoid; Receptors, Drug; Up-Regulation

2001
Beta-CIT-SPECT combined with UPDRS appears to distinguish different parkinsonian conditions.
    Acta neurologica Scandinavica, 2002, Volume: 105, Issue:1

    Topics: Aged; Antiparkinson Agents; Basal Ganglia; Cocaine; Diagnosis, Differential; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Motor Skills; Parkinsonian Disorders; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon

2002
Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:2

    Topics: Consanguinity; Developmental Disabilities; Dopamine; Female; Follow-Up Studies; Humans; Infant; Levodopa; Neurologic Examination; Norepinephrine; Parkinsonian Disorders; Tremor; Tyrosine 3-Monooxygenase

2002
Parkinson syndrome as a manifestation of mitochondriopathy.
    Acta neurologica Scandinavica, 2002, Volume: 105, Issue:5

    Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Biopsy; DNA, Mitochondrial; Dopamine; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Mitochondrial Diseases; Muscle, Skeletal; Oxidative Phosphorylation; Parkinsonian Disorders; Point Mutation; Severity of Illness Index

2002
A patient with proximal myotonic myopathy and parkinsonism.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2002, Volume: 29, Issue:2

    Topics: Aged; Antiparkinson Agents; Brain; Humans; Levodopa; Male; Muscles; Myotonic Disorders; Parkinsonian Disorders

2002